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Bladder Cancer is the 4th most commonly diagnosed cancer in men and the 8th 
most deadly. While non-muscle invasive bladder cancer has a relatively high 5 year 
survival rate, muscle invasive bladder cancer (≥T2) has a 5 year survival rate of ~50% 
with the number decreasing to 15% for non-organ confined disease. Multiple groups 
have performed molecular characterization of bladder tumors in an effort to identify 
bladder cancer subtypes. These groups have been able to effectively differentiate non-
muscle invasive disease (low-grade) from muscle invasive (high-grade); since 
pathologists can reliably identify LG and HG tumors, molecular signatures of these two 
groups are not clinically useful. We sought to define whether there are intrinsic 
molecular subtypes of high-grade bladder cancer.  Consensus Clustering performed on 
gene expression data from a meta-dataset of high-grade, muscle invasive bladder 
tumors identified two intrinsic, molecular subsets of high-grade bladder cancer: “luminal” 
and “basal-like” that have characteristics of different stages of urothelial differentiation, 
reflect the luminal and basal-like molecular subtypes of breast cancer, and have 
clinically meaningful differences in outcome. Prediction analysis of microarrays (PAM) 
defined a gene set predictor: Bladder cancer Analysis of Subtypes by Expression 
(BASE47) that accurately classifies the subtypes. Our data demonstrate that there are 
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at least two molecularly and clinically distinct subtypes of high-grade bladder 
cancer.  As an appreciation of subtype heterogeneity has revolutionized the care of 
breast cancer, these results also suggest stratification for therapy is indicated in bladder 
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 Bladder cancer is the 4th most commonly diagnosed caner in men and 8th 
deadliest in the United States with an estimated 74,690 (56,390 in men and 18,300 in 
women) new cases and 15,580 (11,170 in men and 4,410 in women) deaths for the 
year 2014 (1). Bladder cancer has the highest per patient treatment cost of any cancer, 
costing the US healthcare industry 3.7 billion dollars annually (2). This is of note since 
bladder cancer is predominately a disease of the elderly, specifically elderly men; the 
average age at diagnosis is 65-70 years with an incidence rate of 36.9 for men and 9.1 
for women (per 100,000 people) (1). Although women are diagnosed at a lower 
frequency than men, they have a worse overall prognosis. Studies suggest that gender 
may be an independent risk factor for poor prognosis, with women having a poorer 
outcome (3, 4). However, other reports suggest that when corrected for demographics 
and clinical factors, women had equal survival outcomes to men (5). 
 In addition to gender differences associated with bladder cancer diagnosis, race 
specific differences exist as well (6-8). A direct comparison of five year survival between 
White and African American patients showed a 14 percentage point difference in five-
year overall survival (1). The survival difference in bladder cancer between race is one 
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of the most different as compared to other tumor types This could partially be explained 
by white patients having a higher incidence of low grade tumors as compared to African 
Americans. (9). Additionally, the difference in survival has previously been attributed to 
difference in access to health care and late stage diagnosis. However, multiple studies 
have shown that poor outcome is not fully due to the aforementioned factors, and other, 
yet to be determined factors contribute to race specific survival differences (5, 7, 10, 
11).  
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3.2 Risk Factors 
 
 There are multiple known risk factors for bladder cancer including smoking, 
occupational exposures, environmental exposures and infection. Smoking is the single 
largest risk factor for bladder cancer, increasing a person’s risk 2-4 fold (9). Additionally, 
it has been estimated that 30%-50% of all bladder cancer cases are caused by cigarette 
smoking (9, 12). While the risk of smoking related bladder cancer has been correlated 
to the duration and intensity of smoking, there is also a correlation between the variety 
of tobacco used in the cigarettes and cancer risk; black tobacco has a 2-3 times high 
risk than Virginia or brightleaf tobacco (12). Currently, there is no defined mechanism of 
smoking related carcinogenesis in bladder cancer. It has been hypothesized that the 
absorption of carcinogens such as 2-naphthylamine and 4-aminobiphenyl, which are 
filtered through the urine via the bladder, could act as the causal agents. However, the 
risk of bladder cancer is only increased by inhaled tobacco and not other products such 
as cigar and chewing tobacco, suggesting a more complicated mechanism of 
carcinogen metabolism (13). In addition to the carcinogens from cigarettes, 
carcinogenic exposure at the workplace is also a contributing risk factor to bladder 
cancer.  
 After smoking, occupational exposures represent the second largest risk factor 
for the development of bladder cancer. It is believed that 20% of bladder cancer cases 
can be linked to occupational exposure from wide array of industries such as, textiles, 
dyes, and paint (14). Case and Hosker in 1954 reported that rubber workers in England 
and Wales, who were exposed to naphthylamines had increased risk of developing 
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bladder cancer (15). This has been followed up over the past decades by numerous 
studies demonstrating the link between occupational exposure to carcinogens and 
bladder cancer (12, 16). Aromatic amines such as, benzidine; benzidine; 4-
aminobiphenyl; 2-naphthylamine; 4-chloro-o-toluidine have been shown to be the main 
contributors to occupational related carcinogenesis (12, 14).  
 In addition to occupational exposures, environmental exposure to arsenic is a 
significant contributor to the risk of development of bladder cancer. It was first noted that 
high levels of arsenic in drinking water was statistically associated with cancer in the 
1960s by Tseng et. al. as part of a large population based study in Taiwan. The original 
intent of the project was to investigate the high rate of Blackfoot disease, a peripheral 
vascular disease, in association with arsenic levels, however incidental findings 
revealed a high rate of skin cancer among people with high exposure to arsenic. 
Arsenic concentration in the affect area’s well water was measured at 1.097ppm, 100x 
greater then surrounding villages with arsenic free water (17). In additional follow up 
studies numerous groups identified multiple arsenic associated cancers, including 
bladder cancer (17-20). Currently analysis of bladder cancer risk associated with 
arsenic exposure suggests that a 10ug/L lifetime exposure would increase bladder 
cancer risk to 2 in 1,000, compared to the EPA risk range of 1 in 10,000 (21). Although 
epidemiologic data concerning high-dose exposure is consistent with increased bladder 
cancer risk, recent data suggests that using previously established predictive risk 
models may not be accurate for low-dose exposure (21).  
 Environmental exposures as a risk factor extend beyond chemical carcinogens to 
microorganisms. Although not typically seen in the United States, parasitic infection with 
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Schistosomiasis is endemic in Egypt and the more generally the Middle East. 
Schistosomiasis spreads through infected drinking water and can lead to weakness, 
diarrhea. There are four schistosomes that infect humans; S. haematobium, S. 
Mansoni, S. Japonicum, and S. Mekongi, of these, S. Haematobium is associated with 
increased risk of malignancy. Carcinomas of the intestine, liver and bladder have been 
linked to S. Haematobium infection (22). It is estimated that ~27% of all bladder cancer 
diagnosis in Egypt are associated with S. Haematobium infection (23). Bladder cancers 
associated with infection are more likely to be of the squamous cell carcinoma histologic 
subtype, whereas transitional cell carcinomas are more commonly diagnosed in the 
western world (23, 24). Although the mechanism of cancer initiation is unknown, 
multiple groups have shown that chronic infection, including urinary tract infections, may 
be a contributing risk factor to bladder cancer (25-27)  
 Taken together, bladder cancer represents a significant health concern for the 
elderly population and a large burden for the US healthcare industry. Although there are 
several known risk factors, including lifestyle, occupational and environmental factors, 
more research must be done to understand the mechanisms in which these contribute 




1.3 Bladder Histology, Staging and Pathologic Subtypes 
 
 The urinary bladder has a multi-layered transitional epithelium (urothelium), of 
which the luminal most layer consists of umbrella cells. This specialized epithelium 
allows for a water-tight barrier and resistance to mechanical stress associated 
expansion and contraction of the bladder when filling and voiding urine. These unique 
features of the epithelium are in part conferred by the presence of urothelial plaques on 
the apical surface of cell. The plaques are protein complexes composed of two 
heterodimers bound to a heterotetramer of uroplakins (UP1a/UPK2 and UPK1b/UPK3) 
(28). Hu et. al. demonstrated that lost of the UPK3 significantly increased the cell’s 
membrane permeability to both urea and water (29). Additionally, uroplakin loss is 
associated with decreased umbrella cell size and defects in the urinary tract (30).  
Beneath the umbrella layer are the intermediate and basal layers. The basal cells 
has been proposed to be the progenitor cell for the urothelium and the potential cell of 
origin for bladder cancer (31-33). The basement membrane is a specialized 
extracellular matrix connecting the urothelial compartment to the lamina propria, which 
contains blood and lymphatic vasculature. The muscularis propria consists of three 
layers of muscle, which when contracted allows for the voiding of urine. The outer most 
layer of the bladder is the adventitia, this includes connective tissue and fat that lines 





Figure 1: Bladder histology 
A layer of transitional epithelial cells sits on top of a basement membrane, that 
separates the urothelium from the lamina propria. It is followed by a muscular layer 











 Bladder cancer, which arises from the transformation of urothelial cells, is staged 
based on the degree of invasion into the underlying tissue (Figure 2). Pathologic stage 
is the most important prognostic factor for bladder cancer survival and is critical for 
informing treatment (9). Tumors diagnosed as Ta are tumors that are confined to the 
urothelium and do not invade into the lamina propria. These tumors can exist as either 
be low-grade (LG), papillary tumors, or high-grade (HG), carcinomas in situ (CIS). LG 
papillary tumors account for approximately 70% of tumors at diagnosis with HG tumors 
make up the remaining 30%. LG tumors have a good prognosis with a >95% five year 
survival, however need to be regularly monitored as reoccurrence is common in up to 
80% of patients. Although high grade CIS are confined to the urothelium they are 
aggressive and may progresses to invasive disease (1, 34).  
 Muscle invasive tumors (≥T2) are almost exclusively HG and have a poor 
prognosis as compared to LG non-muscle invasive disease. Patients that are diagnosed 
with T2 tumors have a 63% five-survival rate, which drops to 15% for patients 
diagnosed with T4, metastatic, or non-organ confined disease. Along with stage being 
critical to gauge prognosis, it also is an important factor in the determination of the 







Figure 2: Bladder cancer staging 
A diagram represents the degree of invasion as it relates to stage. Superficial tumors do 
not extent past the lamina propria (T0,T1). Once the tumor invades the muscularis 
propria they are considered invasive (≥T2), tumors that have invaded neighboring 
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1.4 Bladder Cancer Treatment 
 
 As previously mentioned, the stage at diagnosis plays a critical role in 
determining the course of treatment. Currently the gold standard of care for non-muscle 
invasive bladder cancer is excision of the tumor via Transurethral Resection of Bladder 
Tumor (TURBT). During the procedure, the tumor is removed using a cystoscope 
inserted into the bladder through the urethra. Patients may, additionally, receive a one-
time treatment with intravesical chemotherapy at the time of resection or a series 
treatments over a period of multiple weeks. Patients that are deemed intermediate or 
high risk may also receive Bacillus Calmette-Guerin (BCG) treatment in combination 
with intravesical chemotherapy (35) (36). BCG is a live attenuated form of the bacterium 
Mycobacterium bovis. When the bacterium is instilled into the bladder it elicits an 
inflammatory response as well as triggers activation of the adaptive immune system 
(37, 38). It is proposed that this stimulation of the immune system helps to clear residual 
cancer cells after TURBT.  
 
 Whereas TURBT and surveillance is the preferred approach for LG disease, first 
line therapy for HG muscle invasive disease is radical cystectomy, often in combination 
with cisplatin based chemotherapy. Currently the combination treatment of GC 
(gemcitabine and cisplatin) is currently the most widely used, however the 4 drug 
therapy, MVAC (methotrexate, vinblastine, adriamycin and cispatlin), has shown similar 
effectiveness (39, 40). Despite the progress that has been made in other cancer types 
to develop targeted therapies, the paradigm for treatment of bladder cancer has not 
 11 
shifted over the past decades. Because of this, new approaches need to be taken to 
elucidate the underlying mechanisms of bladder cancer in order develop better 






 Bladder cancer is a heterogeneous disease with two main histologic subtypes, 
which have differing histology, treatment and prognosis. Bladder cancer represents a 
major health concern in the geriatric population and a burden on the healthcare 
industry. The main risk factors for bladder cancer: smoking and occupational exposures 
to aromatic amines, are preventable and hopefully with the decrease in smoking rates 
over the past decade there will be a commensurate decrease in bladder cancer 
incidence. This underscores the importance of new research and education initiatives in 
the area of disease prevention and treatment. Although early detection and advances in 
treatment have lead to increases in the five-year survival rate across all cancer types by 
19% over the past 30 years, a similar increase has not been seen in bladder cancer as 
survival rates have only increased by 8% over this same time period (1). The further 
understanding of the genomic underpinnings of this disease may help to facilitate the 




Chapter 2: Bladder Cancer Genetics and Molecular Subtyping 
 
2.1 Bladder Cancer Genetics 
 
 As there is a dichotomy in pathologic/histologic subtypes between LG papillary 
and HG muscle invasive disease, these subtypes also have distinct genomic features 
(Figure 3). LG papillary tumors are characterized by activating mutations in the 
oncogenes fibroblast growth factor 3 (FGFR3) and Harvey rat sarcoma viral oncogene 
homolog (HRAS), whereas HG muscle invasive tumors more typically have mutations 
causing the inactivation of the Retinoblastoma (RB) and p53 pathways (34, 41, 42). 
Additionally, with the advent of next generation sequencing, new highly prevalent 
mutations have been discovered, most notably the alterations in genes involved in 
chromatin modification and remodeling (43, 44). 
 FGFR3 is a receptor tyrosine kinase (RTK) that when activated, dimerizes and 
regulates cellular processes involved in proliferation, migration and survival (45). It has 
been observed that FGFR3 activating mutations occur in up to 80% of LG tumors, 
making it the most frequent alteration in bladder cancer (34). The most frequent FGFR3 
mutation found in bladder cancer is S249C, which occurs within the extracellular 
domain, allowing for its constitutive dimerization and activation (46).  Although FGFR3 
mutations do exist in HG tumors they do so at much less lower frequency, 5 -12% (43, 
44) (34). One pathway FGFR3 maybe signaling through in bladder cancer is the Ras-
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MAPK pathway. Evidence for this is that RAS mutations are frequent in bladder 
occurring in 11-15%% of tumors, however they are mutually exclusive with FGFR3 
mutations (34).  
 In addition to FGFR3 and HRAS, activation of the phosphatidylinositol 3-kinase 
(PI3K) pathway through mutations and copy number alteration of phosphatidylinositol-
4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA)  
has also been correlated with LG tumors (47-49). Interestingly, loss of phosphatase and 
tensin homolog (PTEN), which activates the PI3K pathway, is more associated in 
muscle invasive disease. This implicates the PI3K pathway in both LG and HG 
tumorigenesis, however each subtype has distinct pathway alterations, which are not 
mutually exclusive (48, 50).  
 Recently it has been noted that a significant number of chromatin modifying 
genes are mutated in bladder cancer, of which lysine (K)-specific demethylase 6A 
(KDM6A), also know as UTX, has been associated with LG tumors (44). Gui et. al. 
observed KDM6A mutations in ~30% of non-muscle invasive cases, where as the rate 
was only 15% in muscle invasive cases. Taken as a whole, LG bladder cancer has 
distinct genomic features, of which are a number that are potentially targetable.  
 As with LG bladder cancer, HG disease is associated with a unique set of 
genomic alterations. HG bladder tumors are enriched for mutations in the tumor 
suppressor gene Tumor Protein p65 (TP53) and inactivation of the RB pathway (34, 
43).  TP53 is the most commonly mutated gene in HG bladder cancer with recent 
studies showing that mutations occurring in as many as 40% of bladder tumors (43, 44). 
Disruption of TP53 leads to genomic instability though loss of cell cycle checkpoint 
 15 
control in response to DNA damage (51). Additionally, bladder cancer is the first known 
tumor type to have mutations in the cyclin-dependant kinase inhibitor 1A (CDKN1A), 
p21, (14%).  
 HG bladder cancer also has a high rate of RB pathway alterations with multiple 
genes within the pathway either mutated of having copy number alteration (Figure 4). 
RB1 is mutated in 13% of tumors sequenced by the TCGA and had copy number loss in 
an additional 14% of tumors. Immediately upstream of RB are the cyclin dependent 
kinases CDK4/6 and CDK2, and their regulators cyclin D1 and cyclin E1, which are 
encoded by CCDN1 and CCNE1 respectively. Therefore, in bladder cancer, the focal 
amplification of CCND1 (10%) and CCNE1 (12%) allow for increases in activity of 
CDK4/6 and CDK2 respectively. Unphosphorylated RB normally binds the E2F family of 
transcription factors and prevents them from interacting with DNA.  Cyclin / CDK 
complexes work to phosphorylate RB and this phosphorylation promotes its dissociation 
from E2Fs allowing them to translocate to the nucleus and bind to the promoters of 
target genes inducing cell cycle progression and proliferation (52).  
 Another mechanism by which the RB pathway can become inactivated is through 
loss of cyclin-dependent kinase inhibitor 2A (CDKN2A), which encodes the proteins 
p16/INK4A and p14/ARF. CDKN2A in only mutated in 5% of bladder tumors, however, it 
is the most frequently altered gene by copy number alteration, with 47% of tumors in the 
TCGA have some degree of copy number loss. Loss CDKN2A removes the inhibition of 
CyclinD1/CDK4/6 complex and allows for the phosphorylation of RB. 
 Upon phosphorylation by CDK4/6 or CDK2, RB releases E2F and allows for its 
translocalization to the nucleus. In bladder cancer, it has been observed that high E2F3 
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expression is associated with HG/invasive disease, additionally in the TCGA dataset 
E2F3 is amplified in 20% of the tumors (43, 53).  
 As with LG disease, next generation sequencing efforts have identified chromatin 
modifying genes that are significantly mutated in HG disease. In the TCGA data, after 
TP53, the next 3 most significantly mutated genes were Histone-lysine N-
methyltransferase (MLL2), AT-rich interactive domain-containing protein 1A (ARID1A), 
and KDM6A. Gui et. al. has previously reported that ARID1A mutations are present in 
both HG and LG disease in roughly equal numbers, additionally KDM6A were present in 
both HG and LG, however it was significantly enriched within the LG tumors (44).  
 Both LG and HG bladder tumors have distinct but not necessarily mutually 
exclusive genomic alterations. These mutations and copy number events can lead to 
unique mRNA profiles both between and within the histologic bladder subtypes. These 





Figure 3: Genomic alteration in bladder cancer  
 
Schematic of pathologic subtypes and predominate genomic alterations in each group. 




















Figure 4: RB signaling pathway 
Diagram of the RB signaling pathway. p21 and p16 inhibit CDK4/6 and CDK2 activity, 
respectively. Upon activation, the CDKs phosphorylate RB causing its disassociation 
with E2F3 allowing for E2F3 translocation to the nucleolus. E2F3 is then able to bind the 















2.2 Molecular Signatures of Bladder Cancer 
 
 As previously discussed, LG non-invasive, and HG invasive, tumors have distinct 
genomic alterations. In addition to genomic alterations, numerous group have reported 
on distinct gene expression patterns (54-60). In 2005, Blaveri et. al. reported that, using 
hierarchical clustering, muscle invasive and superficial tumors could be distinguished 
based on gene expression pattern. They then went on to identify a gene signature that 
can discriminate between superficial and muscle invasive disease, as well as signatures 
for prognosis and the classification of tumors as transitional cell carcinoma or squamous 
cell carcinoma (58). Similar approaches used by Sanchez-Carbayo et. al. resulted in 
gene profiles for the same two groups, superficial and invasive; however, they 
additionally reported generation of a signature of progression and metastasis by using 
patients with lymph node metastases and poor survival outcomes (56).  
 The Höglund group over the past 5 years has published a series of papers in 
which they have performed DNA and RNA analysis on a cohort of muscle invasive and 
superficial tumors. These papers initially identified two subtypes that they termed MS1 
and MS2 which correlated highly with LG and HG histology respectively. The MS1 
group contained increased FGFR3 mutations and was relatively genomically stable, 
whereas the MS2 group was enriched for TP53 mutations and high numbers of focal 
genomic amplifications (61). The group then went on to integrate the copy number, 
mutation and RNA data to identify five molecular clusters, of which three were primarily 
composed of invasive tumors (62). This was followed up using microarray data to 
identify five RNA based molecular subtypes of bladder cancer (Urobasal A, Genomically 
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Unstable, Infiltrate, Urobasal B, and SSC-like) . One of these subtypes encompassed 
the MS1 group previously described in Lindgren et. al., however the MS2 group was 
divided into 4 additional subtypes (63). Overall, Urobasal B and SCC-like have similar 
gene expression patterns, differing in the Urobasal B subtype having an increase in an 
FGFR3 signature. The increase in FGFR3 signature in the Urobasal B subtype may be 
the result of the Urobasal B subtype having a higher number of non-invasive tumors, 
whereas the SCC-like subtype has a majority invasive tumors (63). While the subtypes 
appear to be prognostic, it is important to note that the poor performing subtypes, SCC-
like and Urobasal B, have the highest percentage of muscle invasive tumors. In 2013, 
Sjödahl developed an immunohistological staining strategy using 20 markers to identify 
the aforementioned subtypes. This IHC based strategy was only able to accurately 
separate the Urobasal A, SCC-like, and genomically unstable tumors, the authors noted 
that the Urobasal B tumors were unable to be reproducibly identified. 
The inability to distinguish these two subtypes may be a reflection of the fact that 
the Urobasal B and SSC-like groups overall gene expression patterns are very similar. 
One of the common features of the SCC-like and Urobasal B groups is increased 
expression of keratin 5 (KRT5) and 14 (KRT14). The Chan group has since reported 
that high expression of KRT14 is correlated to poor prognosis in bladder cancer (64). 
Both of these studies were performed using cohorts of HG and LG tumors raising the 
question of whether stratification of only muscle invasive tumors along the lines of 
keratin or other gene expression signatures still provide prognostic value.  
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 To this point gene expression profiling efforts have focused on the utilization of a 
combination of LG and HG tumors, however, since pathologists can reliably identify LG 
and HG tumors, molecular signatures of these two groups are not clinically useful. 
  Multiple groups have recently addressed the identification of clinically relevant 
subtypes within HG tumors (43, 65, 66). These studies used cohorts of only HG tumors 
to identify multiple subtypes within HG bladder tumors. Choi et. al. identified three 
subtypes, basal, luminal and p53-like. The basal subtype was associated with 
decreased overall survival and high expression of high molecular weight keratins, 
similar to the SCC-like and Urobasal B subtypes reported by Sjödahl, whereas the 
luminal subtype had improved survival and enrichment for FGFR3 mutations. The third 
subtype, p53-like, was chemoresistant and had expression patterns related to wild type 
p53 expression (66).  
 In parallel, the Cancer Genome Atlas identified four subtypes, two subtypes 
(clusters I and II) had increased expression of markers of urothelial differentiation and 
decreased expression of keratins compared to cluster III and IV (43) This pattern of 
keratin expression was also a hallmark the subtypes identified by Sjödahl et. al. and the 
basal and luminal subtypes identified by Choi et. al. (63, 66). Additionally, TCGA cluster 
IV had increased expression of genes associated with immune/tumor infiltrating cells. 
This similar expression pattern was also present in the subtypes discovered by Choi 
(p53-like) and Sjödahl (infiltrated). Sjödahl noted that the tumors within the infiltrated 
group stained for increased numbers of T cells and myofibroblasts, raising the question 
of whether the differences in gene expression stem from intrinsic tumor cell differences 
or the gene expression patterns of the tumor microenvironment.. 
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 When comparing common features between these three studies, a picture 
emerges of 2-3 unique subtypes; 1) FGFR3 high, UPK high; 2) KRT high with 
squamous differentiation; 3) samples with increased tumor infiltrating cells. While these 
subtypes seem to be reproducible and have been suggested to be prognostic, there still 
remains a need to derive a clinically useful tool for discriminating the subtypes based on 
a minimal set of differentially expressed genes.  
 This dissertation presents work that defines subtypes similar to those previously 
mentioned, creates a prognostic gene expression based classifier, and more broadly 
correlates the expression patterns of bladder cancer to those seen in breast cancer. 
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 Taken together, evidence supports the notion that distinct genomic and 
transcriptional profiles characterize LG and HG disease. LG disease is characterized by 
alterations of FGFR3, PIK3CA, and RAS as well as decreased levels of markers of 
differentiation and proliferation as compared to HG disease. HG bladder tumors are 
genomically unstable as compared to LG tumors and have alterations in DNA-damage 
response and cell cycle control. Additionally, HG bladder cancer is heterogeneous with 
varying degrees in expression of ERBB2, FGFR3 and genes involved in urothelial 
differentiation. While previous studies have identified molecular subtypes with some 
success, none have created a gene expression based predictor to differentiate 
molecular subtypes within HG muscle invasive bladder cancer. 
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Chapter 3: Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks 




We sought to define whether there are intrinsic molecular subtypes of high-grade 
bladder cancer.  Consensus Clustering performed on gene expression data from a 
meta-dataset of high-grade, muscle invasive bladder tumors identified two intrinsic, 
molecular subsets of high-grade bladder cancer: “luminal” and “basal-like” that have 
characteristics of different stages of urothelial differentiation, reflect the luminal and 
basal-like molecular subtypes of breast cancer, and have clinically meaningful 
differences in outcome. A gene set predictor: Bladder cancer Analysis of Subtypes by 
Expression (BASE47) was defined by Prediction analysis of microarrays (PAM) and 
accurately classifies the subtypes. Our data demonstrate that there are at least two 
molecularly and clinically distinct subtypes of high-grade bladder cancer and validate 
the BASE47 as a subtype predictor.  Future studies exploring the predictive value of the 
BASE47 subtypes for standard of care bladder cancer therapies as well as novel 
subtype-specific therapy is warranted. 
  
                                            
1 A version of this work has been previously published and was reprinted with permission from the 
publisher. Damrauer et. al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast 




In the United States, urothelial carcinoma (UC) of the bladder is the fourth most 
common malignancy in men and eight most common in women with 74,690 new cases 
and 15,580 deaths expected in 2014 (1).  Bladder cancer is heterogeneous and can be 
histologically divided into low-grade and high-grade disease.  While low-grade tumors 
are almost invariably non-invasive (Ta), high-grade tumors can be classified based on 
whether tumors have invaded into the muscularis propria of the bladder: non-muscle 
invasive bladder cancer (NMIBC, Tis, Ta, T1) and muscle invasive bladder cancer 
(MIBC, ≥T2).  Low-grade tumors are associated with a high rate of recurrence, yet an 
excellent overall prognosis with a 5-year survival in the range of 90%.  In contrast, high-
grade, muscle-invasive bladder cancer has a relatively poor 5-year overall survival: 68% 
when T2 and decreasing to 15% for non-organ confined disease (pT3 and pT4) (1, 34).  
Along with divergent pathologies and prognosis, low-grade and high-grade UCs 
are associated with distinct genetic alterations. For example, low-grade UC is enriched 
for activating mutations in FGFR3, PIK3CA and inactivating UTX mutations, whereas 
high-grade, muscle-invasive tumors are enriched for TP53 and RB1 pathway alterations 
(41, 42, 44, 47, 62, 67-69). 
Several reports have examined the gene expression profiles of primary bladder 
tumors.  From these studies, it is apparent that low-grade, non-invasive and high-grade, 
muscle-invasive tumors harbor distinct gene expression patterns and that further 
molecular subsets can be found within low-grade and high-grade tumors (56-58, 61, 
70).  Moreover, a number of gene signatures have been developed that can predict 
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tumor stage, lymph node metastases, or bladder cancer progression (54-60). Taken 
together, there are established gene expression patterns that differentiate low-grade 
and high-grade tumors, however there is little data identifying intrinsic subtypes 
specifically within high-grade disease.  We have identified two intrinsic, molecular 
subsets of high-grade bladder cancer: “luminal” and “basal-like” with differences in 
clinical outcome.  In addition, we have developed a 47-gene predictor, “BASE47”, which 
can accurately classify high-grade UC into luminal and basal-like tumors.  The 
molecular subtypes appear to reflect different stages of urothelial differentiation and 





Consensus Cluster reveals two distinct molecular subtypes of high-grade bladder 
cancer.  
Previous studies examining the gene expression changes associated with 
bladder cancer have assessed both low and high grade tumors in aggregate (56-58, 63, 
67, 71).  We therefore looked exclusively for intrinsic subtypes of high-grade disease 
agnostic to clinical stage or outcome. We first created a meta-dataset of 262 high grade, 
muscle-invasive tumors, curated from four publically available datasets (57, 63, 71, 72)) 
(Table 2). In parallel, two independent sets of high-grade tumors from MSKCC and the 
TCGA were used as validation (MSKCC n=49, TCGA n=129) (69).  In both the meta 
and MSKCC datasets, Consensus Cluster identified two groups (K=2) as the optimal 
number of molecular subtypes as defined by the criterion of subclass stability (Figure 
5A, 5B 5C and Supplemental Figure 1A, 1B).   
To validate that the gene expression changes that define the two subtypes are 
similar, we determined the correlation between the median gene expression (using all 
common genes between datasets) for each subtype (yellow = correlation, blue=anti-
correlation) (Figure 5D). There appeared to be a high level of correlation between the 
meta-dataset Cluster 1 (K1) and MSKCC and TCGA Cluster 2 (K2) as well as the meta-
dataset Cluster 2 (K2) and MSKCC and TCGA Cluster 1 (K1).  Therefore, the intrinsic 
molecular subtypes defined by independent discovery in the two datasets are defined 




The intrinsic molecular subtypes of bladder cancer differentially express markers 
of urothelial differentiation.  
To understand the gene expression patterns that differentiate the intrinsic 
subtypes of high-grade bladder cancer, we performed 2-class significance analysis of 
microarrays (SAM) comparing Cluster 1 and Cluster 2 from the meta-dataset.  2,393 
genes were found to be differentially expressed (FDR cut off of 0) (Apendix A). The 
intrinsic molecular subtypes were characterized by gene expression patterns 
representative of urothelial differentiation. Cluster 1 (K1) of the meta-dataset, expressed 
high levels of the high molecular weight keratins [HMWK] (KRT14, KRT5, KRT6B) and 
CD44, which are expressed in urothelial basal cells (33, 73).  In contrast, Cluster 2 (K2) 
expressed high levels of uroplakins (UPK1B, UPK2, UPK3A) as well as the low 
molecular weight keratin (LMWK), KRT20 (Figure 5E), characteristic of urothelial 
umbrella cells (73). Moreover, the gene expression of KRT5 was inversely correlated 
with both UPK2 and KRT20 across all tumors (Supplemental Figure S1D and S1E).  
Similar findings were seen in the MSKCC dataset (Supplemental Figure S1F-S1G).  
Ingenuity Pathway Analysis (IPA) was used to understand if processes other 
than urothelial differentiation were associated with the intrinsic subtypes. IPA revealed 
that Cluster 1 (K1) tumors were enriched in gene pathways involving cancer, cell 
survival, as well as cell movement (Figure 5F). In aggregate, these findings 
demonstrate that the two molecular subtypes of high-grade, muscle-invasive bladder 
cancer represent different stages of urothelial differentiation, leading us to name 
Clusters 1 and 2 “Basal-like” and “Luminal”, respectively.   
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Bladder Cancer Analysis of Subtypes by Expression of 47 genes (BASE47) 
accurately predicts basal-like and luminal subtypes. 
We next sought to define a minimal set of genes that could accurately classify 
bladder tumors into the luminal and basal-like bladder intrinsic subtypes. To this end, 
we applied prediction analysis of microarrays (PAM) to our meta-dataset and derived a 
47-gene signature (Appendix B) that could accurately classify basal-like and luminal 
tumors relative to Consensus Cluster calls (Figure 6). A pairwise comparison of the 
subtype classification by Consensus Cluster relative to classification by BASE47, 
showed a strong correlation in the Meta Dataset, MSKCC  and TCGA datasets (both chi 
square p < 0.001).  
 
BASE47 Subtypes correlate to previously published tumor subtypes 
 Two papers published concurrently with Damrauer et. al. reported multiple 
molecular subtypes within HG bladder cancer. To determine if our subtypes were similar 
to those published by the TCGA and Choi et. al. subtype calls on the TCGA dataset 
were obtained from aforementioned authors. The TCGA data set was then hierarchically 
clustered by the BASE47 gene list and each group’s subtype calls were overlaid (Figure 
7A). The number of tumors called basal or luminal by the BASE 47 were then graphed 
according to the calls from Choi et. al. and the TCGA (Figure 7C and 7D). Overall the 




Intrinsic bladder subtypes have differential survival.  
We next asked whether the intrinsic bladder subtypes, had prognostic 
significance. Basal-like tumors (as determined by BASE47) had a significantly 
decreased disease-specific and overall survival (p=0.0194 and p=0.0198 respectively) 
(Figure 8A).  Moreover, of the clinicopathologic features available to us in the MSKCC 
dataset (TNM Stage, mixed histology, and gender), only BASE47 subtype was found to 
be significant for disease specific survival by univariate analysis (Table 3, and 
Supplemental Figure S2A).  Furthermore, to assess the prognostic value of the BASE47 
relative to published prognostic signatures derived from muscle-invasive, high-grade 
tumors, we generated “Good” and “Poor” prognosis calls on the MSKCC tumors using 
the published gene lists (56, 58) (Supplemental Figure S2B and S3C).  However, 
neither gene signature held prognostic value (Supplemental Figure S2D and S2E).   
Therefore, the BASE47 intrinsic bladder subtypes not only reflect bladder cancer 
biology but have prognostic value.   
Interestingly, while the BASE47 predictor was developed on muscle-invasive 
tumors, we also noted that when applied to a meta-dataset of superficial tumors, it 
classified a significant proportion them as basal-like (Figure 8C), suggesting that the 
intrinsic subtypes may exist in non-muscle invasive bladder cancer and that the 
BASE47 might serve as a prognostic marker of recurrence and / or progression in non-
muscle invasive bladder cancer.  
 
The intrinsic subtypes are associated with distinct genomic alterations. 
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The MSKCC tumors have been previously characterized for bladder cancer 
relevant genetic alterations (69). We examined the relative enrichment of these 
molecular events in the bladder subtypes (Figure 8D).  Notably, FGFR3 (p<0.001) and 
TSC1 (p=0.02) mutations were significantly enriched in the luminal subtype while RB1 
pathway alterations were significantly enriched in basal-like bladder cancer (p = 0.009).  
 Multiple studies have shown that females have a poorer bladder cancer specific 
outcome than males (74). There was a trend towards enrichment of basal-like tumors in 
female patients in the MSKCC dataset (Figure 8D, p = 0.1137), and a significantly 
higher incidence of basal-like bladder cancer in female patients in the meta-dataset with 
annotated gender and TCGA (Figure 8E and Figure 9). This enrichment of basal-like 
bladder cancer may in part explain the decreased cancer specific outcomes in women.  
Additionally, the TCGA provided clinical data associated with race, grade and 
histology. Interestingly, the papillary histology that is classically associated with LG 
tumors, is enriched in the luminal subtype (p=0.018). The luminal subtype was also 
enriched for low-grade tumors, muscle invasive tumors (p=0.011). Basal tumors, as 
previously noted, were enriched for female patients as well as trended toward 
enrichment in African Americans (p=0.07), where as luminal tumors were enriched for 
Asian patients (p=0.0004) (Figure 9).  
 
Basal-like bladder cancer is enriched for the signatures of basal-like breast 
cancer and tumor initiating cells (TIC).  
A number of genes fundamental for breast development and breast cancer were 
co-regulated with genes that regulate urothelial development (Supplemental Figure S3, 
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breast cancer related genes: red, urothelial related genes: blue).  Moreover, when Gene 
Set Enrichment Analysis (GSEA) was performed on the meta-dataset to identify gene 
sets enriched in the intrinsic subtypes, multiple breast cancer-related gene signatures 
were enriched in the basal-like bladder subtype as well as signatures related to 
mammary stem cells (Appendix C). Conversely, multiple breast cancer derived luminal 
gene signatures were enriched in the luminal bladder cancer subtype. In keeping with 
these findings, we saw that a previously published bladder TIC signature (33) was 
enriched in the basal-like subtype by both hierarchical clustering (chi squared p= 2x10-
16) (Supplemental Figure S4A) as well as by GSEA (Supplemental Figure S4B) 
suggesting that basal-like bladder cancer possesses a more “stem-like” phenotype, 
similar to previous observations described in basal-like breast cancer (75).   
 
The intrinsic bladder subtypes reflect the attributes of breast cancer subtypes 
We next asked whether the basal-like and luminal bladder cancer subtypes 
correlated with any of the previously defined molecular subtypes of breast cancer (76, 
77).   To this end, we generated breast molecular subtype classifications (Basal, Her2-
enriched, Luminal A, Luminal B, and Normal-like) on two independent sets of breast 
tumors (TCGA Breast (78) and UNC337 (79))  using the PAM50 nearest centroid 
classifier (80). To see whether the gene expression patterns of luminal and basal-like 
bladder cancer were reflected in the intrinsic breast subtypes, we correlated the centroid 
gene expression (using the breast intrinsic gene list) between the bladder (bladder 
tumors) and breast (breast tumors) subtypes (Figure 10A: yellow=correlation, blue=anti-
correlation).  Basal-like bladder cancer had positive correlations to basal-like breast as 
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well as normal-like breast whereas luminal bladder cancer had positive correlations to 
both lum A and lum B breast subtypes. A similar comparison using published gene 
expression data from The Cancer Genome Atlas (TCGA) showed that while there were 
other cross-cancer similarities, the molecular association between breast and bladder 
cancer was relatively strong (Supplemental Figure S4C).  Finally, strikingly, when the 
PAM50 was applied to our meta-dataset of bladder tumors, there were positive 
correlations between basal-like bladder tumors and the basal centroid and luminal 
bladder tumors and the luminal A centroid (Supplemental Figures 4D and 4E). 
To better visualize this association, we hierarchically clustered the bladder 
tumors using a comprehensive list of 1906 genes (1,426 were present in the meta-
dataset) that have been previously shown to define the intrinsic subtypes of breast 
cancer (80). The breast specific gene list clustered the bladder tumors along the lines of 
basal-like and luminal bladder subtypes (chi squared p=2.2e-16) (Supplemental Figure 
4F).  Furthermore, gene signatures representative of basal-like and luminal breast 
cancer as well as well-defined breast cancer related oncogenic pathway signatures 
faithfully clustered basal-like and luminal bladder tumors in both datasets (Figure 10B 
and Supplemental Figure 5A).  Basal-like bladder tumors displayed enhanced MYC and 
E2F3 pathway signatures while luminal tumors appeared enriched in the set of genes 
characteristic of the HER2 amplicon. These data in aggregate strongly demonstrate that 
the gene expression patterns that distinguish basal-like and luminal bladder cancer 
reflect the RNA expression patterns that define the intrinsic subtypes of breast cancer.  
 
A subset of basal-like bladder tumors are claudin-low 
 35 
The recently described claudin-low molecular subtype of breast cancer is 
characterized by low expression of the claudin tight junction proteins (claudins 3, 4, and 
7) and upregulation of markers of EMT as well as stem cell-like features (79).  Tumors 
from the meta-dataset were classified based on an 807 gene signature, which 
accurately defines claudin-low breast cancer (79). Overall, 16% of the meta-dataset 
tumors (Figure 5A) and 26% of the MSKCC tumors (Supplemental Figure S8) were 
identified as claudin-low. When clustered based on genes that define key molecular 
pathways in claudin-low breast tumors (Breast cancer subtype markers, EMT markers, 
and TIC markers) (Figure 11A and Supplemental Figure 5B), the claudin-low bladder 
tumors displayed expression patterns indicative of claudin-low breast tumors.  
Therefore, a subset of basal-like bladder tumors have claudin-low features.  
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3.4 Discussion  
 
Using independent discovery in distinct datasets, we have defined two molecular 
subsets of high-grade urothelial carcinoma.  The subtypes harbor molecular features 
that reflect different stages of urothelial differentiation.  Luminal bladder cancers 
express markers of terminal urothelial differentiation such as those seen in umbrella 
cells (UPK1B, UPK2, UPK3A, and KRT20) while basal-like tumors express high levels 
of genes that typically mark urothelial basal cells (KRT14, KRT5, and KRT6B). The 
basal cell compartment is a common feature of most organs with stratified or 
pseudostratified epithelium. It is characterized by its proximity to the basal lamina and is 
thought to harbor multipotent tissue stem cells important for normal tissue homeostasis 
and orderly regeneration after injury. Because basal cells are a long-lived population, 
they are potentially more likely to incur multiple genomic alterations including changes 
in their chromatin landscape.  In this regard it is interesting to note that there appears to 
be a relatively high prevalence of mutations in histone and chromatin modifying genes 
in urothelial carcinoma (44). 
The luminal and basal-like subtypes of bladder cancer reflect many of the 
hallmarks of the intrinsic breast cancer subtypes.  For example, a number of basal-like 
and luminal breast cancer specific gene signatures were enriched in the corresponding 
bladder subtype including bon a fide luminal breast cancer pathways such as GATA3 
and estrogen receptor signaling in the luminal bladder subtype.  Moreover, the gene 
expression patterns that define luminal and basal-like bladder cancers corresponded 
highly with the gene expression patterns that define luminal (Lum A and Lum B) and 
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basal-like breast cancer. These similarities may reflect the presence of urothelial basal 
cells and their corollary, the basal/myoepithelial cells of the breast.  In both tissues, 
these basal cells represent a multipotent “stem/progenitor cell” population (81, 82) and 
their similar functional roles may explain their similar molecular profile.   
There were differences between the breast and bladder cancer intrinsic subtypes 
as well.  For example, while we identify a claudin-low subtype of bladder cancer. In 
contrast to breast cancer in which claudin-low tumors arise from multiple intrinsic 
subtypes, all of the claudin-low bladder tumors were a subpopulation of the basal-like 
subtype. Furthermore, despite a subset of luminal bladder tumors having elevated 
expression of the HER2 amplicon, we did not see any significant correlation to the Her2-
enriched breast subtype by our correlation matrix (Figure 10A).       
Our study has created a gene signature, the BASE47, which accurately 
discriminates intrinsic bladder subtypes.  Interestingly, even in superficial bladder 
tumors, there appears to be a significant number of basal-like tumors.  While the 
characteristics of our meta-dataset did not allow us to determine whether the subtypes 
were prognostic or predicted the progression to muscle-invasive disease in superficial 
bladder tumors, these will be important questions to answer and have important clinical 
implications such as early cystectomy for patients with high-grade T1 disease.  The 
ability to accurately classify basal-like and luminal bladder subtypes with only 47 genes 
(BASE47) should allow the adoption of the BASE47 to formalin-fixed, paraffin 
embedded (FFPE) tissues allowing its widespread use.  
Female patients with UC have worse outcomes to males, even when controlled 
for other known prognostic variables, such as stage and grade (74). Interestingly, we 
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found that females have an increased incidence of basal-like bladder cancer, which is 
associated with a worse outcome.  To what extent this increased prevalence of basal-
like bladder tumors in women contributes to their poorer outcome remains unclear.  
Moreover, whether this association suggests that the pathogenesis of bladder cancer in 
females (i.e. chronic inflammation) is different should be of future interest. 
In summary, the basal-like and luminal intrinsic subtypes of bladder cancer 
reflect many aspects of physiologic urothelial development as well as breast cancer 
biology.  These findings underscore the notion that there are common themes 
underlying the development and maintenance of solid tumors that extend beyond 
overlapping mutational spectra. An appreciation of subtype heterogeneity has 
substantially furthered our understanding of breast cancer biology. Our results suggest 
that the intrinsic subtypes of high grade bladder cancer strikingly reflect many aspects 
of breast cancer. It will be particularly interesting to see whether the bladder subtypes, 
like the breast subtypes are useful for stratification for therapy.  
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3.5 Materials and Methods 
 
Training Dataset Analysis – A meta-dataset was generated by combining the muscle 
invasive (≥T2) UC samples from four publically available data sets (GSE13507, 
GSE31684, GSE32894, GSE5287) with clinical annotation provided by the Michor Lab 
(Dana-Farber Cancer Institute, Boston MA). The data were normalized, median 
centered by gene, and merged into a single dataset consisting of n=262 tumors. The 
Mean Absolute Deviation (MAD) was computed across samples by gene. Genes with a 
MAD score of >0.10 were selected for clustering analysis (7303 genes). Consensus 
hierarchical clustering was performed as described previously (83) with 90% resampling 
and 1000 iterations. Two Class significance analysis of microarrays (SAM; FDR=0) was 
performed to generate subtype-specific gene lists (84). The significant genes and 
corresponding fold changes as determined by SAM were analyzed by Ingenuity IPA 
(Ingenuity Systems, Redwood City, CA) for predicted pathway activation. Gene set 
enrichment analysis (GSEA) was performed comparing basal and luminal tumors 
against MSigDBv4.0c2 (85, 86).  
 
Validation Datasets – Gene expression data were derived from 49 high-grade tumors 
from Memorial Sloan-Kettering Cancer Center (MSKCC) using Human HT-12 
Expression BeadChip arrays (Illumina) as previously described 
(69). The MSKCC and TCGA datasets were normalized, median centered and the MAD 
was computed across samples by gene. Genes with a MAD score of >0.10 were 
selected for clustering analysis. Consensus clustering was performed identically to the 
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meta-dataset (83). The resulting subtypes assignments for K=2 using consensus cluster 
plus were used to validate the training dataset. Centroids were generated for both the 
Meta and MSKCC datasets using all common genes and correlations were calculated 
by 1-Pearson correlation.  Copy number alterations and hotspot mutation analyses were 
determined as previously described(69).  
 
Subtype Predictor – Prediction Analysis of Microarrays (PAM) was used to determine 
the minimal number of genes that could accurately predict subtype classification on the 
meta-dataset using the consensus clustering calls as the reference (87). The resulting 
47-gene predictor (delta=6.3) was then used to classify the MSKCC samples (87). 
Tumors were then analyzed for enrichment of mutations or copy number alteration (69) 
by chi square or fisher’s exact test when appropriate. Categoric survival analyses were 
performed using a log-rank test and visualized with Kaplan-Meier plots. The BASE47 
was then applied to superficial tumors, which were excluded from the Meta dataset. The 
superficial were normalized and median centered as previously described and BASE47 
calls were made using PAM. 
 
Correlation to Breast Cancer – The breast cancer dataset from the Cancer Genome 
Atlas project (78) as well as a UNC dataset, UNC337 (GSE18229) mRNA datasets 
were log transformed and median centered. Breast and bladder subtypes were 
compared using a pearson correlation (visualized as 1-pearson) by the median gene 
expression of the breast cancer intrinsic gene list (80). Heatmaps were generated using 
the 1-pearson values. PAM50 calls were made on the individual data sets that 
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composed the meta dataset and the MSKCC dataset as described in (80). Breast 
cancer signature enrichment was performed as described in (88), samples were 
hierarchically clustered and visualized on a heatmap. Claudin low subtype calls were 





Table 2: Dataset Characteristics  
   
 Training Datasets (Meta) Validation Dataset 
 Als  Kim  Riester  Sjödahl  Iyer 
GEO ID GSE5287 GSE13507 GSE31684 GSE32894 cBioPortal 
      
Clinical Characteristic No. No. No. No. No. 
      
    Sex      
              Male NA NA 57 68 35 
              Female NA NA 21 25 14 
      
    Stage         
               pT0 0 23 5 116 4 
               pT1 0 80 10 97 6 
               pT2 0 31 17 85 5 
               pT3 0 19 42 7 17 
               pT4 30 11 19 1 16 




Table 3: MSKCC - Univariable Cox Regression Analysis of Disease Specific Survival 
Variable Comparison HR 95% CI p-value 
BASE47 Basal vs Luminal 3.1722 1.144-8.798 0.0265 
Stage III vs II 3.188 0.040-25 0.27 
 IV vs II 3.409 0.434-26.76 0.243 
Mixed Histology  1.034 0.438-2.438 0.939 





Figure 5: Discovery of two distinct subtypes of bladder cancer 
(A) Consensus Clustering was performed on 262 muscle-invasive tumors, curated from 
four publically available datasets (Meta dataset), yielding two subtypes. (B) Consensus 
Clustering was independently performed on a dataset of high-grade bladder tumors 
obtained from MSKCC (n=49) as well as the (D) TCGA dataset (n=129). (C) The 
median gene expression of all common genes between the datasets were compared 
and the Pearson correlation was plotted (yellow=correlation, blue=anti-correlation).  
Numerical values represent the Pearson correlation. (E) Gene expression of epithelial 
and urothelial markers were visualized by heatmap, supervised by consensus cluster 
plus calls in the meta-dataset. KRT5 mRNA expression was plotted (F) Significantly 
differentially expressed genes between K1 and K2 from the meta-dataset and their 
respective fold change, as determined by 2-class SAM (3,374 genes, FDR=0) were 
analyzed for predicted pathway enrichment by Ingenuity Pathway Analysis (IPA). 
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Figure 6: Generation of the BASE47 subtype predictor 
(A) Prediction Analysis of Microarrays (PAM) was performed using the basal-like and 
luminal subtype calls generated by consensus cluster plus. A predictor consisting of 47 
genes was generated that accurately predict the subtypes from the meta-dataset 
training set (p<0.001) as well as a MSKCC validation dataset (45/47 gens 
present)(p<0.001). (B) The BASE47 gene list was used to cluster the MSKCC dataset, 
showing two distinct expression profiles.  BASE47 genes are listed along the right.  
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Figure 7: BASE47 calls are similar to previously published calls for the TCGA 
dataset (A) Consensus clustering of the TCGA dataset by BASE47 gene signature. 
Graphs representing the number of basal and luminal tumors and how they were 
classed according to (B) Choi et. al. and (C) the TCGA. 
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Figure 8: Luminal and basal bladder cancer have differential survival and are 
associated with distinct genomic alterations 
A Kaplan-Meier plot for muscle-invasive tumors from the MSKCC set (≥ pT2) was 
generated for (A) disease specific and (B) overall survival. Basal-like tumors (n=22) had 
a significantly decreased disease free and overall survival as compared to luminal 
tumors (n=16)  (p=0.0194 and p=0.0081 respectively). (C) Superficial tumors, which 
were not included in the generation of BASE47, were subjected to BASE47 subtype 
prediction. (D) Sequencing was performed on common mutations in bladder cancer. 
FGFR3 and TSC1 alterations were significantly enriched in luminal bladder cancer 
whereas alterations of the RB1 pathway were enriched in basal-like bladder cancer. 
TP53 alterations were distributed evenly in both subtypes. (D) Basal-like and luminal 
tumors from the meta-dataset were annotated for gender (2/4 datasets). Basal-like 
bladder cancer was significantly enriched in female patients (chi square p 
value=0.0203).
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Figure 9: Basal and luminal bladder cancer have distinct clinical features. 
Clinical data for the TCGA tumors were correlated to the basal and luminal subtype 
calls. Basal bladder cancer was enriched for female patients (p=0.036) trended toward 
enrichment in African American patients (p=0.07) Luminal bladder cancer was enriched 
for Asian patients p=0.0004), as well as papillary histology (p=0.018) and low grade 



























Figure 10: Basal-like and luminal bladder cancer correlate to the intrinsic 
molecular subtypes of breast cancer 
 (A) Median gene expression of genes present in the breast cancer specific intrinsic 
gene list were determined for each bladder and breast subtype and 1-pearson 
correlation was calculated comparing bladder subtypes (bladder tumors) to breast 
subtypes (breast tumors) in both the Breast TCGA and UNC337 datasets. (B) Waterfall 
plots representing the correlation of basal-like (black) and luminal (red) bladder tumors 
to the Basal and (C) Luminal A breast cancer centroid as determined by the PAM50. (D) 
The meta-dataset of bladder tumors were clustered by genes that defined the intrinsic 
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subtypes predicted by the breast cancer PAM50 bioclassifier. (E) The meta dataset 
tumors were run against previously published breast cancer related gene sets and the 
resulting pathway scores were clustered by hierarchical clustering and heatmaps were 




Figure 11: A subset of basal-like bladder tumors are claudin-low 
 (A) The meta dataset was hierarchically clustered using representative genes known to 
define claudin-low breast tumors. Claudin low subtype designation was performed using 
a previously defined 807 gene signature. (B) A Kaplan-Meier plot was generated 
comparing disease specific survival and (C) overall survival of the basal, luminal and 
























































Figure 12: Proposed model of urothelial tumorgenesis and relationships to 
intrinsic subtypes of breast cancer 
(A) Low-grade (LG) and high-grade (HG) urothelial carcinoma are associated with 
specific genetic alterations. Low-grade papillary tumors often incur FGFR3, RAS, and 
receptor tyrosine kinase alterations, while high-grade tumors are characterized by loss 
of tumor suppressor genes such as PTEN, TP53, and RB1 pathway alterations. While 
most LG tumors recur as LG, a small proportion will progress to HG tumors in 
association with PTEN, TP53, and RB1 pathways alterations.  We propose that LG 
tumors that progress are likely to be papillary, HG tumors of the luminal molecular 
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subtype. De novo HG tumors are likely to be basal-like in expression subtype.  Whether 
luminal, non-papillary tumors arise from LG tumors is unclear.  (B) Diagram showing the 
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Supplemental Figure 1: Consensus Clustering defines two distinct molecular 
subtypes of invasive bladder cancer (A) Consensus Cumulative Distribution Function 
(CDF) plot were generated by Consensus Cluster Plus clustering on the Meta-dataset 
and the (B) MSKCC dataset. (C) Genes representative of epithelial and urothelial 
differentiation were used to generate a heatmap, supervised by subtype in the MSKCC 
dataset. KRT5 mRNA expression was plotted against UPK2 and KRT20 expression in 




Supplemental Figure 2: Clinical variables are not significantly associated with 
disease specific or overall survival and previous muscle invasive signatures are 
not prognostic in the MSKCC dataset.  (A) Kaplan-Meier plots for disease specific 












































































































































































































survival were generated based on gender, stage and whether a tumor was pure 
urothelial or of mixed differentiation. (B) The MSKCC dataset was hierarchically 
clustered by prognostic signatures from Blaveri et. al. and (C) Sanchez-Carbayo et. al. 
(D,E) The tumors were then classified based on the two major clusters (black and red) 
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Supplemental Figure 3: Makers of luminal breast cancer are co-expressed with 
markers of urothelial differentiation Hierarchal clustering was performed on all 
significantly differentially expressed (2-class SAM) genes from the Meta-dataset. The 
node containing the urothelial makers of differentiation, UPK2 and UPK1A, was isolated 
and overlapped with the Parker et. al. breast cancer intrinsic gene list. A significant 
number of genes within the node overlapped the breast cancer gene list (19/65 genes, 










































































































































































Supplemental Figure 4: Basal-like bladder cancer possesses tumor initiating cell 
traits and is molecular similar to basal breast cancer.  (A) A 467-gene signature of 
bladder TIC expression (330/467 genes present in the meta-dataset) was used to 
hierarchically cluster the tumors from the meta-dataset. (B) GSEA was performed using 
the bladder TIC gene set. The basal subtype was significantly enriched for the TIC 
signature (nominal p value=0.006). (C) The intrinsic breast cancer gene list was used to 
correlate basal, her2, Lum A and Lum B breast tumors from the TCGA to the basal and 
luminal bladder cancer subtypes from the Meta-dataset tumors as well as 7 additional 
tumors from The Caner Genome Atlas (TCGA). (D) Waterfall plots representing the 
correlation of basal-like (black) and luminal (red) bladder tumors to the Basal and (E) 
Luminal A breast cancer centroid as determined by the PAM50. (F) The meta-dataset of 
bladder tumors were clustered by genes that defined the intrinsic subtypes of breast 
cancer. Tracks indicated bladder cancer subtypes as well as subtypes predicted by the 




Supplemental Figure 5: Basal, luminal, Caludin Low and oncogenic breast cancer 
signatures are associated with intrinsic molecular subtypes of bladder cancer. (A) 
The MSKCC datasets tumors were run against previously published breast cancer 
related gene sets (88) and the resulting pathway scores were clustered by hierarchical 
clustering and heatmaps were generated for visualization. (B) The MSKCC dataset was 
hierarchically clustered using representative genes known to define claudin-low breast 
tumors. Claudin low subtype designation was performed using an 807 gene signature. 
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Chapter 4: Future Directions 
4.1 BASE47 as a prognostic tool 
 
Bladder cancer is a heterogeneous disease, histologically and molecularly. We 
have shown, using multiple independent datasets, that there are at least two molecular 
subtypes within HG, muscle invasive bladder cancer that are associated with distinct 
transcriptional and genomic patterns, clinical factors and survival. Additionally, these 
subtypes, basal and luminal bladder cancer, share molecular feature with basal and 
luminal breast cancer, respectively. However, two critical questions remain that need to 
be addressed in order for these subtypes to become clinically valuable: can the 
BASE47 be adapted to a clinically relevant platform and are there expression 
differences between the subtypes that can be exploited for the development of targeted 
therapies.  
The prognostic ability of the BASE47 creates the potential for it to be a clinically 
relevant tool. Our current study allowed us to assess the BASE47’s prognostic ability on 
muscle invasive disease; however, future work to determine its ability to predict 
reoccurrence and progression of non-muscle invasive and muscle invasive disease 
alike, is a critical need. This new information will be key in the determination of therapy 
for patients; one could envision a patient who presents with a HG non-invasive tumor, 
which is classified as basal, undergoing a more aggressive therapeutic regimen, 
whereas a patient with a luminal tumor would undergo a more conservative approach. 
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However for this to come to fruition a mechanism for making this assessment on these 
tumors in a clinical setting must be created. To this end, we have been working to 
transition the BASE47 to the NanoString platform.  
NanoString, which is the basis for the FDA approved Prosigna assay for breast 
cancer, utilizes a fluorescently labeled cDNA oligo code-set for accurate quantification 
of gene expression from formalin fixed paraffin embedded (FFPE) samples, as well as 
fresh frozen tumor (89, 90).  
We are currently assembling a new dataset of previously unanalyzed tumors and 
the corresponding clinical data. All tumors have both fresh frozen and FFPE material, 
allowing us to validate NanoString derived BASE47 calls from FFPE against the gold 
standard of fresh frozen tumors run on microarray.  RNA will be extracted from fresh 
frozen tumor samples and analyzed via microarray. The BASE47 will then be applied to 
the dataset to make subtype calls. In order to develop gene level cutoffs for the 
NanoString assay, RNA from FFPE samples will be extracted and gene expression of 
the BASE47 genes will be determined by NanoString. The subtype assignments derived 
from the microarray will then be applied to the NanoString gene expression data to 
determine the proper expression cutoffs, allowing us to make future BASE47 calls de 
novo from NanoString data. Once the NanoString assay has been validated, we will be 
able to used FFPE samples address the larger questions such as the ability of the 
BASE47 assess overall prognosis and reoccurrence in both non-invasive and invasive 
disease, as well as determine correlations between subtypes and response to therapy. 
  
 66 
4.2 BASE47 as a predictive tool 
In addition to understanding the relationship between the subtypes of bladder 
cancer and their response to therapy, the expression differences between the subtypes 
may aid in the development of novel targeted therapy. This is of critical importance as 
there are currently no FDA approved targeted therapies for bladder cancer, additionally 
as this is a disease of elderly population many patients are unable to undergo traditional 
cisplatin based therapy do to toxicity related complications. Current small molecule 
inhibitors which are approved or in clinical trial for other disease types may show 
effectiveness within either basal or luminal bladder cancer.  
Luminal bladder cancer has over expression of the ERBB2 oncogene as 
compared to basal bladder cancer, this suggests that using a targeted therapy such as 
Trastuzumab may be an appropriate therapy. Trastuzumab is an antibody against the 
Her2 receptor and is FDA approved for use in Her2+ breast cancer as well as 
metastatic gastric and gastroesophageal cancers in which Her2 is overexpressed by 
amplification or IHC staining. 
Additionally, a large proportion of luminal tumors have overexpression of FGFR3. 
Currently, there are 25 open clinical trials for Dovitinib, a small molecular inhibitor 
targetign FGFR3, one of which is a Phase II trial for urothelial carcinoma 
(NCT01732107). However, the inclusion criteria restricts the study to only non-invasive 
disease, T1 or less. Our data suggest invasive tumors may also drive a benefit from this 
therapy and that the BASE47 maybe an appropriate tool for predicting sensitive to 
FGFR3 inhibition. 
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The development of targeted therapy for basal bladder cancer is of utmost 
importance as basal bladder cancer has a worse prognosis, compared to luminal 
bladder cancer. CDK6 ranked as one of the most differentially regulated genes between 
basal and luminal bladder cancer. CDK6, along with CDK4 play a key role in RB 
mediated cell cycle progression. Palbociclib, a CDK4/6 inhibitor developed by Pfizer, is 
currently in Phase III clinical trials for metastatic breast cancer (NCT01942135). In a 
Phase II clinical trial, Palbociclib in combination with letrozole increased patient 
progression free survival to 20.2 months from 10.2 for letrozole alone. This therapy 
shows promise and should be further investigated in basal balder cancer. However, 
when carrying out such a trial, it should be noted that basal tumors also contain down 
stream alteration such as RB1 mutations that would render tumors resistant to CDK4/6 
inhibition. The selection of patients for the trial that have increased expression of 
CDK4/6 along with tumors that have CCND1 amplifications present, yet in the absence 
of RB1 mutations would be critical for the success of this trial. Based on a mutational 
analysis of the TCGA data, ~30% of patients would meet the criteria and be dimed to 
have potentially sensitive tumor (Figure 13).  
Overall, the adoption of the BASE47 to a clinically useful platform would result in 
the better classification of bladder tumors. This would also allow for the use of 
differential gene expression patterns between basal and luminal tumors to inform 
treatment options and the application of novel targeted therapies for bladder cancer. 
More generally, the subtype classification of basal and luminal may not be 
confined to bladder and breast cancer. In other tumor types, such as prostate, it has 
been demonstrated that mutations in luminal vs. basal epithelial cells lead to tumors 
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molecularly distinct tumors in mice (91). This suggests that the basal and luminal 
subtypes may be more broadly applicable to tumors of epithelial origin. As more data 
become available with the completion of the TCGA, these questions can be addressed. 
 




Figure 13: Sensitive to CDK4/6 inhibition by mutational status TCGA tumors were 
classified based on non-silent mutations and copy number alterations (+2,-2 threshold) 




















APPENDIX A: SAM GENE LIST 
	  
Two	  Class	  SAM	   	  	   	  	   	  	   	  	   	  	  
Basal	  vs	  Luminal	  	   	  	   	  	   	  	   	  	   	  	  
FDR=0	   	  	   	  	   	  	   	  	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	  
Basal	  Postive	  
Genes	   	  	   	  	   	  	   	  	   	  	  





CHST15	   9.2814	   0.8233	   0.0887	   1.7694	   0	  
EMP3	   9.0764	   0.6595	   0.0727	   1.5795	   0	  
CORO1C	   8.9796	   0.4885	   0.0544	   1.4030	   0	  
AHNAK2	   8.8714	   1.1001	   0.1240	   2.1437	   0	  
CLIC4	   8.8713	   0.5196	   0.0586	   1.4336	   0	  
CDK6	   8.8580	   0.6742	   0.0761	   1.5958	   0	  
MSN	   8.8440	   0.6955	   0.0786	   1.6194	   0	  
SACS	   8.7394	   0.4444	   0.0508	   1.3607	   0	  
PDGFC	   8.6196	   0.6549	   0.0760	   1.5745	   0	  
PALLD	   8.6056	   0.6431	   0.0747	   1.5617	   0	  
GLIPR1	   8.5678	   0.6666	   0.0778	   1.5873	   0	  
MT1X	   8.5583	   1.0428	   0.1218	   2.0602	   0	  
TUBB6	   8.4656	   0.6735	   0.0796	   1.5949	   0	  
OSMR	   8.3502	   0.4951	   0.0593	   1.4094	   0	  
PRKCDBP	   8.3327	   0.7246	   0.0870	   1.6525	   0	  
CD14	   8.3009	   0.7561	   0.0911	   1.6889	   0	  
DEGS1	   8.2501	   0.5680	   0.0689	   1.4825	   0	  
PRRX1	   8.2416	   0.8125	   0.0986	   1.7563	   0	  
FLNA	   8.2207	   0.3313	   0.0403	   1.2581	   0	  
LRIG1	   8.2050	   0.5522	   0.0673	   1.4663	   0	  
DPYD	   8.1710	   0.5668	   0.0694	   1.4813	   0	  
ANXA5	   8.1057	   0.5642	   0.0696	   1.4786	   0	  
PTGS1	   8.0881	   0.4751	   0.0587	   1.3900	   0	  
ALOX5AP	   8.0850	   0.8974	   0.1110	   1.8627	   0	  
NOD2	   8.0651	   0.5727	   0.0710	   1.4874	   0	  
FAP	   8.0510	   0.8080	   0.1004	   1.7507	   0	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DSE	   8.0472	   0.6558	   0.0815	   1.5755	   0	  
CERK	   8.0371	   0.4124	   0.0513	   1.3309	   0	  
TNC	   8.0014	   0.7539	   0.0942	   1.6863	   0	  
MPP1	   7.9554	   0.4775	   0.0600	   1.3924	   0	  
TLR1	   7.9506	   0.5870	   0.0738	   1.5021	   0	  
MT2A	   7.9128	   1.0304	   0.1302	   2.0426	   0	  
TNFAIP6	   7.8870	   0.8055	   0.1021	   1.7478	   0	  
SNAI2	   7.7733	   0.6866	   0.0883	   1.6095	   0	  
RRAS	   7.7132	   0.5138	   0.0666	   1.4278	   0	  
FAS	   7.6969	   0.3831	   0.0498	   1.3042	   0	  
KCTD12	   7.6850	   0.3398	   0.0442	   1.2656	   0	  
KIAA0922	   7.6503	   0.3637	   0.0475	   1.2867	   0	  
ST3GAL6	   7.6146	   0.4015	   0.0527	   1.3209	   0	  
CD44	   7.5969	   0.6129	   0.0807	   1.5294	   0	  
CD86	   7.5965	   0.4063	   0.0535	   1.3253	   0	  
MT1M	   7.5890	   0.6517	   0.0859	   1.5710	   0	  
C1S	   7.5704	   0.5821	   0.0769	   1.4970	   0	  
SIRPA	   7.5670	   0.5281	   0.0698	   1.4421	   0	  
PTRF	   7.5612	   0.6157	   0.0814	   1.5323	   0	  
ITGA5	   7.5139	   0.6457	   0.0859	   1.5645	   0	  
ZEB2	   7.5106	   0.4296	   0.0572	   1.3469	   0	  
LY96	   7.5041	   0.6479	   0.0863	   1.5669	   0	  
LAMP2	   7.5035	   0.3944	   0.0526	   1.3144	   0	  
HCK	   7.5000	   0.5660	   0.0755	   1.4804	   0	  
EFEMP1	   7.4420	   0.6804	   0.0914	   1.6026	   0	  
PRNP	   7.4413	   0.6518	   0.0876	   1.5711	   0	  
CAV1	   7.4015	   0.5795	   0.0783	   1.4944	   0	  
TGFBI	   7.3419	   0.7521	   0.1024	   1.6843	   0	  
SLA	   7.3285	   0.4087	   0.0558	   1.3275	   0	  
ATXN1	   7.3284	   0.3510	   0.0479	   1.2754	   0	  
AXL	   7.3205	   0.5626	   0.0769	   1.4770	   0	  
FPR3	   7.3200	   0.5754	   0.0786	   1.4901	   0	  
CSF1R	   7.2959	   0.6776	   0.0929	   1.5995	   0	  
IL15RA	   7.2578	   0.3527	   0.0486	   1.2769	   0	  
FCGR2A	   7.2285	   0.4669	   0.0646	   1.3822	   0	  
SAMSN1	   7.2264	   0.4559	   0.0631	   1.3717	   0	  
NMT2	   7.2259	   0.3821	   0.0529	   1.3032	   0	  
SPI1	   7.2232	   0.4340	   0.0601	   1.3510	   0	  
IFITM2	   7.2164	   0.5625	   0.0780	   1.4769	   0	  
SERPINA3	   7.2059	   1.0643	   0.1477	   2.0912	   0	  
NCF2	   7.1870	   0.4859	   0.0676	   1.4005	   0	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RNASE6	   7.1834	   0.5212	   0.0726	   1.4351	   0	  
SYNC	   7.1736	   0.4816	   0.0671	   1.3963	   0	  
RGS2	   7.1545	   0.6432	   0.0899	   1.5618	   0	  
C1QA	   7.1505	   0.5197	   0.0727	   1.4337	   0	  
AP1S2	   7.1447	   0.4771	   0.0668	   1.3919	   0	  
NFIL3	   7.1411	   0.4430	   0.0620	   1.3594	   0	  
TMEM45A	   7.1406	   0.8884	   0.1244	   1.8512	   0	  
FCER1G	   7.1327	   0.7079	   0.0992	   1.6334	   0	  
SPHK1	   7.1262	   0.6289	   0.0882	   1.5464	   0	  
TIMP2	   7.1075	   0.5160	   0.0726	   1.4299	   0	  
WIPF1	   7.1020	   0.4574	   0.0644	   1.3731	   0	  
C5AR1	   7.0874	   0.5552	   0.0783	   1.4693	   0	  
CD163	   7.0846	   0.6525	   0.0921	   1.5719	   0	  
STX2	   7.0776	   0.5387	   0.0761	   1.4526	   0	  
PMEPA1	   7.0768	   0.5351	   0.0756	   1.4490	   0	  
SLC7A7	   7.0715	   0.6146	   0.0869	   1.5311	   0	  
MYO5A	   7.0573	   0.3959	   0.0561	   1.3158	   0	  
GPR68	   7.0536	   0.5586	   0.0792	   1.4728	   0	  
MS4A4A	   7.0394	   0.4172	   0.0593	   1.3353	   0	  
ZNF532	   7.0112	   0.3303	   0.0471	   1.2573	   0	  
TYMP	   7.0039	   0.5545	   0.0792	   1.4687	   0	  
GAS1	   6.9774	   0.6863	   0.0984	   1.6092	   0	  
KIAA0226L	   6.9665	   0.3042	   0.0437	   1.2348	   0	  
COL5A2	   6.9605	   0.6867	   0.0987	   1.6096	   0	  
CASP1	   6.9602	   0.6038	   0.0868	   1.5197	   0	  
RAB27A	   6.9595	   0.2611	   0.0375	   1.1984	   0	  
NXN	   6.9541	   0.5560	   0.0800	   1.4702	   0	  
SRGN	   6.9539	   0.7493	   0.1077	   1.6809	   0	  
SLAMF8	   6.9537	   0.4721	   0.0679	   1.3871	   0	  
FYB	   6.9528	   0.4456	   0.0641	   1.3619	   0	  
COL6A2	   6.9404	   0.4685	   0.0675	   1.3837	   0	  
SERPINA1	   6.9360	   0.5955	   0.0859	   1.5110	   0	  
CDA	   6.9349	   0.5734	   0.0827	   1.4880	   0	  
ADCY7	   6.9074	   0.2671	   0.0387	   1.2034	   0	  
NR3C1	   6.8989	   0.2131	   0.0309	   1.1592	   0	  
DACT1	   6.8890	   0.4660	   0.0676	   1.3812	   0	  
ROR2	   6.8864	   0.4555	   0.0661	   1.3712	   0	  
SLC15A3	   6.8851	   0.5382	   0.0782	   1.4522	   0	  
GPM6B	   6.8793	   0.3320	   0.0483	   1.2588	   0	  
CRYAB	   6.8787	   0.5798	   0.0843	   1.4946	   0	  
CALD1	   6.8774	   0.4996	   0.0726	   1.4138	   0	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IFI30	   6.8592	   0.5322	   0.0776	   1.4461	   0	  
RBP1	   6.8556	   0.7022	   0.1024	   1.6270	   0	  
MT1E	   6.8510	   0.4840	   0.0707	   1.3987	   0	  
CYBB	   6.8452	   0.5222	   0.0763	   1.4361	   0	  
AEBP1	   6.8409	   0.7326	   0.1071	   1.6617	   0	  
RAC2	   6.8390	   0.6109	   0.0893	   1.5272	   0	  
EPB41L2	   6.8381	   0.3403	   0.0498	   1.2660	   0	  
MAF	   6.8314	   0.3870	   0.0567	   1.3077	   0	  
CPVL	   6.8311	   0.5740	   0.0840	   1.4886	   0	  
IL32	   6.8308	   0.5541	   0.0811	   1.4683	   0	  
ARL4C	   6.8301	   0.2877	   0.0421	   1.2207	   0	  
VIM	   6.8054	   0.5817	   0.0855	   1.4966	   0	  
CLEC4A	   6.7943	   0.5519	   0.0812	   1.4661	   0	  
GREM1	   6.7931	   0.7757	   0.1142	   1.7120	   0	  
IL10RA	   6.7914	   0.4803	   0.0707	   1.3951	   0	  
FMOD	   6.7908	   0.4972	   0.0732	   1.4115	   0	  
FBN1	   6.7870	   0.3327	   0.0490	   1.2594	   0	  
COL5A1	   6.7822	   0.7246	   0.1068	   1.6524	   0	  
GLT8D2	   6.7811	   0.5695	   0.0840	   1.4840	   0	  
C1QB	   6.7789	   0.7567	   0.1116	   1.6896	   0	  
SH2B3	   6.7785	   0.4460	   0.0658	   1.3622	   0	  
AK4	   6.7696	   0.5303	   0.0783	   1.4442	   0	  
C3AR1	   6.7654	   0.3862	   0.0571	   1.3069	   0	  
SERPING1	   6.7648	   0.5716	   0.0845	   1.4862	   0	  
ECI2	   6.7631	   0.4441	   0.0657	   1.3605	   0	  
IFI16	   6.7605	   0.6147	   0.0909	   1.5312	   0	  
PLAUR	   6.7525	   0.5263	   0.0779	   1.4402	   0	  
ACTN1	   6.7433	   0.5075	   0.0753	   1.4216	   0	  
LILRB2	   6.7378	   0.4870	   0.0723	   1.4015	   0	  
IFITM3	   6.7148	   0.5888	   0.0877	   1.5040	   0	  
RGS1	   6.6982	   0.7142	   0.1066	   1.6405	   0	  
GFPT2	   6.6752	   0.5807	   0.0870	   1.4956	   0	  
VSNL1	   6.6744	   0.6152	   0.0922	   1.5317	   0	  
OAT	   6.6726	   0.6061	   0.0908	   1.5222	   0	  
EVI2A	   6.6575	   0.4457	   0.0669	   1.3620	   0	  
SULF1	   6.6477	   0.8334	   0.1254	   1.7819	   0	  
MN1	   6.6473	   0.4121	   0.0620	   1.3307	   0	  
COL6A1	   6.6440	   0.7122	   0.1072	   1.6383	   0	  
COL16A1	   6.6390	   0.6128	   0.0923	   1.5292	   0	  
TNFSF4	   6.6385	   0.3936	   0.0593	   1.3136	   0	  
LAPTM5	   6.6369	   0.5950	   0.0897	   1.5105	   0	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ITGB2	   6.6353	   0.6867	   0.1035	   1.6096	   0	  
SLC2A3	   6.6274	   0.6342	   0.0957	   1.5521	   0	  
MNDA	   6.6233	   0.4457	   0.0673	   1.3620	   0	  
MT1F	   6.6170	   0.5914	   0.0894	   1.5067	   0	  
BIN1	   6.6150	   0.5051	   0.0764	   1.4192	   0	  
TYROBP	   6.6041	   0.6766	   0.1024	   1.5983	   0	  
FGL2	   6.5663	   0.6007	   0.0915	   1.5164	   0	  
IL15	   6.5439	   0.3058	   0.0467	   1.2361	   0	  
NCKAP1L	   6.5365	   0.3399	   0.0520	   1.2657	   0	  
EDNRA	   6.5326	   0.4344	   0.0665	   1.3514	   0	  
NNMT	   6.5239	   0.5137	   0.0787	   1.4277	   0	  
CLIP4	   6.5221	   0.3528	   0.0541	   1.2770	   0	  
PRDM1	   6.5206	   0.2645	   0.0406	   1.2013	   0	  
MAFB	   6.5144	   0.5047	   0.0775	   1.4188	   0	  
CCL8	   6.4903	   0.7202	   0.1110	   1.6475	   0	  
CLEC5A	   6.4860	   0.4141	   0.0638	   1.3324	   0	  
AIF1	   6.4801	   0.5297	   0.0817	   1.4437	   0	  
PDLIM3	   6.4767	   0.5873	   0.0907	   1.5024	   0	  
HIF1A	   6.4752	   0.3747	   0.0579	   1.2965	   0	  
ADAM19	   6.4648	   0.6289	   0.0973	   1.5464	   0	  
TRPS1	   6.4621	   0.2330	   0.0361	   1.1753	   0	  
ZYX	   6.4567	   0.3480	   0.0539	   1.2728	   0	  
CFI	   6.4479	   0.4757	   0.0738	   1.3906	   0	  
VSIG4	   6.4464	   0.4185	   0.0649	   1.3365	   0	  
ISG20	   6.4460	   0.6310	   0.0979	   1.5486	   0	  
HPSE	   6.4419	   0.3638	   0.0565	   1.2868	   0	  
EGR2	   6.4352	   0.6068	   0.0943	   1.5228	   0	  
LGALS1	   6.4275	   0.6131	   0.0954	   1.5296	   0	  
MS4A6A	   6.4025	   0.5895	   0.0921	   1.5048	   0	  
GNLY	   6.3943	   0.4349	   0.0680	   1.3518	   0	  
IL1RAP	   6.3892	   0.3639	   0.0569	   1.2869	   0	  
COL1A2	   6.3851	   0.6517	   0.1021	   1.5710	   0	  
POSTN	   6.3829	   0.7819	   0.1225	   1.7194	   0	  
RUNX3	   6.3794	   0.5953	   0.0933	   1.5107	   0	  
IGSF6	   6.3751	   0.4710	   0.0739	   1.3861	   0	  
BNC2	   6.3726	   0.3212	   0.0504	   1.2494	   0	  
SOCS1	   6.3667	   0.3263	   0.0512	   1.2538	   0	  
PSMB9	   6.3648	   0.4899	   0.0770	   1.4044	   0	  
HS3ST3A1	   6.3582	   0.6183	   0.0972	   1.5351	   0	  
CYBRD1	   6.3550	   0.5285	   0.0832	   1.4424	   0	  
HEG1	   6.3480	   0.3560	   0.0561	   1.2798	   0	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ACOT9	   6.3463	   0.3536	   0.0557	   1.2778	   0	  
ATP8B2	   6.3421	   0.2192	   0.0346	   1.1641	   0	  
NID2	   6.3344	   0.4058	   0.0641	   1.3248	   0	  
GEM	   6.3334	   0.3734	   0.0590	   1.2954	   0	  
CREB5	   6.3216	   0.2910	   0.0460	   1.2235	   0	  
TGFB3	   6.3169	   0.4858	   0.0769	   1.4004	   0	  
CXCL10	   6.3153	   0.8965	   0.1419	   1.8615	   0	  
HBEGF	   6.3087	   0.5001	   0.0793	   1.4143	   0	  
SRPX	   6.3071	   0.7440	   0.1180	   1.6748	   0	  
CCR1	   6.3026	   0.3272	   0.0519	   1.2546	   0	  
CYTIP	   6.2984	   0.4641	   0.0737	   1.3795	   0	  
THEMIS2	   6.2965	   0.2876	   0.0457	   1.2206	   0	  
KCNMB1	   6.2932	   0.5240	   0.0833	   1.4380	   0	  
BLVRA	   6.2866	   0.3738	   0.0595	   1.2958	   0	  
GPR183	   6.2678	   0.5576	   0.0890	   1.4718	   0	  
COL6A3	   6.2477	   0.6403	   0.1025	   1.5587	   0	  
CTGF	   6.2429	   0.5909	   0.0946	   1.5061	   0	  
ISLR	   6.2340	   0.3993	   0.0641	   1.3189	   0	  
GAS6	   6.2325	   0.4122	   0.0661	   1.3307	   0	  
IL7R	   6.2190	   0.5910	   0.0950	   1.5063	   0	  
OLFML3	   6.2175	   0.4827	   0.0776	   1.3974	   0	  
DPYSL2	   6.2154	   0.4308	   0.0693	   1.3480	   0	  
KIAA0247	   6.2133	   0.3182	   0.0512	   1.2468	   0	  
PLEK	   6.2108	   0.6584	   0.1060	   1.5784	   0	  
IFITM1	   6.2065	   0.6296	   0.1014	   1.5472	   0	  
FMO1	   6.2064	   0.4497	   0.0725	   1.3658	   0	  
IRAK3	   6.2012	   0.4595	   0.0741	   1.3751	   0	  
IGFBP6	   6.1972	   0.6547	   0.1057	   1.5743	   0	  
PAM	   6.1825	   0.3991	   0.0646	   1.3187	   0	  
CEP112	   6.1824	   0.2221	   0.0359	   1.1664	   0	  
PTP4A1	   6.1793	   0.2399	   0.0388	   1.1809	   0	  
CXCL11	   6.1774	   0.7020	   0.1136	   1.6267	   0	  
WARS	   6.1742	   0.5324	   0.0862	   1.4463	   0	  
FERMT2	   6.1556	   0.4817	   0.0783	   1.3964	   0	  
TPM1	   6.1455	   0.3770	   0.0614	   1.2987	   0	  
TGFB1I1	   6.1436	   0.2931	   0.0477	   1.2253	   0	  
SPON2	   6.1365	   0.3888	   0.0634	   1.3093	   0	  
C7orf10	   6.1357	   0.4440	   0.0724	   1.3604	   0	  
MMP9	   6.1229	   0.8715	   0.1423	   1.8295	   0	  
ZBED2	   6.1176	   0.5682	   0.0929	   1.4827	   0	  
DOCK10	   6.1025	   0.4382	   0.0718	   1.3549	   0	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EVI2B	   6.0985	   0.5183	   0.0850	   1.4322	   0	  
HLA-­‐G	   6.0923	   0.4328	   0.0710	   1.3499	   0	  
C1R	   6.0916	   0.4838	   0.0794	   1.3985	   0	  
OGFRL1	   6.0888	   0.3285	   0.0540	   1.2557	   0	  
DPT	   6.0829	   0.4225	   0.0695	   1.3402	   0	  
TMEM158	   6.0750	   0.7037	   0.1158	   1.6287	   0	  
BMP2K	   6.0743	   0.1757	   0.0289	   1.1295	   0	  
PHLDA1	   6.0700	   0.6438	   0.1061	   1.5625	   0	  
FN1	   6.0681	   0.2929	   0.0483	   1.2251	   0	  
COPZ2	   6.0666	   0.3108	   0.0512	   1.2404	   0	  
ROBO1	   6.0660	   0.4241	   0.0699	   1.3417	   0	  
CEBPB	   6.0645	   0.3770	   0.0622	   1.2986	   0	  
PRR16	   6.0632	   0.2640	   0.0435	   1.2008	   0	  
SLC39A14	   6.0632	   0.4009	   0.0661	   1.3203	   0	  
PIK3CD	   6.0577	   0.2992	   0.0494	   1.2305	   0	  
TLR2	   6.0518	   0.2493	   0.0412	   1.1887	   0	  
STK17B	   6.0472	   0.2557	   0.0423	   1.1940	   0	  
MT1H	   6.0457	   0.3561	   0.0589	   1.2800	   0	  
GPR65	   6.0438	   0.4294	   0.0710	   1.3466	   0	  
ZEB1	   6.0389	   0.2274	   0.0377	   1.1707	   0	  
DIXDC1	   6.0387	   0.2227	   0.0369	   1.1669	   0	  
SOD2	   6.0373	   0.3979	   0.0659	   1.3176	   0	  
HLA-­‐F	   6.0352	   0.4759	   0.0788	   1.3908	   0	  
RAB31	   6.0290	   0.4530	   0.0751	   1.3689	   0	  
KRT6B	   6.0274	   0.8162	   0.1354	   1.7608	   0	  
SGK1	   6.0249	   0.4906	   0.0814	   1.4050	   0	  
SGCB	   6.0249	   0.2152	   0.0357	   1.1609	   0	  
LST1	   6.0173	   0.3784	   0.0629	   1.2999	   0	  
GALNT10	   6.0164	   0.3382	   0.0562	   1.2642	   0	  
TLR8	   6.0126	   0.2791	   0.0464	   1.2135	   0	  
SLC43A3	   6.0102	   0.2837	   0.0472	   1.2174	   0	  
PNMA1	   6.0085	   0.2756	   0.0459	   1.2105	   0	  
COPS8	   6.0081	   0.2062	   0.0343	   1.1537	   0	  
ACVR1	   6.0019	   0.3285	   0.0547	   1.2557	   0	  
PTPLA	   5.9979	   0.5398	   0.0900	   1.4538	   0	  
ECM2	   5.9973	   0.2751	   0.0459	   1.2101	   0	  
ARSJ	   5.9906	   0.3227	   0.0539	   1.2507	   0	  
PDLIM4	   5.9806	   0.2369	   0.0396	   1.1785	   0	  
TRIM22	   5.9794	   0.4805	   0.0804	   1.3953	   0	  
CCDC109B	   5.9793	   0.3912	   0.0654	   1.3115	   0	  
EIF5A2	   5.9783	   0.2949	   0.0493	   1.2268	   0	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F3	   5.9757	   0.6102	   0.1021	   1.5265	   0	  
GZMB	   5.9693	   0.6703	   0.1123	   1.5914	   0	  
ITGA4	   5.9584	   0.2860	   0.0480	   1.2193	   0	  
DSG3	   5.9499	   0.8449	   0.1420	   1.7962	   0	  
GZMA	   5.9443	   0.6568	   0.1105	   1.5765	   0	  
WISP1	   5.9293	   0.4097	   0.0691	   1.3284	   0	  
NT5E	   5.9186	   0.5729	   0.0968	   1.4875	   0	  
DNAJB4	   5.9174	   0.2978	   0.0503	   1.2293	   0	  
FAM198B	   5.9137	   0.4160	   0.0703	   1.3342	   0	  
PLSCR4	   5.9109	   0.4046	   0.0685	   1.3238	   0	  
ADAP2	   5.9038	   0.3639	   0.0616	   1.2869	   0	  
KITLG	   5.8963	   0.3167	   0.0537	   1.2455	   0	  
PLEKHO1	   5.8945	   0.3530	   0.0599	   1.2772	   0	  
EMILIN1	   5.8903	   0.4965	   0.0843	   1.4108	   0	  
THBS1	   5.8848	   0.5655	   0.0961	   1.4799	   0	  
EGR3	   5.8793	   0.2903	   0.0494	   1.2229	   0	  
LOX	   5.8712	   0.5949	   0.1013	   1.5104	   0	  
PDGFRB	   5.8710	   0.4706	   0.0802	   1.3857	   0	  
MYO1B	   5.8697	   0.3885	   0.0662	   1.3090	   0	  
CAV2	   5.8685	   0.3885	   0.0662	   1.3091	   0	  
LAT2	   5.8662	   0.3237	   0.0552	   1.2516	   0	  
RAB23	   5.8639	   0.2435	   0.0415	   1.1838	   0	  
GFOD1	   5.8634	   0.3748	   0.0639	   1.2967	   0	  
TSPAN4	   5.8628	   0.3770	   0.0643	   1.2986	   0	  
CDH11	   5.8574	   0.5844	   0.0998	   1.4994	   0	  
STOM	   5.8470	   0.3441	   0.0588	   1.2693	   0	  
CTSC	   5.8447	   0.3593	   0.0615	   1.2828	   0	  
ECM1	   5.8419	   0.3809	   0.0652	   1.3022	   0	  
FAM129A	   5.8376	   0.4339	   0.0743	   1.3509	   0	  
KAL1	   5.8366	   0.3272	   0.0561	   1.2546	   0	  
COL3A1	   5.8342	   0.5395	   0.0925	   1.4534	   0	  
RRAD	   5.8253	   0.4010	   0.0688	   1.3204	   0	  
COLEC12	   5.8184	   0.5547	   0.0953	   1.4689	   0	  
MYL9	   5.7986	   0.4316	   0.0744	   1.3487	   0	  
BCAT1	   5.7981	   0.5299	   0.0914	   1.4439	   0	  
COL8A2	   5.7966	   0.3267	   0.0564	   1.2541	   0	  
PLAU	   5.7924	   0.6304	   0.1088	   1.5480	   0	  
PDPN	   5.7899	   0.5698	   0.0984	   1.4843	   0	  
BCL2A1	   5.7830	   0.4462	   0.0772	   1.3625	   0	  
ANXA6	   5.7759	   0.2601	   0.0450	   1.1975	   0	  
PRPS1	   5.7751	   0.2725	   0.0472	   1.2079	   0	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IFFO1	   5.7746	   0.2988	   0.0518	   1.2302	   0	  
DYRK3	   5.7705	   0.2475	   0.0429	   1.1872	   0	  
CXCL1	   5.7695	   0.6865	   0.1190	   1.6094	   0	  
PTPN12	   5.7649	   0.3131	   0.0543	   1.2424	   0	  
AGPAT4	   5.7636	   0.3556	   0.0617	   1.2795	   0	  
LAMA4	   5.7614	   0.3786	   0.0657	   1.3001	   0	  
IFIH1	   5.7581	   0.4158	   0.0722	   1.3340	   0	  
DOCK2	   5.7563	   0.4760	   0.0827	   1.3909	   0	  
IL6	   5.7491	   0.6178	   0.1075	   1.5345	   0	  
MFAP5	   5.7488	   0.6213	   0.1081	   1.5383	   0	  
PLA2G7	   5.7481	   0.4906	   0.0853	   1.4050	   0	  
PCDH7	   5.7475	   0.3927	   0.0683	   1.3129	   0	  
MFGE8	   5.7461	   0.4768	   0.0830	   1.3916	   0	  
ITGA1	   5.7433	   0.3090	   0.0538	   1.2388	   0	  
ACOX2	   5.7183	   0.4011	   0.0701	   1.3205	   0	  
PARVB	   5.7112	   0.2212	   0.0387	   1.1657	   0	  
COL18A1	   5.7091	   0.2456	   0.0430	   1.1856	   0	  
ENTPD1	   5.7084	   0.3246	   0.0569	   1.2523	   0	  
MSC	   5.6964	   0.3454	   0.0606	   1.2705	   0	  
ZFPM2	   5.6848	   0.3400	   0.0598	   1.2658	   0	  
MBNL1	   5.6835	   0.2273	   0.0400	   1.1706	   0	  
AFAP1	   5.6830	   0.3474	   0.0611	   1.2723	   0	  
NINJ2	   5.6777	   0.3907	   0.0688	   1.3111	   0	  
ELL2	   5.6765	   0.3537	   0.0623	   1.2778	   0	  
FXYD6	   5.6746	   0.4063	   0.0716	   1.3252	   0	  
IDO1	   5.6703	   0.7465	   0.1317	   1.6777	   0	  
RAMP1	   5.6582	   0.3462	   0.0612	   1.2712	   0	  
CD300A	   5.6544	   0.3767	   0.0666	   1.2984	   0	  
DOK2	   5.6541	   0.2119	   0.0375	   1.1582	   0	  
KRT5	   5.6537	   1.0668	   0.1887	   2.0947	   0	  
ITGAM	   5.6490	   0.4182	   0.0740	   1.3362	   0	  
DPYSL3	   5.6478	   0.5530	   0.0979	   1.4671	   0	  
IL1R2	   5.6404	   0.3580	   0.0635	   1.2817	   0	  
IFIT1	   5.6358	   0.4465	   0.0792	   1.3627	   0	  
GCNT1	   5.6339	   0.2992	   0.0531	   1.2305	   0	  
CCL5	   5.6332	   0.6534	   0.1160	   1.5728	   0	  
LY86	   5.6249	   0.3962	   0.0704	   1.3160	   0	  
SP110	   5.6213	   0.3092	   0.0550	   1.2390	   0	  
ZNF281	   5.6152	   0.2747	   0.0489	   1.2097	   0	  
CTSK	   5.5749	   0.6329	   0.1135	   1.5507	   0	  
TCF7L1	   5.5658	   0.3055	   0.0549	   1.2358	   0	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TPM2	   5.5638	   0.3640	   0.0654	   1.2870	   0	  
CD248	   5.5632	   0.4988	   0.0897	   1.4130	   0	  
NUAK1	   5.5620	   0.4135	   0.0744	   1.3320	   0	  
CSGALNACT2	   5.5600	   0.1758	   0.0316	   1.1296	   0	  
CHST7	   5.5589	   0.3405	   0.0613	   1.2662	   0	  
COL11A1	   5.5561	   0.5785	   0.1041	   1.4933	   0	  
RGS4	   5.5522	   0.4433	   0.0799	   1.3598	   0	  
FLI1	   5.5494	   0.2020	   0.0364	   1.1503	   0	  
ATP6V1B2	   5.5465	   0.2761	   0.0498	   1.2109	   0	  
COL1A1	   5.5431	   0.6219	   0.1122	   1.5389	   0	  
BHLHE40	   5.5376	   0.4648	   0.0839	   1.3801	   0	  
TEAD4	   5.5369	   0.2858	   0.0516	   1.2191	   0	  
MAP1B	   5.5324	   0.2885	   0.0522	   1.2214	   0	  
HTRA1	   5.5300	   0.4869	   0.0881	   1.4015	   0	  
OLFML2B	   5.5131	   0.4788	   0.0869	   1.3936	   0	  
ALDH2	   5.5128	   0.4709	   0.0854	   1.3860	   0	  
ANXA1	   5.5099	   0.5734	   0.1041	   1.4881	   0	  
CD53	   5.5047	   0.3788	   0.0688	   1.3002	   0	  
PTPN22	   5.4997	   0.2423	   0.0441	   1.1829	   0	  
NKG7	   5.4965	   0.5470	   0.0995	   1.4610	   0	  
SSFA2	   5.4961	   0.3183	   0.0579	   1.2469	   0	  
GULP1	   5.4941	   0.2420	   0.0441	   1.1827	   0	  
FYN	   5.4863	   0.2788	   0.0508	   1.2132	   0	  
TNFAIP3	   5.4860	   0.4652	   0.0848	   1.3805	   0	  
IQGAP2	   5.4856	   0.2702	   0.0493	   1.2059	   0	  
NCK1	   5.4806	   0.3056	   0.0558	   1.2359	   0	  
NAB1	   5.4805	   0.3067	   0.0560	   1.2368	   0	  
EXOG	   5.4782	   0.5691	   0.1039	   1.4836	   0	  
BTK	   5.4749	   0.3471	   0.0634	   1.2720	   0	  
PDE4B	   5.4739	   0.3883	   0.0709	   1.3089	   0	  
RNASE2	   5.4725	   0.3160	   0.0577	   1.2449	   0	  
PANX1	   5.4725	   0.2508	   0.0458	   1.1899	   0	  
TRPV2	   5.4692	   0.3587	   0.0656	   1.2822	   0	  
CHSY1	   5.4688	   0.2211	   0.0404	   1.1656	   0	  
IFI44	   5.4652	   0.5693	   0.1042	   1.4838	   0	  
CCL2	   5.4553	   0.5797	   0.1063	   1.4946	   0	  
CD84	   5.4509	   0.2080	   0.0382	   1.1551	   0	  
TM6SF1	   5.4496	   0.2640	   0.0485	   1.2008	   0	  
FBLN2	   5.4490	   0.4154	   0.0762	   1.3337	   0	  
FCGR2B	   5.4455	   0.3323	   0.0610	   1.2590	   0	  
MMP12	   5.4450	   0.8126	   0.1492	   1.7563	   0	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EMP1	   5.4441	   0.4655	   0.0855	   1.3808	   0	  
CCND2	   5.4431	   0.4337	   0.0797	   1.3507	   0	  
NAP1L3	   5.4329	   0.3606	   0.0664	   1.2840	   0	  
CD37	   5.4298	   0.3992	   0.0735	   1.3187	   0	  
JAK2	   5.4264	   0.2788	   0.0514	   1.2132	   0	  
TAGLN	   5.4264	   0.3901	   0.0719	   1.3105	   0	  
CDC25B	   5.4214	   0.4587	   0.0846	   1.3743	   0	  
OLFML1	   5.4209	   0.3766	   0.0695	   1.2983	   0	  
CXCL9	   5.4199	   0.7784	   0.1436	   1.7153	   0	  
SERPINB2	   5.4151	   0.7397	   0.1366	   1.6699	   0	  
FSCN1	   5.4148	   0.5021	   0.0927	   1.4163	   0	  
MT1G	   5.4131	   0.6228	   0.1150	   1.5398	   0	  
NRP1	   5.4130	   0.3588	   0.0663	   1.2823	   0	  
KIAA1644	   5.4084	   0.2758	   0.0510	   1.2107	   0	  
FKBP5	   5.3968	   0.3991	   0.0740	   1.3187	   0	  
MYLK	   5.3953	   0.4155	   0.0770	   1.3338	   0	  
CCPG1	   5.3946	   0.2470	   0.0458	   1.1867	   0	  
P4HA2	   5.3888	   0.2908	   0.0540	   1.2233	   0	  
LPXN	   5.3848	   0.4376	   0.0813	   1.3543	   0	  
KLF9	   5.3839	   0.4473	   0.0831	   1.3635	   0	  
VCAN	   5.3821	   0.5551	   0.1031	   1.4693	   0	  
SERPINB4	   5.3815	   0.8234	   0.1530	   1.7695	   0	  
PAPPA	   5.3793	   0.4752	   0.0883	   1.3901	   0	  
CAP2	   5.3729	   0.4638	   0.0863	   1.3792	   0	  
SAV1	   5.3714	   0.2587	   0.0482	   1.1964	   0	  
RND3	   5.3708	   0.4429	   0.0825	   1.3593	   0	  
CXCL12	   5.3682	   0.4100	   0.0764	   1.3287	   0	  
PCOLCE2	   5.3646	   0.5252	   0.0979	   1.4391	   0	  
TGM2	   5.3620	   0.4035	   0.0752	   1.3227	   0	  
ST8SIA4	   5.3614	   0.1927	   0.0359	   1.1429	   0	  
RAB3IL1	   5.3601	   0.4027	   0.0751	   1.3220	   0	  
BMP1	   5.3594	   0.2101	   0.0392	   1.1568	   0	  
OSTM1	   5.3593	   0.2318	   0.0433	   1.1743	   0	  
STX11	   5.3499	   0.3833	   0.0716	   1.3043	   0	  
CELF2	   5.3449	   0.2201	   0.0412	   1.1648	   0	  
TBXAS1	   5.3426	   0.3761	   0.0704	   1.2978	   0	  
RTN1	   5.3419	   0.3337	   0.0625	   1.2602	   0	  
STAT1	   5.3400	   0.4746	   0.0889	   1.3895	   0	  
COL10A1	   5.3398	   0.6675	   0.1250	   1.5883	   0	  
S100A10	   5.3397	   0.4654	   0.0872	   1.3807	   0	  
SNX10	   5.3350	   0.3688	   0.0691	   1.2913	   0	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ITGAV	   5.3321	   0.3263	   0.0612	   1.2538	   0	  
FLRT2	   5.3252	   0.3039	   0.0571	   1.2345	   0	  
NREP	   5.3169	   0.4496	   0.0846	   1.3656	   0	  
ST6GALNAC5	   5.3139	   0.2515	   0.0473	   1.1905	   0	  
HK3	   5.3070	   0.3371	   0.0635	   1.2632	   0	  
PTHLH	   5.3048	   0.6411	   0.1209	   1.5595	   0	  
MILR1	   5.2997	   0.2302	   0.0434	   1.1730	   0	  
NABP1	   5.2797	   0.3576	   0.0677	   1.2813	   0	  
PRRX2	   5.2791	   0.3953	   0.0749	   1.3152	   0	  
LAMA3	   5.2728	   0.4582	   0.0869	   1.3738	   0	  
COL15A1	   5.2728	   0.4399	   0.0834	   1.3565	   0	  
RGS20	   5.2703	   0.5117	   0.0971	   1.4258	   0	  
LCP1	   5.2683	   0.4451	   0.0845	   1.3614	   0	  
LILRB3	   5.2651	   0.2907	   0.0552	   1.2232	   0	  
AMPD3	   5.2567	   0.1526	   0.0290	   1.1116	   0	  
LAP3	   5.2532	   0.3131	   0.0596	   1.2424	   0	  
ANTXR1	   5.2508	   0.2782	   0.0530	   1.2127	   0	  
DKK3	   5.2478	   0.3879	   0.0739	   1.3085	   0	  
UCHL1	   5.2474	   0.5389	   0.1027	   1.4529	   0	  
G0S2	   5.2450	   0.5349	   0.1020	   1.4488	   0	  
IL8	   5.2447	   0.8499	   0.1621	   1.8024	   0	  
DUSP14	   5.2446	   0.2991	   0.0570	   1.2303	   0	  
ARHGAP24	   5.2411	   0.1421	   0.0271	   1.1035	   0	  
FPR1	   5.2383	   0.4477	   0.0855	   1.3638	   0	  
TPST1	   5.2370	   0.3380	   0.0645	   1.2640	   0	  
VEGFC	   5.2358	   0.4168	   0.0796	   1.3350	   0	  
CD68	   5.2325	   0.2740	   0.0524	   1.2092	   0	  
DCLK1	   5.2309	   0.2382	   0.0455	   1.1795	   0	  
C1orf54	   5.2305	   0.3346	   0.0640	   1.2610	   0	  
FUT8	   5.2281	   0.3273	   0.0626	   1.2547	   0	  
DCBLD2	   5.2273	   0.5436	   0.1040	   1.4576	   0	  
PDZRN3	   5.2270	   0.2110	   0.0404	   1.1575	   0	  
LUM	   5.2246	   0.5518	   0.1056	   1.4660	   0	  
AOAH	   5.2228	   0.2677	   0.0512	   1.2039	   0	  
PAPSS2	   5.2114	   0.3910	   0.0750	   1.3113	   0	  
MOB3B	   5.2092	   0.2735	   0.0525	   1.2087	   0	  
RIN3	   5.2057	   0.1510	   0.0290	   1.1103	   0	  
COL5A3	   5.2032	   0.2689	   0.0517	   1.2049	   0	  
BATF3	   5.2019	   0.2491	   0.0479	   1.1884	   0	  
CST7	   5.2019	   0.3751	   0.0721	   1.2970	   0	  
TDO2	   5.2018	   0.3655	   0.0703	   1.2883	   0	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FGD6	   5.1996	   0.2584	   0.0497	   1.1961	   0	  
DDR2	   5.1941	   0.3562	   0.0686	   1.2800	   0	  
PCOLCE	   5.1938	   0.4768	   0.0918	   1.3916	   0	  
CTSB	   5.1920	   0.3444	   0.0663	   1.2697	   0	  
CXCL2	   5.1909	   0.5582	   0.1075	   1.4724	   0	  
CCDC88A	   5.1893	   0.2024	   0.0390	   1.1506	   0	  
NRP2	   5.1802	   0.1529	   0.0295	   1.1118	   0	  
CSRP1	   5.1801	   0.2744	   0.0530	   1.2095	   0	  
40061	   5.1774	   0.2303	   0.0445	   1.1731	   0	  
ALDH1A1	   5.1749	   0.5796	   0.1120	   1.4944	   0	  
THY1	   5.1650	   0.4205	   0.0814	   1.3384	   0	  
BGN	   5.1641	   0.3972	   0.0769	   1.3169	   0	  
OLR1	   5.1587	   0.5731	   0.1111	   1.4878	   0	  
IL13RA1	   5.1560	   0.2877	   0.0558	   1.2207	   0	  
EXT1	   5.1549	   0.3499	   0.0679	   1.2744	   0	  
IMPDH1	   5.1532	   0.1962	   0.0381	   1.1457	   0	  
FAM216A	   5.1509	   0.3006	   0.0584	   1.2317	   0	  
DNAJB5	   5.1479	   0.1577	   0.0306	   1.1155	   0	  
FLNC	   5.1408	   0.5782	   0.1125	   1.4930	   0	  
TRAM2	   5.1353	   0.3111	   0.0606	   1.2407	   0	  
MAP7D1	   5.1327	   0.2423	   0.0472	   1.1829	   0	  
TNFRSF1B	   5.1318	   0.3398	   0.0662	   1.2655	   0	  
TWIST1	   5.1313	   0.3566	   0.0695	   1.2804	   0	  
ARSB	   5.1298	   0.1694	   0.0330	   1.1246	   0	  
RHOG	   5.1297	   0.2464	   0.0480	   1.1863	   0	  
RAB32	   5.1245	   0.3327	   0.0649	   1.2594	   0	  
EVC	   5.1241	   0.2011	   0.0392	   1.1495	   0	  
ADAMDEC1	   5.1213	   0.5426	   0.1059	   1.4566	   0	  
KLF10	   5.1200	   0.2065	   0.0403	   1.1539	   0	  
CD97	   5.1183	   0.3184	   0.0622	   1.2469	   0	  
SLC24A3	   5.1143	   0.3648	   0.0713	   1.2877	   0	  
LY6E	   5.1139	   0.5521	   0.1080	   1.4662	   0	  
ARHGAP22	   5.1127	   0.2992	   0.0585	   1.2305	   0	  
S100A3	   5.1108	   0.5422	   0.1061	   1.4562	   0	  
ADA	   5.1099	   0.4400	   0.0861	   1.3566	   0	  
FILIP1L	   5.1096	   0.3423	   0.0670	   1.2678	   0	  
CXCL13	   5.1038	   0.5794	   0.1135	   1.4942	   0	  
RASA3	   5.1022	   0.1601	   0.0314	   1.1174	   0	  
IFIT3	   5.1021	   0.4047	   0.0793	   1.3238	   0	  
FHL3	   5.0935	   0.2183	   0.0429	   1.1633	   0	  
CD38	   5.0924	   0.4364	   0.0857	   1.3532	   0	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IL2RB	   5.0900	   0.4158	   0.0817	   1.3340	   0	  
KIRREL	   5.0821	   0.1720	   0.0338	   1.1266	   0	  
SLCO2B1	   5.0798	   0.3775	   0.0743	   1.2991	   0	  
EHD2	   5.0776	   0.3124	   0.0615	   1.2418	   0	  
SEC23A	   5.0766	   0.1697	   0.0334	   1.1248	   0	  
ELOVL4	   5.0736	   0.4136	   0.0815	   1.3320	   0	  
CDC42EP1	   5.0722	   0.2206	   0.0435	   1.1653	   0	  
HDAC4	   5.0697	   0.2589	   0.0511	   1.1966	   0	  
WAS	   5.0683	   0.4201	   0.0829	   1.3381	   0	  
DIO2	   5.0655	   0.4535	   0.0895	   1.3694	   0	  
HERC5	   5.0603	   0.5093	   0.1006	   1.4233	   0	  
KDELC1	   5.0544	   0.2531	   0.0501	   1.1918	   0	  
ANGPTL2	   5.0525	   0.4441	   0.0879	   1.3605	   0	  
HPS5	   5.0400	   0.1588	   0.0315	   1.1164	   0	  
SERPINF1	   5.0399	   0.4506	   0.0894	   1.3666	   0	  
PRR5L	   5.0392	   0.2947	   0.0585	   1.2266	   0	  
KLF13	   5.0384	   0.3257	   0.0646	   1.2533	   0	  
CHN1	   5.0381	   0.3803	   0.0755	   1.3016	   0	  
CD4	   5.0372	   0.2290	   0.0455	   1.1721	   0	  
MMP11	   5.0333	   0.6959	   0.1383	   1.6199	   0	  
PCNXL4	   5.0268	   0.2164	   0.0430	   1.1618	   0	  
CLEC11A	   5.0259	   0.3899	   0.0776	   1.3103	   0	  
CILP	   5.0247	   0.4054	   0.0807	   1.3244	   0	  
ROR1	   5.0241	   0.1963	   0.0391	   1.1458	   0	  
TIMP1	   5.0235	   0.3916	   0.0780	   1.3119	   0	  
MAPKAPK2	   5.0213	   0.1709	   0.0340	   1.1257	   0	  
STAT4	   5.0211	   0.3608	   0.0719	   1.2841	   0	  
CD82	   5.0163	   0.2798	   0.0558	   1.2140	   0	  
MYC	   5.0146	   0.5171	   0.1031	   1.4311	   0	  
CD69	   5.0146	   0.5219	   0.1041	   1.4358	   0	  
CD7	   5.0145	   0.4027	   0.0803	   1.3220	   0	  
MFSD12	   5.0138	   0.1639	   0.0327	   1.1203	   0	  
TPM4	   5.0098	   0.2709	   0.0541	   1.2066	   0	  
EHBP1	   5.0079	   0.2669	   0.0533	   1.2032	   0	  
RCN3	   5.0075	   0.4318	   0.0862	   1.3489	   0	  
RGS10	   5.0051	   0.2235	   0.0447	   1.1676	   0	  
ANXA2	   4.9963	   0.3486	   0.0698	   1.2733	   0	  
PLEKHO2	   4.9955	   0.2698	   0.0540	   1.2057	   0	  
MRC2	   4.9859	   0.1925	   0.0386	   1.1427	   0	  
OLFML2A	   4.9854	   0.3960	   0.0794	   1.3158	   0	  
CNTN1	   4.9846	   0.3400	   0.0682	   1.2658	   0	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MITF	   4.9832	   0.1543	   0.0310	   1.1129	   0	  
BIRC3	   4.9804	   0.3344	   0.0671	   1.2608	   0	  
RECQL	   4.9762	   0.1925	   0.0387	   1.1427	   0	  
IL27RA	   4.9751	   0.3180	   0.0639	   1.2466	   0	  
NOX4	   4.9747	   0.3140	   0.0631	   1.2432	   0	  
LAIR1	   4.9717	   0.2022	   0.0407	   1.1505	   0	  
COL7A1	   4.9711	   0.5856	   0.1178	   1.5006	   0	  
VCAM1	   4.9702	   0.3541	   0.0712	   1.2782	   0	  
GUCY1B3	   4.9684	   0.1769	   0.0356	   1.1305	   0	  
DUSP22	   4.9664	   0.2124	   0.0428	   1.1586	   0	  
CLEC7A	   4.9663	   0.2156	   0.0434	   1.1612	   0	  
MAOB	   4.9632	   0.1940	   0.0391	   1.1440	   0	  
PMAIP1	   4.9623	   0.3802	   0.0766	   1.3015	   0	  
FCGR3B	   4.9545	   0.3452	   0.0697	   1.2704	   0	  
SLC38A6	   4.9543	   0.2655	   0.0536	   1.2021	   0	  
MXRA5	   4.9397	   0.5379	   0.1089	   1.4519	   0	  
LRRC17	   4.9364	   0.3092	   0.0626	   1.2390	   0	  
MYO1F	   4.9321	   0.2396	   0.0486	   1.1807	   0	  
SLMO1	   4.9320	   0.3017	   0.0612	   1.2326	   0	  
TREM2	   4.9286	   0.2804	   0.0569	   1.2146	   0	  
PTPRC	   4.9242	   0.2474	   0.0502	   1.1871	   0	  
BNC1	   4.9211	   0.3327	   0.0676	   1.2594	   0	  
PCNX	   4.9176	   0.2368	   0.0482	   1.1784	   0	  
ADAMTS2	   4.9098	   0.1810	   0.0369	   1.1337	   0	  
CXCR4	   4.9057	   0.4160	   0.0848	   1.3342	   0	  
SLC39A8	   4.9035	   0.2867	   0.0585	   1.2199	   0	  
RASSF4	   4.8980	   0.1875	   0.0383	   1.1388	   0	  
GLRX	   4.8961	   0.3341	   0.0682	   1.2606	   0	  
DCN	   4.8958	   0.5062	   0.1034	   1.4203	   0	  
CALU	   4.8933	   0.2932	   0.0599	   1.2253	   0	  
PTMS	   4.8906	   0.3221	   0.0659	   1.2502	   0	  
CASP4	   4.8853	   0.1872	   0.0383	   1.1386	   0	  
STAB1	   4.8846	   0.3573	   0.0731	   1.2810	   0	  
KCNJ8	   4.8816	   0.2788	   0.0571	   1.2132	   0	  
IER3	   4.8807	   0.4921	   0.1008	   1.4065	   0	  
ILK	   4.8794	   0.2210	   0.0453	   1.1655	   0	  
CYTH4	   4.8774	   0.4113	   0.0843	   1.3299	   0	  
CNN2	   4.8746	   0.2528	   0.0519	   1.1915	   0	  
JAG1	   4.8739	   0.3528	   0.0724	   1.2770	   0	  
HLA-­‐DPA1	   4.8639	   0.5132	   0.1055	   1.4272	   0	  
OPTN	   4.8632	   0.2796	   0.0575	   1.2138	   0	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SLIT2	   4.8627	   0.3626	   0.0746	   1.2858	   0	  
SFRP4	   4.8617	   0.4333	   0.0891	   1.3503	   0	  
ESD	   4.8569	   0.2288	   0.0471	   1.1719	   0	  
NUDT11	   4.8559	   0.3392	   0.0699	   1.2650	   0	  
ETF1	   4.8456	   0.1744	   0.0360	   1.1285	   0	  
P2RY13	   4.8422	   0.2596	   0.0536	   1.1972	   0	  
TFPI2	   4.8359	   0.5316	   0.1099	   1.4456	   0	  
ABL2	   4.8352	   0.1758	   0.0364	   1.1296	   0	  
RECK	   4.8310	   0.2137	   0.0442	   1.1597	   0	  
GUCY1A3	   4.8291	   0.3415	   0.0707	   1.2671	   0	  
EMR2	   4.8280	   0.3391	   0.0702	   1.2649	   0	  
LCP2	   4.8276	   0.2367	   0.0490	   1.1783	   0	  
TSC22D3	   4.8261	   0.2718	   0.0563	   1.2073	   0	  
SLC2A5	   4.8261	   0.3476	   0.0720	   1.2724	   0	  
RASSF9	   4.8228	   0.2481	   0.0514	   1.1877	   0	  
PLK2	   4.8224	   0.2462	   0.0511	   1.1861	   0	  
PKD2	   4.8213	   0.1995	   0.0414	   1.1483	   0	  
MXRA7	   4.8196	   0.1869	   0.0388	   1.1383	   0	  
STXBP1	   4.8184	   0.2152	   0.0447	   1.1609	   0	  
MMD	   4.8150	   0.3526	   0.0732	   1.2769	   0	  
PLGRKT	   4.8134	   0.2853	   0.0593	   1.2186	   0	  
TNS1	   4.8058	   0.2099	   0.0437	   1.1566	   0	  
AQP9	   4.8045	   0.5309	   0.1105	   1.4449	   0	  
NCOR2	   4.8031	   0.2417	   0.0503	   1.1824	   0	  
CDV3	   4.8012	   0.2329	   0.0485	   1.1752	   0	  
ADCY9	   4.7911	   0.2033	   0.0424	   1.1514	   0	  
SERPINB1	   4.7889	   0.3990	   0.0833	   1.3186	   0	  
SPP1	   4.7880	   0.6523	   0.1362	   1.5717	   0	  
TMEM176A	   4.7816	   0.3740	   0.0782	   1.2959	   0	  
PRF1	   4.7815	   0.3172	   0.0663	   1.2459	   0	  
UBTD1	   4.7779	   0.2619	   0.0548	   1.1991	   0	  
CPE	   4.7743	   0.4012	   0.0840	   1.3206	   0	  
RBMS3	   4.7721	   0.1431	   0.0300	   1.1043	   0	  
IL2RG	   4.7698	   0.1811	   0.0380	   1.1338	   0	  
PFKFB3	   4.7698	   0.2806	   0.0588	   1.2147	   0	  
KIAA1598	   4.7683	   0.3288	   0.0690	   1.2560	   0	  
IRF7	   4.7668	   0.3261	   0.0684	   1.2536	   0	  
PI3	   4.7617	   0.9720	   0.2041	   1.9615	   0	  
EFR3A	   4.7536	   0.1926	   0.0405	   1.1428	   0	  
LRRC32	   4.7465	   0.3786	   0.0798	   1.3001	   0	  
CAPN2	   4.7460	   0.2652	   0.0559	   1.2018	   0	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HLA-­‐DQA1	   4.7447	   0.6101	   0.1286	   1.5264	   0	  
TPP1	   4.7399	   0.2656	   0.0560	   1.2021	   0	  
PLAGL1	   4.7386	   0.2825	   0.0596	   1.2163	   0	  
NXPE3	   4.7245	   0.1685	   0.0357	   1.1239	   0	  
PTX3	   4.7193	   0.2904	   0.0615	   1.2230	   0	  
NPC1	   4.7144	   0.2617	   0.0555	   1.1989	   0	  
ETV5	   4.7134	   0.2187	   0.0464	   1.1637	   0	  
PIP4K2A	   4.7050	   0.1612	   0.0343	   1.1182	   0	  
RHOC	   4.6952	   0.2364	   0.0504	   1.1781	   0	  
IRF8	   4.6928	   0.4319	   0.0920	   1.3490	   0	  
PTPRG	   4.6907	   0.1974	   0.0421	   1.1467	   0	  
LEPRE1	   4.6898	   0.2653	   0.0566	   1.2019	   0	  
SERPINE2	   4.6880	   0.5760	   0.1229	   1.4907	   0	  
TLR6	   4.6843	   0.1854	   0.0396	   1.1371	   0	  
LMCD1	   4.6838	   0.3633	   0.0776	   1.2864	   0	  
GRAMD4	   4.6812	   0.2324	   0.0496	   1.1748	   0	  
MCTP1	   4.6812	   0.2001	   0.0427	   1.1488	   0	  
PLN	   4.6807	   0.2892	   0.0618	   1.2220	   0	  
IRF1	   4.6799	   0.3652	   0.0780	   1.2880	   0	  
GZMH	   4.6756	   0.4266	   0.0912	   1.3441	   0	  
SYNM	   4.6724	   0.3600	   0.0771	   1.2835	   0	  
SAMD4A	   4.6684	   0.2014	   0.0431	   1.1498	   0	  
SASH3	   4.6680	   0.2822	   0.0605	   1.2161	   0	  
LYN	   4.6672	   0.2984	   0.0639	   1.2297	   0	  
MCL1	   4.6648	   0.2342	   0.0502	   1.1763	   0	  
AKIP1	   4.6644	   0.1859	   0.0399	   1.1375	   0	  
SLCO1B3	   4.6632	   0.4928	   0.1057	   1.4072	   0	  
HSD11B1	   4.6585	   0.2608	   0.0560	   1.1981	   0	  
LILRB4	   4.6569	   0.3185	   0.0684	   1.2470	   0	  
LRP1	   4.6547	   0.1659	   0.0357	   1.1219	   0	  
SIGLEC1	   4.6522	   0.2141	   0.0460	   1.1600	   0	  
GPSM3	   4.6455	   0.2946	   0.0634	   1.2265	   0	  
PLA2G4C	   4.6444	   0.2998	   0.0645	   1.2309	   0	  
NQO2	   4.6421	   0.2495	   0.0537	   1.1888	   0	  
PLXNC1	   4.6390	   0.1522	   0.0328	   1.1113	   0	  
ATP8B4	   4.6264	   0.2772	   0.0599	   1.2118	   0	  
DDX60	   4.6163	   0.3604	   0.0781	   1.2838	   0	  
RSAD2	   4.6160	   0.4705	   0.1019	   1.3856	   0	  
CD47	   4.6149	   0.2650	   0.0574	   1.2017	   0	  
PDLIM7	   4.6144	   0.1756	   0.0381	   1.1294	   0	  
IL2RA	   4.5992	   0.1558	   0.0339	   1.1141	   0	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KCTD15	   4.5990	   0.2666	   0.0580	   1.2030	   0	  
FBXL7	   4.5953	   0.1690	   0.0368	   1.1243	   0	  
CD74	   4.5946	   0.4215	   0.0917	   1.3393	   0	  
TCF4	   4.5929	   0.3120	   0.0679	   1.2414	   0	  
PI15	   4.5890	   0.2688	   0.0586	   1.2048	   0	  
SGCD	   4.5872	   0.1836	   0.0400	   1.1357	   0	  
IL6ST	   4.5863	   0.1218	   0.0266	   1.0881	   0	  
EMR1	   4.5849	   0.2154	   0.0470	   1.1610	   0	  
PLOD1	   4.5824	   0.2648	   0.0578	   1.2015	   0	  
RELB	   4.5787	   0.2141	   0.0468	   1.1600	   0	  
ACP5	   4.5698	   0.4143	   0.0907	   1.3326	   0	  
NINJ1	   4.5674	   0.2936	   0.0643	   1.2257	   0	  
ANK2	   4.5664	   0.1558	   0.0341	   1.1140	   0	  
ARHGAP25	   4.5656	   0.2941	   0.0644	   1.2261	   0	  
JAM2	   4.5642	   0.3018	   0.0661	   1.2326	   0	  
SCG5	   4.5637	   0.4681	   0.1026	   1.3833	   0	  
CTLA4	   4.5602	   0.2224	   0.0488	   1.1666	   0	  
CNN1	   4.5589	   0.4730	   0.1038	   1.3880	   0	  
SLC12A8	   4.5587	   0.3679	   0.0807	   1.2905	   0	  
ARNTL	   4.5473	   0.1888	   0.0415	   1.1398	   0	  
CLIC2	   4.5459	   0.1963	   0.0432	   1.1457	   0	  
TUBA4A	   4.5459	   0.4183	   0.0920	   1.3363	   0	  
TPD52L1	   4.5445	   0.2908	   0.0640	   1.2233	   0	  
SLC16A2	   4.5434	   0.1772	   0.0390	   1.1307	   0	  
PELO	   4.5418	   0.2042	   0.0450	   1.1521	   0	  
MFI2	   4.5402	   0.1927	   0.0425	   1.1429	   0	  
ARFGAP3	   4.5395	   0.2088	   0.0460	   1.1558	   0	  
ST5	   4.5384	   0.2039	   0.0449	   1.1518	   0	  
KLHL2	   4.5287	   0.2407	   0.0532	   1.1816	   0	  
GBP1	   4.5278	   0.4063	   0.0897	   1.3253	   0	  
HDAC9	   4.5223	   0.1370	   0.0303	   1.0996	   0	  
HCFC2	   4.5206	   0.1662	   0.0368	   1.1221	   0	  
ELOVL5	   4.5201	   0.2799	   0.0619	   1.2141	   0	  
MALT1	   4.5170	   0.1742	   0.0386	   1.1284	   0	  
TANK	   4.5078	   0.1741	   0.0386	   1.1283	   0	  
PDZD2	   4.5018	   0.1984	   0.0441	   1.1474	   0	  
BACH2	   4.4973	   0.1516	   0.0337	   1.1108	   0	  
TINF2	   4.4853	   0.2693	   0.0600	   1.2052	   0	  
LHFP	   4.4851	   0.2900	   0.0647	   1.2226	   0	  
TNFSF12	   4.4833	   0.2622	   0.0585	   1.1993	   0	  
WWTR1	   4.4821	   0.1708	   0.0381	   1.1257	   0	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GHR	   4.4716	   0.3297	   0.0737	   1.2568	   0	  
PTAFR	   4.4705	   0.1853	   0.0414	   1.1370	   0	  
FSTL1	   4.4678	   0.2868	   0.0642	   1.2200	   0	  
SAMD9	   4.4654	   0.4258	   0.0954	   1.3434	   0	  
LYZ	   4.4628	   0.4656	   0.1043	   1.3809	   0	  
CCDC91	   4.4622	   0.2062	   0.0462	   1.1536	   0	  
TAP2	   4.4612	   0.2358	   0.0528	   1.1775	   0	  
GLI2	   4.4596	   0.1546	   0.0347	   1.1131	   0	  
B2M	   4.4595	   0.2144	   0.0481	   1.1602	   0	  
HOXD11	   4.4586	   0.3175	   0.0712	   1.2461	   0	  
CD48	   4.4582	   0.4331	   0.0971	   1.3501	   0	  
DFNA5	   4.4469	   0.4853	   0.1091	   1.3999	   0	  
DCHS1	   4.4417	   0.1539	   0.0347	   1.1126	   0	  
HLA-­‐A	   4.4416	   0.2843	   0.0640	   1.2178	   0	  
LAG3	   4.4291	   0.3861	   0.0872	   1.3069	   0	  
F2R	   4.4235	   0.1701	   0.0385	   1.1252	   0	  
PLOD2	   4.4147	   0.3581	   0.0811	   1.2817	   0	  
MAMLD1	   4.4103	   0.1972	   0.0447	   1.1465	   0	  
IL21R	   4.4060	   0.2158	   0.0490	   1.1613	   0	  
ME1	   4.4051	   0.3817	   0.0866	   1.3029	   0	  
PRSS23	   4.4037	   0.2990	   0.0679	   1.2303	   0	  
SYT11	   4.4021	   0.3511	   0.0797	   1.2755	   0	  
FHL1	   4.4020	   0.3486	   0.0792	   1.2733	   0	  
NLRP3	   4.4012	   0.3025	   0.0687	   1.2333	   0	  
ACTG2	   4.3993	   0.5735	   0.1304	   1.4882	   0	  
SH3BGRL3	   4.3988	   0.2419	   0.0550	   1.1825	   0	  
NIN	   4.3965	   0.1390	   0.0316	   1.1011	   0	  
AMD1	   4.3955	   0.2006	   0.0456	   1.1491	   0	  
MSR1	   4.3940	   0.1504	   0.0342	   1.1099	   0	  
VRK2	   4.3897	   0.2180	   0.0497	   1.1631	   0	  
HES2	   4.3811	   0.3889	   0.0888	   1.3094	   0	  
TFPI	   4.3781	   0.3309	   0.0756	   1.2578	   0	  
LAIR2	   4.3778	   0.2672	   0.0610	   1.2035	   0	  
TRAF3	   4.3739	   0.1449	   0.0331	   1.1056	   0	  
SEMA3A	   4.3736	   0.2203	   0.0504	   1.1650	   0	  
GZMK	   4.3722	   0.4913	   0.1124	   1.4058	   0	  
IFNG	   4.3670	   0.3751	   0.0859	   1.2969	   0	  
FADS3	   4.3661	   0.1667	   0.0382	   1.1225	   0	  
ACTR3	   4.3658	   0.2114	   0.0484	   1.1578	   0	  
NFIX	   4.3603	   0.3382	   0.0776	   1.2642	   0	  
STAT3	   4.3574	   0.1755	   0.0403	   1.1294	   0	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DENND5A	   4.3547	   0.2334	   0.0536	   1.1756	   0	  
CD40	   4.3544	   0.2238	   0.0514	   1.1678	   0	  
ATP2B4	   4.3465	   0.2323	   0.0534	   1.1747	   0	  
SELPLG	   4.3454	   0.1588	   0.0366	   1.1164	   0	  
IFI44L	   4.3413	   0.5796	   0.1335	   1.4944	   0	  
CALB2	   4.3367	   0.2658	   0.0613	   1.2023	   0	  
FRMD4B	   4.3365	   0.1294	   0.0298	   1.0938	   0	  
NAMPT	   4.3359	   0.3451	   0.0796	   1.2702	   0	  
HLX	   4.3324	   0.1760	   0.0406	   1.1297	   0	  
CD80	   4.3258	   0.1584	   0.0366	   1.1161	   0	  
SYDE1	   4.3209	   0.2013	   0.0466	   1.1497	   0	  
TNF	   4.3196	   0.2950	   0.0683	   1.2269	   0	  
PPFIBP1	   4.3185	   0.1796	   0.0416	   1.1326	   0	  
GIMAP4	   4.3181	   0.3503	   0.0811	   1.2748	   0	  
KLK6	   4.3170	   0.6892	   0.1597	   1.6124	   0	  
ICOS	   4.3164	   0.3022	   0.0700	   1.2330	   0	  
CLIP3	   4.3131	   0.3445	   0.0799	   1.2697	   0	  
FSTL3	   4.3096	   0.3381	   0.0785	   1.2641	   0	  
NAALADL1	   4.3075	   0.2013	   0.0467	   1.1497	   0	  
SERPINB7	   4.3072	   0.3539	   0.0822	   1.2780	   0	  
ARL2BP	   4.3027	   0.1820	   0.0423	   1.1345	   0	  
CYP26B1	   4.2990	   0.3163	   0.0736	   1.2451	   0	  
PGM1	   4.2990	   0.3201	   0.0745	   1.2484	   0	  
MMP7	   4.2965	   0.7792	   0.1814	   1.7162	   0	  
AIM2	   4.2964	   0.4227	   0.0984	   1.3405	   0	  
YBX3	   4.2938	   0.2344	   0.0546	   1.1764	   0	  
ADAMTS6	   4.2903	   0.1475	   0.0344	   1.1077	   0	  
PLIN3	   4.2876	   0.1994	   0.0465	   1.1483	   0	  
CD33	   4.2855	   0.2042	   0.0477	   1.1521	   0	  
BAG3	   4.2831	   0.2426	   0.0566	   1.1831	   0	  
RARB	   4.2805	   0.1729	   0.0404	   1.1273	   0	  
SDC2	   4.2788	   0.2479	   0.0579	   1.1875	   0	  
VAV1	   4.2784	   0.2066	   0.0483	   1.1540	   0	  
IFI6	   4.2777	   0.4441	   0.1038	   1.3605	   0	  
DSC3	   4.2770	   0.4510	   0.1055	   1.3670	   0	  
BTN3A3	   4.2736	   0.2617	   0.0612	   1.1989	   0	  
HSPA13	   4.2731	   0.1480	   0.0346	   1.1080	   0	  
SOAT1	   4.2689	   0.1971	   0.0462	   1.1464	   0	  
ANGPT1	   4.2687	   0.2484	   0.0582	   1.1879	   0	  
LYL1	   4.2646	   0.2479	   0.0581	   1.1875	   0	  
SYNDIG1	   4.2636	   0.2361	   0.0554	   1.1778	   0	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MAPRE2	   4.2619	   0.2522	   0.0592	   1.1910	   0	  
MAP3K6	   4.2576	   0.2236	   0.0525	   1.1676	   0	  
THBS2	   4.2522	   0.5205	   0.1224	   1.4344	   0	  
CHRDL1	   4.2489	   0.2355	   0.0554	   1.1773	   0	  
KCTD9	   4.2461	   0.2058	   0.0485	   1.1533	   0	  
ACTA2	   4.2452	   0.3481	   0.0820	   1.2729	   0	  
AGTPBP1	   4.2423	   0.1660	   0.0391	   1.1220	   0	  
PTPRZ1	   4.2413	   0.3179	   0.0750	   1.2465	   0	  
RNF19B	   4.2408	   0.2121	   0.0500	   1.1584	   0	  
SOX9	   4.2386	   0.4610	   0.1088	   1.3765	   0	  
OSM	   4.2377	   0.4005	   0.0945	   1.3199	   0	  
CD8A	   4.2353	   0.3246	   0.0766	   1.2523	   0	  
CYTH1	   4.2345	   0.1474	   0.0348	   1.1076	   0	  
LAMC2	   4.2300	   0.4382	   0.1036	   1.3549	   0	  
CDK14	   4.2273	   0.2258	   0.0534	   1.1694	   0	  
ELMO1	   4.2249	   0.1675	   0.0396	   1.1231	   0	  
IL33	   4.2216	   0.3794	   0.0899	   1.3008	   0	  
KLHL21	   4.2176	   0.1924	   0.0456	   1.1427	   0	  
PPP3CC	   4.2164	   0.1724	   0.0409	   1.1269	   0	  
C9orf91	   4.2153	   0.1893	   0.0449	   1.1402	   0	  
IFI35	   4.2130	   0.3065	   0.0727	   1.2367	   0	  
CD2	   4.2074	   0.4301	   0.1022	   1.3474	   0	  
KLRD1	   4.2073	   0.2157	   0.0513	   1.1613	   0	  
TSPAN7	   4.2033	   0.4062	   0.0966	   1.3252	   0	  
SERPINB9	   4.2010	   0.1748	   0.0416	   1.1288	   0	  
MAP7D3	   4.2008	   0.1424	   0.0339	   1.1037	   0	  
SERPINB3	   4.2000	   0.7036	   0.1675	   1.6285	   0	  
SPOCK1	   4.1996	   0.4905	   0.1168	   1.4049	   0	  
GAS7	   4.1988	   0.2676	   0.0637	   1.2038	   0	  
STON1	   4.1987	   0.2050	   0.0488	   1.1527	   0	  
HMGA2	   4.1975	   0.1666	   0.0397	   1.1224	   0	  
IL36G	   4.1972	   0.4212	   0.1004	   1.3390	   0	  
PTGER2	   4.1971	   0.2302	   0.0548	   1.1730	   0	  
PSTPIP1	   4.1960	   0.2092	   0.0499	   1.1561	   0	  
HSPA12A	   4.1943	   0.2865	   0.0683	   1.2197	   0	  
GGT5	   4.1939	   0.1681	   0.0401	   1.1236	   0	  
HLA-­‐DRA	   4.1936	   0.4266	   0.1017	   1.3441	   0	  
COL17A1	   4.1927	   0.5320	   0.1269	   1.4460	   0	  
FAM49B	   4.1920	   0.2144	   0.0511	   1.1602	   0	  
IFIT2	   4.1828	   0.3810	   0.0911	   1.3023	   0	  
OGN	   4.1820	   0.3098	   0.0741	   1.2396	   0	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SERPINB13	   4.1811	   0.5377	   0.1286	   1.4517	   0	  
JAM3	   4.1810	   0.2998	   0.0717	   1.2310	   0	  
POLR3G	   4.1809	   0.1331	   0.0318	   1.0966	   0	  
WNT5B	   4.1789	   0.2571	   0.0615	   1.1951	   0	  
CANX	   4.1778	   0.1860	   0.0445	   1.1376	   0	  
MEF2C	   4.1762	   0.2161	   0.0517	   1.1616	   0	  
APBB2	   4.1754	   0.1207	   0.0289	   1.0873	   0	  
MYO10	   4.1729	   0.3134	   0.0751	   1.2427	   0	  
ARRB2	   4.1685	   0.2152	   0.0516	   1.1608	   0	  
CFH	   4.1667	   0.3279	   0.0787	   1.2552	   0	  
SECTM1	   4.1619	   0.1692	   0.0407	   1.1244	   0	  
FAT2	   4.1603	   0.4367	   0.1050	   1.3535	   0	  
S100A8	   4.1564	   0.7005	   0.1685	   1.6250	   0	  
TLN1	   4.1527	   0.2019	   0.0486	   1.1502	   0	  
SCO2	   4.1512	   0.2343	   0.0564	   1.1763	   0	  
CNN3	   4.1507	   0.2418	   0.0583	   1.1825	   0	  
SLCO3A1	   4.1503	   0.1763	   0.0425	   1.1300	   0	  
BDKRB1	   4.1480	   0.1906	   0.0459	   1.1412	   0	  
AVEN	   4.1469	   0.2018	   0.0487	   1.1501	   0	  
RBMS2	   4.1468	   0.1900	   0.0458	   1.1408	   0	  
IL18RAP	   4.1458	   0.2457	   0.0593	   1.1857	   0	  
ZBP1	   4.1452	   0.2100	   0.0507	   1.1567	   0	  
TAP1	   4.1433	   0.3446	   0.0832	   1.2698	   0	  
TNFRSF9	   4.1430	   0.1601	   0.0386	   1.1173	   0	  
HLA-­‐B	   4.1421	   0.3595	   0.0868	   1.2830	   0	  
GIMAP6	   4.1420	   0.2793	   0.0674	   1.2136	   0	  
CYLD	   4.1355	   0.1607	   0.0389	   1.1179	   0	  
CRISPLD2	   4.1340	   0.3645	   0.0882	   1.2874	   0	  
ZCCHC24	   4.1276	   0.2774	   0.0672	   1.2120	   0	  
ITK	   4.1169	   0.3068	   0.0745	   1.2370	   0	  
SEC14L2	   4.1118	   0.2028	   0.0493	   1.1509	   0	  
FTSJ1	   4.1104	   0.1390	   0.0338	   1.1012	   0	  
SH3PXD2A	   4.1097	   0.2962	   0.0721	   1.2279	   0	  
SEC61B	   4.1046	   0.1359	   0.0331	   1.0988	   0	  
SCRG1	   4.1030	   0.2861	   0.0697	   1.2193	   0	  
PPP3CA	   4.1026	   0.1504	   0.0367	   1.1099	   0	  
RUNX1T1	   4.1020	   0.1993	   0.0486	   1.1481	   0	  
CISD1	   4.1019	   0.1763	   0.0430	   1.1300	   0	  
PRUNE2	   4.0977	   0.1526	   0.0372	   1.1116	   0	  
KLK11	   4.0973	   0.5018	   0.1225	   1.4160	   0	  
PCSK5	   4.0960	   0.3065	   0.0748	   1.2367	   0	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MEOX2	   4.0951	   0.1882	   0.0460	   1.1394	   0	  
ITPR2	   4.0928	   0.1602	   0.0391	   1.1175	   0	  
PTPRO	   4.0899	   0.1757	   0.0430	   1.1295	   0	  
CCL20	   4.0885	   0.5787	   0.1415	   1.4935	   0	  
CD300C	   4.0859	   0.1709	   0.0418	   1.1257	   0	  
MUSK	   4.0850	   0.1823	   0.0446	   1.1347	   0	  
DUSP1	   4.0849	   0.4305	   0.1054	   1.3477	   0	  
TGFB2	   4.0849	   0.1462	   0.0358	   1.1066	   0	  
FGR	   4.0812	   0.2851	   0.0699	   1.2185	   0	  
SH3BGRL	   4.0803	   0.2811	   0.0689	   1.2151	   0	  
ALDH1B1	   4.0796	   0.2091	   0.0513	   1.1560	   0	  
HLA-­‐DQB1	   4.0770	   0.4001	   0.0981	   1.3196	   0	  
LILRA2	   4.0751	   0.1996	   0.0490	   1.1484	   0	  
RNASE1	   4.0745	   0.3066	   0.0753	   1.2368	   0	  
CLUAP1	   4.0731	   0.1469	   0.0361	   1.1072	   0	  
ADAM12	   4.0728	   0.1578	   0.0388	   1.1156	   0	  
KRT16	   4.0685	   0.5152	   0.1266	   1.4292	   0	  
CSPG4	   4.0665	   0.2502	   0.0615	   1.1893	   0	  
ZFHX4	   4.0650	   0.2288	   0.0563	   1.1719	   0	  
SPSB1	   4.0633	   0.2015	   0.0496	   1.1499	   0	  
PDP1	   4.0588	   0.2535	   0.0625	   1.1921	   0	  
IFI27	   4.0582	   0.5451	   0.1343	   1.4591	   0	  
TXNDC15	   4.0563	   0.1463	   0.0361	   1.1067	   0	  
UBE2L6	   4.0554	   0.2705	   0.0667	   1.2063	   0	  
LPAR1	   4.0537	   0.2104	   0.0519	   1.1570	   0	  
KIAA0930	   4.0521	   0.1458	   0.0360	   1.1064	   0	  
STRN3	   4.0489	   0.1725	   0.0426	   1.1270	   0	  
RNF130	   4.0428	   0.2466	   0.0610	   1.1864	   0	  
DOK3	   4.0405	   0.1214	   0.0301	   1.0878	   0	  
GPR124	   4.0397	   0.2501	   0.0619	   1.1893	   0	  
IGF2BP2	   4.0392	   0.4128	   0.1022	   1.3312	   0	  
CD93	   4.0378	   0.2678	   0.0663	   1.2040	   0	  
SERPINH1	   4.0367	   0.2642	   0.0655	   1.2010	   0	  
DSC2	   4.0348	   0.4011	   0.0994	   1.3205	   0	  
GPR37	   4.0334	   0.2718	   0.0674	   1.2073	   0	  
GYPC	   4.0314	   0.2327	   0.0577	   1.1750	   0	  
MGAT2	   4.0294	   0.1717	   0.0426	   1.1264	   0	  
PLP2	   4.0266	   0.2332	   0.0579	   1.1754	   0	  
EREG	   4.0265	   0.2456	   0.0610	   1.1855	   0	  
MARCO	   4.0220	   0.3190	   0.0793	   1.2475	   0	  
TXNRD1	   4.0205	   0.2547	   0.0634	   1.1931	   0	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ST8SIA1	   4.0187	   0.1795	   0.0447	   1.1325	   0	  
CAB39	   4.0174	   0.1845	   0.0459	   1.1364	   0	  
CD209	   4.0171	   0.2665	   0.0663	   1.2029	   0	  
ELK3	   4.0170	   0.1036	   0.0258	   1.0744	   0	  
MMP14	   4.0169	   0.1881	   0.0468	   1.1393	   0	  
DDX58	   4.0139	   0.2131	   0.0531	   1.1592	   0	  
TMEM38B	   4.0084	   0.1768	   0.0441	   1.1304	   0	  
CTSL1	   4.0075	   0.2558	   0.0638	   1.1940	   0	  
COL4A2	   4.0070	   0.2485	   0.0620	   1.1880	   0	  
GABRP	   4.0045	   0.4682	   0.1169	   1.3834	   0	  
EVA1B	   4.0037	   0.1768	   0.0442	   1.1304	   0	  
DPP4	   4.0035	   0.3249	   0.0811	   1.2525	   0	  
IFIT5	   4.0027	   0.1665	   0.0416	   1.1223	   0	  
RAP2C	   4.0022	   0.1813	   0.0453	   1.1339	   0	  
PTTG2	   4.0017	   0.1852	   0.0463	   1.1369	   0	  
TMX4	   3.9967	   0.1967	   0.0492	   1.1460	   0	  
ITGAX	   3.9964	   0.2213	   0.0554	   1.1658	   0	  
FAM65B	   3.9956	   0.3329	   0.0833	   1.2595	   0	  
EPYC	   3.9955	   0.3276	   0.0820	   1.2550	   0	  
PTPRD	   3.9950	   0.1486	   0.0372	   1.1085	   0	  
COX7A1	   3.9941	   0.2842	   0.0712	   1.2177	   0	  
IL12RB1	   3.9923	   0.1288	   0.0323	   1.0934	   0	  
GSN	   3.9900	   0.1607	   0.0403	   1.1178	   0	  
ITGB5	   3.9885	   0.2638	   0.0661	   1.2006	   0	  
ADAM23	   3.9880	   0.2448	   0.0614	   1.1849	   0	  
SETBP1	   3.9870	   0.2963	   0.0743	   1.2280	   0	  
MMP3	   3.9849	   0.5230	   0.1313	   1.4370	   0	  
MCFD2	   3.9847	   0.1553	   0.0390	   1.1137	   0	  
MFAP4	   3.9837	   0.5445	   0.1367	   1.4585	   0	  
RFTN1	   3.9831	   0.2680	   0.0673	   1.2041	   0	  
GIMAP5	   3.9799	   0.2728	   0.0685	   1.2081	   0	  
C12orf5	   3.9785	   0.2099	   0.0528	   1.1566	   0	  
MACF1	   3.9747	   0.1302	   0.0327	   1.0944	   0	  
GOLT1B	   3.9743	   0.1951	   0.0491	   1.1448	   0	  
DENND1A	   3.9738	   0.1587	   0.0399	   1.1163	   0	  
NRG1	   3.9735	   0.2095	   0.0527	   1.1563	   0	  
LRP8	   3.9703	   0.2126	   0.0535	   1.1588	   0	  
ENPEP	   3.9664	   0.2137	   0.0539	   1.1597	   0	  
RRAS2	   3.9645	   0.2286	   0.0577	   1.1717	   0	  
MOXD1	   3.9641	   0.3413	   0.0861	   1.2669	   0	  
LMF2	   3.9621	   0.1941	   0.0490	   1.1440	   0	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GPNMB	   3.9577	   0.4176	   0.1055	   1.3357	   0	  
MMP2	   3.9547	   0.2072	   0.0524	   1.1544	   0	  
PIK3CG	   3.9543	   0.2246	   0.0568	   1.1684	   0	  
FHOD3	   3.9508	   0.3365	   0.0852	   1.2627	   0	  
CORO1A	   3.9486	   0.3089	   0.0782	   1.2388	   0	  
GFI1	   3.9482	   0.2125	   0.0538	   1.1587	   0	  
SPEG	   3.9457	   0.1148	   0.0291	   1.0828	   0	  
SAT1	   3.9446	   0.2611	   0.0662	   1.1984	   0	  
UAP1L1	   3.9444	   0.2006	   0.0509	   1.1492	   0	  
IL18R1	   3.9427	   0.2148	   0.0545	   1.1606	   0	  
SSBP2	   3.9409	   0.2006	   0.0509	   1.1491	   0	  
NID1	   3.9403	   0.1602	   0.0407	   1.1174	   0	  
NEIL3	   3.9400	   0.1999	   0.0507	   1.1486	   0	  
DBN1	   3.9374	   0.3223	   0.0819	   1.2503	   0	  
RALB	   3.9356	   0.1740	   0.0442	   1.1282	   0	  
SEC14L1	   3.9350	   0.1591	   0.0404	   1.1166	   0	  
MAP4K4	   3.9335	   0.2187	   0.0556	   1.1636	   0	  
CYR61	   3.9334	   0.3601	   0.0916	   1.2835	   0	  
CDC42EP3	   3.9325	   0.1779	   0.0452	   1.1312	   0	  
ZNF365	   3.9267	   0.3987	   0.1015	   1.3183	   0	  
SORBS3	   3.9229	   0.2222	   0.0567	   1.1665	   0	  
CCL21	   3.9211	   0.3221	   0.0822	   1.2502	   0	  
TREM1	   3.9208	   0.2782	   0.0710	   1.2127	   0	  
WWC3	   3.9193	   0.1980	   0.0505	   1.1471	   0	  
KPNA3	   3.9188	   0.2004	   0.0511	   1.1490	   0	  
PLAC8	   3.9169	   0.4298	   0.1097	   1.3471	   0	  
OSBPL8	   3.9160	   0.1628	   0.0416	   1.1194	   0	  
NTM	   3.9149	   0.3139	   0.0802	   1.2430	   0	  
PNP	   3.9137	   0.2235	   0.0571	   1.1676	   0	  
CREM	   3.9131	   0.1641	   0.0419	   1.1205	   0	  
GPX7	   3.9090	   0.3357	   0.0859	   1.2620	   0	  
ACTB	   3.9075	   0.1954	   0.0500	   1.1451	   0	  
TUBA1A	   3.9021	   0.1856	   0.0476	   1.1373	   0	  
GBE1	   3.9011	   0.2285	   0.0586	   1.1717	   0	  
CSRP2	   3.9001	   0.2779	   0.0713	   1.2124	   0	  
WNT2	   3.8986	   0.2810	   0.0721	   1.2150	   0	  
TRPC1	   3.8967	   0.2127	   0.0546	   1.1589	   0	  
APOE	   3.8911	   0.4350	   0.1118	   1.3519	   0	  
JUN	   3.8863	   0.3546	   0.0913	   1.2787	   0	  
SAP30	   3.8843	   0.2206	   0.0568	   1.1652	   0	  
FGFBP1	   3.8835	   0.6333	   0.1631	   1.5511	   0	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SPTSSA	   3.8829	   0.2297	   0.0592	   1.1726	   0	  
BDKRB2	   3.8814	   0.1704	   0.0439	   1.1254	   0	  
PPP1R12A	   3.8803	   0.2021	   0.0521	   1.1504	   0	  
GRK5	   3.8776	   0.1656	   0.0427	   1.1217	   0	  
SGPP1	   3.8766	   0.1625	   0.0419	   1.1192	   0	  
EPHA3	   3.8726	   0.1901	   0.0491	   1.1408	   0	  
SNCAIP	   3.8713	   0.3558	   0.0919	   1.2797	   0	  
C1QTNF1	   3.8704	   0.2223	   0.0574	   1.1666	   0	  
GTF2H1	   3.8698	   0.1610	   0.0416	   1.1181	   0	  
HAS2	   3.8692	   0.2113	   0.0546	   1.1578	   0	  
DRAP1	   3.8687	   0.1856	   0.0480	   1.1373	   0	  
GM2A	   3.8644	   0.2393	   0.0619	   1.1804	   0	  
CDKN3	   3.8628	   0.2846	   0.0737	   1.2180	   0	  
RIN2	   3.8617	   0.1981	   0.0513	   1.1472	   0	  
FBLN5	   3.8610	   0.2600	   0.0673	   1.1975	   0	  
IGFBP7	   3.8547	   0.2741	   0.0711	   1.2093	   0	  
ICAM1	   3.8538	   0.1430	   0.0371	   1.1042	   0	  
40062	   3.8526	   0.2224	   0.0577	   1.1667	   0	  
STRA6	   3.8489	   0.1897	   0.0493	   1.1406	   0	  
MFNG	   3.8440	   0.2505	   0.0652	   1.1896	   0	  
OMD	   3.8437	   0.1728	   0.0449	   1.1272	   0	  
STK17A	   3.8407	   0.1199	   0.0312	   1.0867	   0	  
FKBP10	   3.8402	   0.1918	   0.0500	   1.1422	   0	  
ACTR10	   3.8382	   0.1429	   0.0372	   1.1041	   0	  
GAL3ST4	   3.8350	   0.1535	   0.0400	   1.1123	   0	  
CD72	   3.8345	   0.2091	   0.0545	   1.1560	   0	  
CD302	   3.8335	   0.1647	   0.0430	   1.1209	   0	  
SLC11A1	   3.8334	   0.3513	   0.0917	   1.2757	   0	  
CD1D	   3.8326	   0.1867	   0.0487	   1.1382	   0	  
MATK	   3.8320	   0.1993	   0.0520	   1.1481	   0	  
LMOD1	   3.8319	   0.2059	   0.0537	   1.1534	   0	  
PDCD1LG2	   3.8281	   0.1177	   0.0307	   1.0850	   0	  
SPARC	   3.8278	   0.3162	   0.0826	   1.2450	   0	  
PLCL1	   3.8277	   0.1065	   0.0278	   1.0766	   0	  
ASAP1	   3.8272	   0.1951	   0.0510	   1.1448	   0	  
IFNGR1	   3.8260	   0.2243	   0.0586	   1.1682	   0	  
PRKCQ	   3.8202	   0.2132	   0.0558	   1.1592	   0	  
HLA-­‐DMB	   3.8196	   0.3576	   0.0936	   1.2812	   0	  
ATP10D	   3.8188	   0.1610	   0.0422	   1.1181	   0	  
NAP1L1	   3.8176	   0.1565	   0.0410	   1.1146	   0	  
MEOX1	   3.8174	   0.2070	   0.0542	   1.1543	   0	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CCL18	   3.8163	   0.2487	   0.0652	   1.1882	   0	  
PKIG	   3.8163	   0.1113	   0.0292	   1.0802	   0	  
COL13A1	   3.8162	   0.1720	   0.0451	   1.1266	   0	  
HIPK3	   3.8106	   0.1246	   0.0327	   1.0902	   0	  
RASL12	   3.8055	   0.2440	   0.0641	   1.1843	   0	  
TAF4B	   3.8040	   0.1742	   0.0458	   1.1284	   0	  
FOLR2	   3.8016	   0.2550	   0.0671	   1.1933	   0	  
LIF	   3.7967	   0.2048	   0.0539	   1.1525	   0	  
MEF2A	   3.7939	   0.1177	   0.0310	   1.0850	   0	  
PILRA	   3.7939	   0.1800	   0.0474	   1.1329	   0	  
CNIH	   3.7938	   0.2034	   0.0536	   1.1514	   0	  
DNM1	   3.7932	   0.1796	   0.0474	   1.1326	   0	  
KYNU	   3.7926	   0.3778	   0.0996	   1.2994	   0	  
LYST	   3.7896	   0.1179	   0.0311	   1.0852	   0	  
HEXB	   3.7850	   0.1624	   0.0429	   1.1191	   0	  
KLK5	   3.7844	   0.3846	   0.1016	   1.3055	   0	  
GSTO1	   3.7819	   0.1906	   0.0504	   1.1412	   0	  
ARHGEF4	   3.7814	   0.1755	   0.0464	   1.1294	   0	  
P2RY10	   3.7803	   0.1626	   0.0430	   1.1193	   0	  
LAMP3	   3.7776	   0.3087	   0.0817	   1.2386	   0	  
BACE1	   3.7776	   0.1197	   0.0317	   1.0865	   0	  
GLI3	   3.7758	   0.1738	   0.0460	   1.1280	   0	  
F8	   3.7747	   0.1499	   0.0397	   1.1095	   0	  
CD59	   3.7692	   0.1730	   0.0459	   1.1274	   0	  
CLEC10A	   3.7682	   0.1599	   0.0424	   1.1172	   0	  
RELN	   3.7672	   0.1923	   0.0511	   1.1426	   0	  
RARRES3	   3.7657	   0.5208	   0.1383	   1.4348	   0	  
ITGBL1	   3.7656	   0.1835	   0.0487	   1.1356	   0	  
IL24	   3.7654	   0.2733	   0.0726	   1.2086	   0	  
MPP6	   3.7635	   0.2706	   0.0719	   1.2063	   0	  
CYTH3	   3.7631	   0.1135	   0.0302	   1.0818	   0	  
LAMA2	   3.7609	   0.1884	   0.0501	   1.1395	   0	  
MMP13	   3.7605	   0.4406	   0.1172	   1.3572	   0	  
CSDC2	   3.7581	   0.1515	   0.0403	   1.1107	   0	  
HSD17B6	   3.7575	   0.2961	   0.0788	   1.2279	   0	  
NOTCH1	   3.7564	   0.2464	   0.0656	   1.1862	   0	  
HEPH	   3.7560	   0.2794	   0.0744	   1.2137	   0	  
SLC25A46	   3.7549	   0.1875	   0.0499	   1.1388	   0	  
SH3BP4	   3.7527	   0.2048	   0.0546	   1.1525	   0	  
TRIP12	   3.7507	   0.1602	   0.0427	   1.1174	   0	  
XAF1	   3.7497	   0.3430	   0.0915	   1.2684	   0	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PER2	   3.7482	   0.1977	   0.0527	   1.1469	   0	  
SLC46A3	   3.7463	   0.2311	   0.0617	   1.1738	   0	  
THRA	   3.7463	   0.2099	   0.0560	   1.1566	   0	  
DYNC1LI1	   3.7450	   0.1221	   0.0326	   1.0883	   0	  
STK38L	   3.7428	   0.1361	   0.0364	   1.0990	   0	  
CPED1	   3.7419	   0.2515	   0.0672	   1.1904	   0	  
RHCG	   3.7413	   0.2973	   0.0795	   1.2289	   0	  
CDH13	   3.7398	   0.2630	   0.0703	   1.2000	   0	  
ABCA12	   3.7383	   0.2219	   0.0594	   1.1663	   0	  
SMTN	   3.7352	   0.1465	   0.0392	   1.1069	   0	  
TRAF5	   3.7346	   0.1851	   0.0496	   1.1369	   0	  
IQGAP1	   3.7343	   0.1699	   0.0455	   1.1250	   0	  
CLTB	   3.7288	   0.1434	   0.0384	   1.1045	   0	  
ITGAL	   3.7264	   0.2663	   0.0715	   1.2027	   0	  
ACTC1	   3.7263	   0.3334	   0.0895	   1.2600	   0	  
CD3D	   3.7263	   0.3763	   0.1010	   1.2980	   0	  
CLEC2B	   3.7221	   0.2593	   0.0697	   1.1969	   0	  
KIAA1199	   3.7217	   0.3952	   0.1062	   1.3151	   0	  
PRDM8	   3.7173	   0.2587	   0.0696	   1.1964	   0	  
CCL7	   3.7162	   0.1489	   0.0401	   1.1088	   0	  
FHOD1	   3.7134	   0.2002	   0.0539	   1.1489	   0	  
SOCS3	   3.7102	   0.2200	   0.0593	   1.1647	   0	  
NTN1	   3.7069	   0.1518	   0.0409	   1.1109	   0	  
RGS19	   3.7063	   0.1643	   0.0443	   1.1206	   0	  
GRP	   3.7053	   0.2249	   0.0607	   1.1687	   0	  
SDCBP	   3.7043	   0.2287	   0.0617	   1.1718	   0	  
MRAS	   3.7042	   0.1356	   0.0366	   1.0986	   0	  
FOSL1	   3.7019	   0.2922	   0.0789	   1.2245	   0	  
IL18BP	   3.7000	   0.1706	   0.0461	   1.1255	   0	  
IGF1	   3.6997	   0.2462	   0.0666	   1.1861	   0	  
EDIL3	   3.6957	   0.1155	   0.0313	   1.0834	   0	  
NSMF	   3.6956	   0.1984	   0.0537	   1.1474	   0	  
CNTNAP1	   3.6937	   0.1987	   0.0538	   1.1477	   0	  
CPA4	   3.6889	   0.3223	   0.0874	   1.2503	   0	  
ACAP1	   3.6888	   0.2499	   0.0677	   1.1891	   0	  
CPA3	   3.6885	   0.3797	   0.1030	   1.3011	   0	  
SLC47A1	   3.6867	   0.2032	   0.0551	   1.1513	   0	  
NR4A3	   3.6850	   0.1377	   0.0374	   1.1002	   0	  
PTPN1	   3.6795	   0.1496	   0.0407	   1.1093	   0	  
GNA12	   3.6764	   0.1461	   0.0397	   1.1066	   0	  
KLK7	   3.6720	   0.4318	   0.1176	   1.3490	   0	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TRIM21	   3.6694	   0.1840	   0.0501	   1.1360	   0	  
CD52	   3.6688	   0.4008	   0.1092	   1.3202	   0	  
SDS	   3.6684	   0.1849	   0.0504	   1.1367	   0	  
NACC2	   3.6660	   0.1904	   0.0519	   1.1411	   0	  
HSPA1A	   3.6660	   0.4838	   0.1320	   1.3984	   0	  
PRKCB	   3.6641	   0.1980	   0.0540	   1.1471	   0	  
KLK10	   3.6638	   0.2618	   0.0715	   1.1990	   0	  
TNFRSF12A	   3.6613	   0.3954	   0.1080	   1.3153	   0	  
MMP1	   3.6546	   0.5486	   0.1501	   1.4627	   0	  
MICAL2	   3.6536	   0.1489	   0.0408	   1.1087	   0	  
P2RY6	   3.6485	   0.1440	   0.0395	   1.1050	   0	  
HSPB2	   3.6470	   0.1463	   0.0401	   1.1067	   0	  
TGM1	   3.6470	   0.3129	   0.0858	   1.2422	   0	  
FXYD5	   3.6468	   0.2633	   0.0722	   1.2002	   0	  
STK10	   3.6440	   0.1558	   0.0427	   1.1140	   0	  
ASB1	   3.6439	   0.1901	   0.0522	   1.1409	   0	  
MTHFD2	   3.6385	   0.2332	   0.0641	   1.1754	   0	  
WWC2	   3.6380	   0.1007	   0.0277	   1.0723	   0	  
FBXL2	   3.6354	   0.1889	   0.0520	   1.1399	   0	  
COL4A1	   3.6351	   0.2261	   0.0622	   1.1697	   0	  
ARHGEF3	   3.6308	   0.1903	   0.0524	   1.1410	   0	  
MCTS1	   3.6282	   0.1926	   0.0531	   1.1428	   0	  
GCNT2	   3.6273	   0.1575	   0.0434	   1.1153	   0	  
KIAA1033	   3.6266	   0.1646	   0.0454	   1.1209	   0	  
SP140	   3.6265	   0.1618	   0.0446	   1.1187	   0	  
TBC1D2	   3.6256	   0.2374	   0.0655	   1.1789	   0	  
CKAP4	   3.6239	   0.2049	   0.0565	   1.1526	   0	  
SP100	   3.6233	   0.1395	   0.0385	   1.1015	   0	  
PLS3	   3.6227	   0.2091	   0.0577	   1.1560	   0	  
IL11	   3.6144	   0.2194	   0.0607	   1.1642	   0	  
POPDC3	   3.6138	   0.3099	   0.0858	   1.2396	   0	  
SPRR1B	   3.6125	   0.4845	   0.1341	   1.3991	   0	  
AZI2	   3.6111	   0.1372	   0.0380	   1.0998	   0	  
BTG1	   3.6104	   0.2049	   0.0568	   1.1526	   0	  
SLC35G2	   3.6079	   0.2243	   0.0622	   1.1682	   0	  
ACOT7	   3.6069	   0.1975	   0.0548	   1.1467	   0	  
GALNT6	   3.6057	   0.2250	   0.0624	   1.1688	   0	  
CACNA2D3	   3.6012	   0.1521	   0.0422	   1.1112	   0	  
LIMS2	   3.5998	   0.1521	   0.0423	   1.1112	   0	  
CDH2	   3.5992	   0.4150	   0.1153	   1.3333	   0	  
LILRA5	   3.5983	   0.1775	   0.0493	   1.1309	   0	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SNX24	   3.5982	   0.1444	   0.0401	   1.1053	   0	  
IGFLR1	   3.5967	   0.2179	   0.0606	   1.1630	   0	  
ELMO2	   3.5967	   0.0989	   0.0275	   1.0710	   0	  
SSH1	   3.5953	   0.1494	   0.0416	   1.1091	   0	  
RAB38	   3.5902	   0.4031	   0.1123	   1.3224	   0	  
ANXA3	   3.5872	   0.4118	   0.1148	   1.3303	   0	  
CXCL5	   3.5872	   0.4226	   0.1178	   1.3404	   0	  
PPP4R4	   3.5859	   0.1572	   0.0438	   1.1151	   0	  
NCS1	   3.5841	   0.1981	   0.0553	   1.1472	   0	  
APP	   3.5817	   0.1947	   0.0544	   1.1445	   0	  
ADORA3	   3.5768	   0.1747	   0.0488	   1.1287	   0	  
MAPK9	   3.5738	   0.1430	   0.0400	   1.1042	   0	  
MUC16	   3.5710	   0.4169	   0.1168	   1.3351	   0	  
APOBEC3A	   3.5672	   0.3166	   0.0887	   1.2454	   0	  
CXCL6	   3.5640	   0.4772	   0.1339	   1.3920	   0	  
EMILIN2	   3.5614	   0.2539	   0.0713	   1.1924	   0	  
ARHGEF10	   3.5603	   0.2371	   0.0666	   1.1786	   0	  
NCF4	   3.5602	   0.1972	   0.0554	   1.1465	   0	  
LAMP5	   3.5593	   0.1968	   0.0553	   1.1462	   0	  
SMOX	   3.5589	   0.2066	   0.0580	   1.1540	   0	  
CARD10	   3.5575	   0.2464	   0.0693	   1.1862	   0	  
TPST2	   3.5569	   0.1966	   0.0553	   1.1460	   0	  
DENND3	   3.5543	   0.1506	   0.0424	   1.1100	   0	  
FCN1	   3.5522	   0.3602	   0.1014	   1.2836	   0	  
SLAMF7	   3.5502	   0.1804	   0.0508	   1.1332	   0	  
GATA6	   3.5498	   0.1347	   0.0379	   1.0979	   0	  
EYA4	   3.5494	   0.1326	   0.0374	   1.0962	   0	  
ST6GALNAC4	   3.5490	   0.1369	   0.0386	   1.0995	   0	  
TNIP1	   3.5480	   0.1765	   0.0497	   1.1301	   0	  
SLC22A4	   3.5476	   0.1886	   0.0532	   1.1396	   0	  
PIGK	   3.5458	   0.1586	   0.0447	   1.1162	   0	  
SEC24D	   3.5454	   0.1809	   0.0510	   1.1336	   0	  
ST6GAL1	   3.5420	   0.1979	   0.0559	   1.1470	   0	  
RUSC2	   3.5400	   0.1243	   0.0351	   1.0900	   0	  
DENND5B	   3.5372	   0.1862	   0.0526	   1.1377	   0	  
SOD3	   3.5353	   0.1825	   0.0516	   1.1349	   0	  
MCAM	   3.5346	   0.1057	   0.0299	   1.0760	   0	  
CASQ2	   3.5339	   0.2348	   0.0664	   1.1767	   0	  
GPC4	   3.5334	   0.2805	   0.0794	   1.2146	   0	  
BEST1	   3.5333	   0.1148	   0.0325	   1.0828	   0	  
PITX1	   3.5328	   0.3162	   0.0895	   1.2450	   0	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TIAM2	   3.5327	   0.1470	   0.0416	   1.1072	   0	  
SLC22A3	   3.5324	   0.1436	   0.0407	   1.1047	   0	  
PPEF1	   3.5307	   0.1594	   0.0451	   1.1168	   0	  
TPPP3	   3.5263	   0.1793	   0.0508	   1.1323	   0	  
AP3S1	   3.5256	   0.1762	   0.0500	   1.1299	   0	  
PSMB8	   3.5245	   0.2056	   0.0583	   1.1531	   0	  
GPR132	   3.5157	   0.1054	   0.0300	   1.0758	   0	  
LBH	   3.5152	   0.1255	   0.0357	   1.0909	   0	  
ME2	   3.5140	   0.1613	   0.0459	   1.1183	   0	  
OSBPL1A	   3.5134	   0.1980	   0.0564	   1.1471	   0	  
DZIP1	   3.5110	   0.1676	   0.0477	   1.1232	   0	  
HLA-­‐E	   3.5088	   0.2156	   0.0614	   1.1612	   0	  
ADAMTS3	   3.5040	   0.1260	   0.0360	   1.0913	   0	  
OXCT1	   3.5038	   0.1832	   0.0523	   1.1354	   0	  
OLFM1	   3.5038	   0.2712	   0.0774	   1.2068	   0	  
NT5DC3	   3.5034	   0.1846	   0.0527	   1.1365	   0	  
SLC17A9	   3.5021	   0.1574	   0.0449	   1.1152	   0	  
IKZF1	   3.5001	   0.2185	   0.0624	   1.1635	   0	  
SFRP1	   3.5000	   0.3686	   0.1053	   1.2911	   0	  
PJA2	   3.4990	   0.1549	   0.0443	   1.1133	   0	  
S100A7	   3.4953	   0.7545	   0.2159	   1.6871	   0	  
CDH3	   3.4915	   0.4423	   0.1267	   1.3588	   0	  
NAV3	   3.4904	   0.0967	   0.0277	   1.0693	   0	  
LITAF	   3.4895	   0.2022	   0.0580	   1.1505	   0	  
MFF	   3.4868	   0.1871	   0.0536	   1.1384	   0	  
ARHGAP4	   3.4843	   0.2456	   0.0705	   1.1856	   0	  
MAP1A	   3.4841	   0.1607	   0.0461	   1.1178	   0	  
LHFPL2	   3.4787	   0.1771	   0.0509	   1.1306	   0	  
DES	   3.4765	   0.2947	   0.0848	   1.2266	   0	  
PPP2CB	   3.4759	   0.1282	   0.0369	   1.0930	   0	  
MPHOSPH9	   3.4740	   0.1340	   0.0386	   1.0974	   0	  
LARP6	   3.4720	   0.2316	   0.0667	   1.1741	   0	  
OLFM4	   3.4717	   0.4854	   0.1398	   1.4000	   0	  
RASGRP1	   3.4694	   0.2412	   0.0695	   1.1819	   0	  
L1CAM	   3.4684	   0.1353	   0.0390	   1.0983	   0	  
LRRK1	   3.4664	   0.1339	   0.0386	   1.0972	   0	  
TCN2	   3.4646	   0.2145	   0.0619	   1.1603	   0	  
RUNX2	   3.4637	   0.1278	   0.0369	   1.0926	   0	  
SLC16A3	   3.4626	   0.2788	   0.0805	   1.2132	   0	  
HLA-­‐DPB1	   3.4605	   0.2737	   0.0791	   1.2089	   0	  
CSNK1A1	   3.4599	   0.1108	   0.0320	   1.0798	   0	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SPON1	   3.4560	   0.3898	   0.1128	   1.3102	   0	  
C11orf95	   3.4545	   0.1343	   0.0389	   1.0976	   0	  
PARP8	   3.4475	   0.1889	   0.0548	   1.1399	   0	  
F13A1	   3.4460	   0.3267	   0.0948	   1.2541	   0	  
KRT14	   3.4452	   0.6404	   0.1859	   1.5588	   0	  
ACVRL1	   3.4408	   0.1497	   0.0435	   1.1094	   0	  
NES	   3.4397	   0.1957	   0.0569	   1.1453	   0	  
HAT1	   3.4390	   0.1735	   0.0505	   1.1278	   0	  
LTB	   3.4384	   0.2906	   0.0845	   1.2231	   0	  
SATB2	   3.4355	   0.2000	   0.0582	   1.1487	   0	  
AOX1	   3.4321	   0.2173	   0.0633	   1.1625	   0	  
CRIP1	   3.4303	   0.3230	   0.0942	   1.2510	   0	  
C9orf3	   3.4294	   0.1776	   0.0518	   1.1310	   0	  
ARHGAP15	   3.4288	   0.2822	   0.0823	   1.2160	   0	  
SCG2	   3.4274	   0.2639	   0.0770	   1.2007	   0	  
RNH1	   3.4252	   0.1335	   0.0390	   1.0969	   0	  
CXorf21	   3.4245	   0.0888	   0.0259	   1.0635	   0	  
STEAP4	   3.4232	   0.1699	   0.0496	   1.1250	   0	  
LDHA	   3.4206	   0.1965	   0.0575	   1.1459	   0	  
POU2F2	   3.4133	   0.0985	   0.0289	   1.0707	   0	  
FBXO5	   3.4126	   0.1823	   0.0534	   1.1347	   0	  
SORBS1	   3.4120	   0.1646	   0.0483	   1.1209	   0	  
PFKP	   3.4119	   0.2524	   0.0740	   1.1912	   0	  
FOXD1	   3.4111	   0.3613	   0.1059	   1.2846	   0	  
PPP2R3C	   3.4101	   0.1313	   0.0385	   1.0952	   0	  
PGK1	   3.4068	   0.1973	   0.0579	   1.1466	   0	  
CYB5R3	   3.4032	   0.1469	   0.0432	   1.1072	   0	  
KLF12	   3.4014	   0.1231	   0.0362	   1.0891	   0	  
PVRIG	   3.3991	   0.2403	   0.0707	   1.1813	   0	  
EXOC5	   3.3980	   0.1169	   0.0344	   1.0844	   0	  
PER1	   3.3977	   0.0989	   0.0291	   1.0709	   0	  
PSME2	   3.3947	   0.1979	   0.0583	   1.1471	   0	  
TOX	   3.3925	   0.1411	   0.0416	   1.1028	   0	  
SLC6A9	   3.3919	   0.1724	   0.0508	   1.1269	   0	  
YIPF5	   3.3896	   0.1988	   0.0587	   1.1477	   0	  
DAAM2	   3.3873	   0.1420	   0.0419	   1.1034	   0	  
ANPEP	   3.3868	   0.2844	   0.0840	   1.2179	   0	  
MAP2	   3.3867	   0.1969	   0.0582	   1.1463	   0	  
TRDMT1	   3.3859	   0.1041	   0.0307	   1.0748	   0	  
ETS1	   3.3841	   0.1861	   0.0550	   1.1377	   0	  
ACAT1	   3.3824	   0.1900	   0.0562	   1.1408	   0	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AK1	   3.3823	   0.1847	   0.0546	   1.1366	   0	  
SCEL	   3.3801	   0.2624	   0.0776	   1.1995	   0	  
SCML1	   3.3793	   0.1904	   0.0564	   1.1411	   0	  
CLDND1	   3.3759	   0.1616	   0.0479	   1.1185	   0	  
CASP5	   3.3737	   0.1071	   0.0318	   1.0771	   0	  
IL1B	   3.3717	   0.4536	   0.1345	   1.3695	   0	  
CCL11	   3.3708	   0.2706	   0.0803	   1.2063	   0	  
VAMP1	   3.3703	   0.2043	   0.0606	   1.1521	   0	  
EGR1	   3.3701	   0.3331	   0.0989	   1.2598	   0	  
CD70	   3.3693	   0.2565	   0.0761	   1.1945	   0	  
CMKLR1	   3.3665	   0.1045	   0.0310	   1.0751	   0	  
LAMC1	   3.3653	   0.1713	   0.0509	   1.1260	   0	  
TRIM36	   3.3647	   0.0987	   0.0293	   1.0708	   0	  
MAGEH1	   3.3535	   0.1290	   0.0385	   1.0936	   0	  
PDZK1IP1	   3.3527	   0.3737	   0.1115	   1.2957	   0	  
C11orf73	   3.3497	   0.1551	   0.0463	   1.1135	   0	  
MICB	   3.3469	   0.2566	   0.0767	   1.1947	   0	  
SSR1	   3.3457	   0.1348	   0.0403	   1.0979	   0	  
IRX5	   3.3455	   0.2984	   0.0892	   1.2298	   0	  
DUSP7	   3.3449	   0.1041	   0.0311	   1.0748	   0	  
KIF18A	   3.3437	   0.2061	   0.0616	   1.1536	   0	  
P2RX7	   3.3426	   0.1240	   0.0371	   1.0898	   0	  
PNMA2	   3.3399	   0.2211	   0.0662	   1.1656	   0	  
FAM134B	   3.3388	   0.1712	   0.0513	   1.1260	   0	  
TOM1	   3.3386	   0.1304	   0.0391	   1.0946	   0	  
NACAD	   3.3384	   0.2131	   0.0638	   1.1592	   0	  
SNX6	   3.3359	   0.0967	   0.0290	   1.0693	   0	  
CLEC2D	   3.3347	   0.1323	   0.0397	   1.0960	   0	  
ZFP36L1	   3.3342	   0.1807	   0.0542	   1.1334	   0	  
ASB9	   3.3310	   0.1794	   0.0539	   1.1324	   0	  
ATOX1	   3.3308	   0.1593	   0.0478	   1.1167	   0	  
PLD1	   3.3272	   0.1851	   0.0556	   1.1369	   0	  
ATF2	   3.3259	   0.1145	   0.0344	   1.0826	   0	  
EYA1	   3.3248	   0.1691	   0.0509	   1.1244	   0	  
LILRB5	   3.3222	   0.1744	   0.0525	   1.1285	   0	  
PIM2	   3.3218	   0.2950	   0.0888	   1.2269	   0	  
BCHE	   3.3192	   0.2519	   0.0759	   1.1908	   0	  
CDCA4	   3.3192	   0.1418	   0.0427	   1.1033	   0	  
RHOH	   3.3189	   0.1360	   0.0410	   1.0988	   0	  
STARD8	   3.3187	   0.1287	   0.0388	   1.0933	   0	  
CD247	   3.3180	   0.2971	   0.0895	   1.2286	   0	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YWHAH	   3.3136	   0.1414	   0.0427	   1.1030	   0	  
USP25	   3.3105	   0.1063	   0.0321	   1.0765	   0	  
HERC6	   3.3104	   0.2775	   0.0838	   1.2121	   0	  
PID1	   3.3102	   0.1878	   0.0567	   1.1390	   0	  
CCNA1	   3.3079	   0.2219	   0.0671	   1.1663	   0	  
AKAP13	   3.3072	   0.1349	   0.0408	   1.0980	   0	  
CYSLTR1	   3.3070	   0.1867	   0.0564	   1.1381	   0	  
PNMAL1	   3.3052	   0.2230	   0.0675	   1.1672	   0	  
KCNE4	   3.3034	   0.0932	   0.0282	   1.0668	   0	  
KIR2DL3	   3.3004	   0.2093	   0.0634	   1.1561	   0	  
PARVA	   3.2998	   0.1511	   0.0458	   1.1104	   0	  
PITPNB	   3.2975	   0.1185	   0.0359	   1.0856	   0	  
SEMA6B	   3.2972	   0.1149	   0.0348	   1.0829	   0	  
KIAA0040	   3.2936	   0.1225	   0.0372	   1.0886	   0	  
LPHN2	   3.2918	   0.2284	   0.0694	   1.1716	   0	  
AGPS	   3.2909	   0.1726	   0.0525	   1.1271	   0	  
COLGALT1	   3.2840	   0.1809	   0.0551	   1.1336	   0	  
HSPB11	   3.2829	   0.2029	   0.0618	   1.1510	   0	  
LSP1	   3.2794	   0.1173	   0.0358	   1.0847	   0	  
WDR44	   3.2770	   0.1077	   0.0329	   1.0775	   0	  
CHI3L2	   3.2749	   0.2523	   0.0770	   1.1911	   0	  
BST2	   3.2728	   0.3643	   0.1113	   1.2873	   0	  
LILRA3	   3.2715	   0.1671	   0.0511	   1.1228	   0	  
LCK	   3.2705	   0.1802	   0.0551	   1.1331	   0	  
STAMBPL1	   3.2704	   0.1796	   0.0549	   1.1326	   0	  
NFKB2	   3.2698	   0.1231	   0.0376	   1.0890	   0	  
FJX1	   3.2671	   0.2487	   0.0761	   1.1881	   0	  
CH25H	   3.2661	   0.2858	   0.0875	   1.2191	   0	  
XRCC4	   3.2593	   0.1052	   0.0323	   1.0756	   0	  
GNG11	   3.2592	   0.2635	   0.0809	   1.2004	   0	  
TFE3	   3.2512	   0.1069	   0.0329	   1.0769	   0	  
PLEKHG3	   3.2497	   0.2115	   0.0651	   1.1579	   0	  
SH3TC1	   3.2496	   0.2031	   0.0625	   1.1512	   0	  
P2RY14	   3.2483	   0.1436	   0.0442	   1.1047	   0	  
TMSB10	   3.2469	   0.1158	   0.0357	   1.0835	   0	  
IQCG	   3.2462	   0.1725	   0.0531	   1.1270	   0	  
MAP3K7	   3.2441	   0.1026	   0.0316	   1.0737	   0	  
RABEPK	   3.2433	   0.1215	   0.0375	   1.0878	   0	  
FAM171A1	   3.2418	   0.2649	   0.0817	   1.2016	   0	  
CD3G	   3.2417	   0.2009	   0.0620	   1.1494	   0	  
SERPINE1	   3.2398	   0.3505	   0.1082	   1.2750	   0	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APOL3	   3.2370	   0.2448	   0.0756	   1.1850	   0	  
NUMB	   3.2352	   0.1213	   0.0375	   1.0877	   0	  
RARRES2	   3.2337	   0.3521	   0.1089	   1.2765	   0	  
	  
TRIM3	   3.2334	   0.0966	   0.0299	   1.0693	   0	  
TNNT1	   3.2330	   0.1846	   0.0571	   1.1365	   0	  
MME	   3.2325	   0.3499	   0.1083	   1.2745	   0	  
CSF3	   3.2300	   0.1290	   0.0399	   1.0935	   0	  
IGFBP5	   3.2297	   0.4261	   0.1319	   1.3436	   0	  
AEN	   3.2270	   0.1502	   0.0466	   1.1097	   0	  
PPIC	   3.2268	   0.2113	   0.0655	   1.1577	   0	  
VNN2	   3.2243	   0.2019	   0.0626	   1.1502	   0	  
NCL	   3.2197	   0.1166	   0.0362	   1.0842	   0	  
GNB5	   3.2181	   0.1273	   0.0395	   1.0922	   0	  
ATP1B3	   3.2180	   0.1619	   0.0503	   1.1188	   0	  
FAT4	   3.2165	   0.1297	   0.0403	   1.0941	   0	  
GABBR1	   3.2118	   0.1954	   0.0609	   1.1451	   0	  
MGLL	   3.2113	   0.1834	   0.0571	   1.1355	   0	  
CDK17	   3.2098	   0.0861	   0.0268	   1.0615	   0	  
PTTG1	   3.2090	   0.2233	   0.0696	   1.1674	   0	  
BICD1	   3.2080	   0.0996	   0.0311	   1.0715	   0	  
HCLS1	   3.2075	   0.3409	   0.1063	   1.2665	   0	  
SCD5	   3.1997	   0.1209	   0.0378	   1.0874	   0	  
ADORA1	   3.1981	   0.1372	   0.0429	   1.0998	   0	  
CSF3R	   3.1980	   0.2265	   0.0708	   1.1700	   0	  
AKT3	   3.1970	   0.1217	   0.0381	   1.0880	   0	  
ADORA2B	   3.1952	   0.3037	   0.0951	   1.2343	   0	  
SLC7A6	   3.1948	   0.1313	   0.0411	   1.0953	   0	  
HSPA4L	   3.1948	   0.2392	   0.0749	   1.1803	   0	  
PCMT1	   3.1943	   0.1198	   0.0375	   1.0866	   0	  
FMO2	   3.1932	   0.1505	   0.0471	   1.1099	   0	  
DHRS9	   3.1860	   0.3408	   0.1070	   1.2665	   0	  
DNAJC24	   3.1854	   0.1217	   0.0382	   1.0880	   0	  
FGF7	   3.1830	   0.1048	   0.0329	   1.0754	   0	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APPENDIX B: PAM GENE LIST 
List	  of	  Significant	  Genes	  
Offset	  Quantile	   50	   	  	   Offset	  Value	   0.283592351	  
	  	   both	   	  	   RNG	  Seed	   420473	  
	  	   Prior	  Distribution	  (Sample	  Prior)	  
	  	   	  	   Class	   1	   2	  
	  	   	  	   Prob.	   0.541984733	   0.458015267	  
  id name 1 score 2 score 
	  	   UPK2	   UPK2	   -­‐0.1166	   0.138	  
	  	   SCNN1B	   SCNN1B	   -­‐0.0955	   0.113	  
	  	   PPARG	   PPARG	   -­‐0.0815	   0.0965	  
	  	   TOX3	   TOX3	   -­‐0.0652	   0.0771	  
	  	   GATA3	   GATA3	   -­‐0.0629	   0.0745	  
	  	   HMGCS2	   HMGCS2	   -­‐0.0611	   0.0723	  
	  	   RAB15	   RAB15	   -­‐0.0583	   0.069	  
	  	   AHNAK2	   AHNAK2	   0.0569	   -­‐0.0674	  
	  	   ADIRF	   ADIRF	   -­‐0.0558	   0.066	  
	  	   SEMA5A	   SEMA5A	   -­‐0.0491	   0.0581	  
	  	   CHST15	   CHST15	   0.0476	   -­‐0.0563	  
	  	   TRAK1	   TRAK1	   -­‐0.0453	   0.0536	  
	  	   SCNN1G	   SCNN1G	   -­‐0.0433	   0.0512	  
	  	   MT1X	   MT1X	   0.0411	   -­‐0.0486	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   TMPRSS2	   TMPRSS2	   -­‐0.041	   0.0485	  
	  	   VGLL1	   VGLL1	   -­‐0.036	   0.0426	  
	  	   TBX2	   TBX2	   -­‐0.0326	   0.0386	  
	  	   UPK1A	   UPK1A	   -­‐0.03	   0.0355	  
	  	   GAREM	   GAREM	   -­‐0.0296	   0.035	  
	  	   BHMT	   BHMT	   -­‐0.0234	   0.0277	  
	  	   SPINK1	   SPINK1	   -­‐0.0209	   0.0248	  
	  	   GPD1L	   GPD1L	   -­‐0.0196	   0.0232	  
	  	   RNF128	   RNF128	   -­‐0.0196	   0.0232	  
	  	   CYP2J2	   CYP2J2	   -­‐0.0194	   0.023	  
	  	   EMP3	   EMP3	   0.0194	   -­‐0.0229	  
	  	   GDPD3	   GDPD3	   -­‐0.0188	   0.0222	  
	  	   FBP1	   FBP1	   -­‐0.0184	   0.0218	  
	  	   MSN	   MSN	   0.0174	   -­‐0.0206	  
	  	   MT2A	   MT2A	   0.0153	   -­‐0.0181	  
	  	   CDK6	   CDK6	   0.0149	   -­‐0.0176	  
	  	   ALOX5AP	   ALOX5AP	   0.0125	   -­‐0.0148	  
	  	   PRRX1	   PRRX1	   0.0107	   -­‐0.0127	  
	  	   SLC27A2	   SLC27A2	   -­‐0.0097	   0.0115	  
	  	   TMEM97	   TMEM97	   -­‐0.0077	   0.0091	  
	  	   CD14	   CD14	   0.007	   -­‐0.0082	  
	  	   PLEKHG6	   PLEKHG6	   -­‐0.006	   0.0071	  
	  	   CYP4B1	   CYP4B1	   -­‐0.005	   0.0059	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   GLIPR1	   GLIPR1	   0.0047	   -­‐0.0055	  
	  	   PDGFC	   PDGFC	   0.0046	   -­‐0.0055	  
	  	   PRKCDBP	   PRKCDBP	   0.0045	   -­‐0.0053	  
	  	   FAP	   FAP	   0.0035	   -­‐0.0042	  
	  	   CAPN5	   CAPN5	   -­‐0.0035	   0.0041	  
	  	   PALLD	   PALLD	   0.0025	   -­‐0.003	  
	  	   TUBB6	   TUBB6	   0.0024	   -­‐0.0028	  
	  	   SLC9A2	   SLC9A2	   -­‐0.0022	   0.0026	  
	  	   PPFIBP2	   PPFIBP2	   -­‐0.0013	   0.0015	  
	  	   FAM174B	   FAM174B	   -­‐0.001	   0.0012	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APPENDIX C: GENE SET ENRICHEMENT ANALYSIS 
 
  Enriched in Basal (nom pvalue<1%)         
Rank MSigDB SIZE ES NES NOM p-val 
1 
CHARAFE_BREAST_CANCER_LUMINAL_V
S_MESENCHYMAL_DN 364 0.69 2.25 0 
2 
HOSHIDA_LIVER_CANCER_SUBCLASS_S
1 224 0.64 2.18 0 
3 
AZARE_NEOPLASTIC_TRANSFORMATION
_BY_STAT3_DN 114 0.64 2.16 0 
4 
PANGAS_TUMOR_SUPPRESSION_BY_SM
AD1_AND_SMAD5_UP 88 0.64 2.11 0 
5 
VECCHI_GASTRIC_CANCER_ADVANCED_
VS_EARLY_UP 128 0.74 2.11 0 
6 CUI_TCF21_TARGETS_UP 33 0.71 2.1 0 
7 
SCHUETZ_BREAST_CANCER_DUCTAL_IN
VASIVE_UP 327 0.78 2.1 0 
8 
CHARAFE_BREAST_CANCER_LUMINAL_V
S_BASAL_DN 374 0.64 2.09 0 
9 LIM_MAMMARY_STEM_CELL_UP 356 0.65 2.09 0.002 
10 
TURASHVILI_BREAST_LOBULAR_CARCIN
OMA_VS_DUCTAL_NORMAL_UP 54 0.8 2.06 0 
11 
LAIHO_COLORECTAL_CANCER_SERRAT
ED_UP 103 0.6 2.06 0 
12 IGLESIAS_E2F_TARGETS_UP 140 0.59 2.06 0 
13 POOLA_INVASIVE_BREAST_CANCER_UP 258 0.69 2.06 0 
14 WAMUNYOKOLI_OVARIAN_CANCER_LMP 153 0.58 2.04 0 
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_DN 
15 RODWELL_AGING_KIDNEY_UP 352 0.62 2.04 0.002 
16 SERVITJA_ISLET_HNF1A_TARGETS_UP 136 0.62 2.04 0 
17 
TURASHVILI_BREAST_LOBULAR_CARCIN
OMA_VS_LOBULAR_NORMAL_DN 57 0.74 2.03 0 
18 
HINATA_NFKB_TARGETS_FIBROBLAST_U
P 79 0.59 2.03 0 
19 KHETCHOUMIAN_TRIM24_TARGETS_UP 43 0.7 2.03 0.002 
20 PLASARI_TGFB1_TARGETS_10HR_UP 158 0.59 2.03 0 
21 
LINDGREN_BLADDER_CANCER_CLUSTE
R_2B 318 0.72 2.02 0 
22 
CHIARADONNA_NEOPLASTIC_TRANSFO
RMATION_CDC25_UP 98 0.57 2.01 0 
23 ROZANOV_MMP14_TARGETS_UP 199 0.56 2.01 0 
24 
LINDSTEDT_DENDRITIC_CELL_MATURATI
ON_A 59 0.73 2.01 0 
25 BOQUEST_STEM_CELL_UP 244 0.64 2.01 0 
26 
PETROVA_ENDOTHELIUM_LYMPHATIC_V
S_BLOOD_DN 151 0.61 2.01 0 
27 SMID_BREAST_CANCER_LUMINAL_B_DN 500 0.58 2.01 0 
28 THUM_SYSTOLIC_HEART_FAILURE_UP 328 0.53 2 0 
29 LINDVALL_IMMORTALIZED_BY_TERT_DN 62 0.67 2 0.002 
30 VERHAAK_GLIOBLASTOMA_NEURAL 195 0.59 2 0.002 
31 
LINDGREN_BLADDER_CANCER_CLUSTE
R_2A_DN 115 0.65 2 0 
32 
RODWELL_AGING_KIDNEY_NO_BLOOD_




_UP 181 0.54 1.99 0 
34 KIM_GLIS2_TARGETS_UP 77 0.72 1.99 0.002 
35 BURTON_ADIPOGENESIS_7 47 0.62 1.98 0 
36 
OKAMOTO_LIVER_CANCER_MULTICENT
RIC_OCCURRENCE_UP 23 0.69 1.98 0 
37 AZARE_STAT3_TARGETS 23 0.72 1.98 0 
38 
LIEN_BREAST_CARCINOMA_METAPLASTI
C_VS_DUCTAL_UP 66 0.67 1.98 0.002 
39 CROMER_TUMORIGENESIS_UP 58 0.77 1.98 0 
40 CHICAS_RB1_TARGETS_CONFLUENT 436 0.52 1.98 0 
41 MARKEY_RB1_ACUTE_LOF_UP 174 0.61 1.98 0.002 
42 
MCMURRAY_TP53_HRAS_COOPERATION
_RESPONSE_UP 23 0.7 1.98 0 
43 MCLACHLAN_DENTAL_CARIES_DN 219 0.68 1.97 0.002 
44 MCLACHLAN_DENTAL_CARIES_UP 228 0.72 1.97 0.002 
45 PID_INTEGRIN1_PATHWAY 62 0.72 1.97 0 
46 
BRUECKNER_TARGETS_OF_MIRLET7A3_
DN 61 0.66 1.97 0 
47 
SASSON_RESPONSE_TO_FORSKOLIN_D
N 86 0.55 1.97 0.002 
48 JISON_SICKLE_CELL_DISEASE_UP 169 0.54 1.97 0 
49 
TAKEDA_TARGETS_OF_NUP98_HOXA9_F
USION_8D_DN 149 0.63 1.96 0 
50 DASU_IL6_SIGNALING_UP 57 0.62 1.96 0.002 
51 
LINDGREN_BLADDER_CANCER_HIGH_RE




_D7_UP 86 0.74 1.96 0.004 
53 POTTI_TOPOTECAN_SENSITIVITY 120 0.56 1.96 0 
54 
MIYAGAWA_TARGETS_OF_EWSR1_ETS_
FUSIONS_DN 159 0.59 1.95 0 
55 
JECHLINGER_EPITHELIAL_TO_MESENCH
YMAL_TRANSITION_UP 65 0.7 1.95 0.004 
56 LIM_MAMMARY_LUMINAL_MATURE_DN 82 0.63 1.95 0.006 
57 RAMALHO_STEMNESS_DN 57 0.66 1.95 0 
58 
ZWANG_CLASS_2_TRANSIENTLY_INDUC
ED_BY_EGF 35 0.63 1.95 0.004 
59 
NIELSEN_MALIGNAT_FIBROUS_HISTIOCY
TOMA_UP 18 0.83 1.95 0.002 
60 KONDO_EZH2_TARGETS 172 0.48 1.95 0 
61 PID_UPA_UPAR_PATHWAY 38 0.66 1.94 0.002 
62 
REN_ALVEOLAR_RHABDOMYOSARCOMA
_DN 391 0.56 1.94 0.008 
63 
YAMASHITA_METHYLATED_IN_PROSTAT
E_CANCER 41 0.65 1.94 0 
64 
LABBE_TARGETS_OF_TGFB1_AND_WNT3
A_UP 89 0.54 1.94 0 
65 HAN_JNK_SINGALING_UP 28 0.69 1.94 0.002 
66 
CHARAFE_BREAST_CANCER_BASAL_VS
_MESENCHYMAL_DN 38 0.72 1.93 0 
67 NADLER_OBESITY_UP 58 0.66 1.93 0.004 
68 WANG_SMARCE1_TARGETS_UP 193 0.56 1.93 0.004 
69 GRAESSMANN_RESPONSE_TO_MC_AND 156 0.54 1.93 0 
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_SERUM_DEPRIVATION_UP 
70 DOANE_BREAST_CANCER_CLASSES_DN 29 0.72 1.93 0 
71 
KEEN_RESPONSE_TO_ROSIGLITAZONE_
DN 92 0.6 1.93 0.002 
72 APRELIKOVA_BRCA1_TARGETS 46 0.55 1.93 0.002 
73 LIAN_LIPA_TARGETS_6M 55 0.69 1.93 0.002 
74 
ZHAN_LATE_DIFFERENTIATION_GENES_
UP 32 0.59 1.92 0 
75 PID_CXCR4_PATHWAY 92 0.55 1.92 0 
76 KEGG_FOCAL_ADHESION 172 0.54 1.92 0.004 
77 HUANG_DASATINIB_RESISTANCE_UP 70 0.71 1.92 0.002 
78 
SASSON_RESPONSE_TO_GONADOTROP
HINS_DN 84 0.53 1.92 0.002 
79 
HOFFMANN_PRE_BI_TO_LARGE_PRE_BII
_LYMPHOCYTE_DN 59 0.57 1.92 0 
80 PASINI_SUZ12_TARGETS_DN 255 0.54 1.92 0.004 
81 CHEN_ETV5_TARGETS_SERTOLI 19 0.82 1.92 0 
82 
REACTOME_CELL_SURFACE_INTERACTI
ONS_AT_THE_VASCULAR_WALL 76 0.57 1.92 0.006 
83 
LENAOUR_DENDRITIC_CELL_MATURATI
ON_DN 121 0.59 1.92 0.004 
84 GROSS_ELK3_TARGETS_DN 28 0.66 1.92 0 
85 
VART_KSHV_INFECTION_ANGIOGENIC_M
ARKERS_UP 138 0.57 1.91 0.002 
86 HUANG_GATA2_TARGETS_UP 125 0.54 1.91 0.004 
87 
FONTAINE_FOLLICULAR_THYROID_ADEN




_35D_UP 104 0.64 1.91 0.006 
89 
NIELSEN_GIST_AND_SYNOVIAL_SARCO
MA_DN 20 0.85 1.91 0 
90 
WIEDERSCHAIN_TARGETS_OF_BMI1_AN
D_PCGF2 49 0.65 1.9 0.006 
91 SWEET_KRAS_TARGETS_UP 79 0.63 1.9 0.002 
92 
WAMUNYOKOLI_OVARIAN_CANCER_GRA
DES_1_2_DN 54 0.59 1.9 0.004 
93 GAL_LEUKEMIC_STEM_CELL_DN 220 0.5 1.9 0.002 
94 
SARTIPY_BLUNTED_BY_INSULIN_RESIST
ANCE_UP 17 0.77 1.9 0 
95 ONO_AML1_TARGETS_DN 29 0.68 1.9 0.002 
96 
NAKAYAMA_SOFT_TISSUE_TUMORS_PC
A1_UP 68 0.76 1.9 0.006 
97 PETROVA_PROX1_TARGETS_DN 60 0.68 1.9 0.002 
98 
BOQUEST_STEM_CELL_CULTURED_VS_
FRESH_UP 400 0.5 1.9 0 
99 
MAHADEVAN_GIST_MORPHOLOGICAL_S
WITCH 15 0.8 1.9 0 
100 
EBAUER_MYOGENIC_TARGETS_OF_PAX
3_FOXO1_FUSION 41 0.62 1.9 0.006 
101 
KEGG_CYTOKINE_CYTOKINE_RECEPTO
R_INTERACTION 185 0.57 1.9 0 
102 
GOTZMANN_EPITHELIAL_TO_MESENCHY
MAL_TRANSITION_UP 62 0.58 1.89 0.002 





DN 133 0.54 1.89 0.002 
105 WOO_LIVER_CANCER_RECURRENCE_UP 97 0.56 1.89 0.004 
106 LIU_PROSTATE_CANCER_DN 371 0.53 1.89 0.002 
107 GERHOLD_ADIPOGENESIS_DN 60 0.57 1.89 0.002 
108 PID_INTEGRIN3_PATHWAY 40 0.68 1.89 0.006 
109 
PICCALUGA_ANGIOIMMUNOBLASTIC_LY
MPHOMA_UP 176 0.66 1.89 0.012 
110 
GRUETZMANN_PANCREATIC_CANCER_U
P 338 0.47 1.89 0.002 
111 FOSTER_TOLERANT_MACROPHAGE_DN 303 0.5 1.89 0.002 
112 
CHIARADONNA_NEOPLASTIC_TRANSFO
RMATION_KRAS_CDC25_DN 41 0.65 1.89 0.002 
113 MIKKELSEN_MEF_LCP_WITH_H3K4ME3 85 0.56 1.89 0 
114 ROY_WOUND_BLOOD_VESSEL_UP 46 0.71 1.89 0.008 
115 GHANDHI_BYSTANDER_IRRADIATION_UP 70 0.64 1.89 0.01 
116 
KEGG_COMPLEMENT_AND_COAGULATIO
N_CASCADES 52 0.63 1.88 0.002 
117 DANG_REGULATED_BY_MYC_DN 227 0.49 1.88 0 
118 
KAN_RESPONSE_TO_ARSENIC_TRIOXID
E 116 0.55 1.88 0.002 
119 
REACTOME_INTEGRIN_CELL_SURFACE_I
NTERACTIONS 74 0.58 1.88 0.002 
120 
MATSUDA_NATURAL_KILLER_DIFFERENT
IATION 374 0.4 1.88 0 




TION_6 64 0.57 1.87 0.004 
123 NIELSEN_LEIOMYOSARCOMA_CNN1_UP 18 0.8 1.87 0.004 
124 
HINATA_NFKB_TARGETS_KERATINOCYT
E_UP 90 0.6 1.87 0.004 
125 COWLING_MYCN_TARGETS 31 0.7 1.87 0.004 
126 CERVERA_SDHB_TARGETS_2 91 0.5 1.87 0.002 
127 
IWANAGA_CARCINOGENESIS_BY_KRAS_
PTEN_DN 235 0.43 1.87 0 
128 
REACTOME_EXTRACELLULAR_MATRIX_
ORGANIZATION 68 0.66 1.87 0.01 
129 
RUTELLA_RESPONSE_TO_HGF_VS_CSF2
RB_AND_IL4_UP 381 0.49 1.87 0.006 
130 WIELAND_UP_BY_HBV_INFECTION 96 0.73 1.87 0.01 
131 ROZANOV_MMP14_TARGETS_SUBSET 30 0.77 1.87 0.004 
132 
BROCKE_APOPTOSIS_REVERSED_BY_IL
6 139 0.54 1.87 0.006 
133 
WALLACE_PROSTATE_CANCER_RACE_U
P 263 0.7 1.87 0.004 
134 
RUTELLA_RESPONSE_TO_CSF2RB_AND_
IL4_DN 297 0.51 1.86 0.012 
135 KEGG_HEMATOPOIETIC_CELL_LINEAGE 68 0.68 1.86 0 
136 LIAN_LIPA_TARGETS_3M 45 0.7 1.86 0.008 
137 QI_PLASMACYTOMA_UP 226 0.56 1.86 0.006 
138 
SAMOLS_TARGETS_OF_KHSV_MIRNAS_
DN 52 0.52 1.86 0.002 





_TRANSITION_SIGNATURE 61 0.86 1.86 0.01 
141 
SEITZ_NEOPLASTIC_TRANSFORMATION_
BY_8P_DELETION_UP 71 0.61 1.86 0.006 
142 
SMID_BREAST_CANCER_RELAPSE_IN_B
ONE_DN 269 0.48 1.86 0.006 
143 
IZADPANAH_STEM_CELL_ADIPOSE_VS_B
ONE_UP 103 0.53 1.86 0.006 
144 
BEGUM_TARGETS_OF_PAX3_FOXO1_FU
SION_DN 45 0.63 1.86 0.004 
145 
FULCHER_INFLAMMATORY_RESPONSE_
LECTIN_VS_LPS_DN 354 0.51 1.86 0.008 
146 FRIDMAN_SENESCENCE_UP 75 0.55 1.86 0 
147 HUANG_FOXA2_TARGETS_DN 35 0.67 1.86 0.002 
148 
DUNNE_TARGETS_OF_AML1_MTG8_FUSI
ON_DN 19 0.7 1.86 0.002 
149 
LIU_VAV3_PROSTATE_CARCINOGENESIS
_UP 80 0.59 1.86 0.012 
150 NAKAMURA_METASTASIS 32 0.57 1.86 0.002 
151 
BOYAULT_LIVER_CANCER_SUBCLASS_G
5_DN 26 0.73 1.85 0.006 
152 
FLECHNER_BIOPSY_KIDNEY_TRANSPLA
NT_REJECTED_VS_OK_UP 82 0.74 1.85 0.006 
153 ALONSO_METASTASIS_EMT_UP 34 0.63 1.85 0.002 
154 PID_IL23PATHWAY 32 0.7 1.85 0.004 
155 JEON_SMAD6_TARGETS_UP 21 0.74 1.85 0.004 
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156 KANG_GIST_WITH_PDGFRA_UP 46 0.64 1.85 0.008 
157 PID_IL6_7PATHWAY 46 0.56 1.85 0.004 
158 
GAZDA_DIAMOND_BLACKFAN_ANEMIA_P
ROGENITOR_UP 39 0.57 1.85 0.004 
159 DER_IFN_GAMMA_RESPONSE_UP 68 0.6 1.85 0.006 
160 KEGG_ECM_RECEPTOR_INTERACTION 71 0.61 1.84 0.008 
161 
REACTOME_SMOOTH_MUSCLE_CONTRA
CTION 23 0.75 1.84 0.004 
162 
REACTOME_G_ALPHA_I_SIGNALLING_EV
ENTS 120 0.52 1.84 0.004 
163 HOSHIDA_LIVER_CANCER_SURVIVAL_UP 69 0.51 1.84 0 
164 
FONTAINE_THYROID_TUMOR_UNCERTAI
N_MALIGNANCY_DN 22 0.64 1.84 0.002 
165 LI_INDUCED_T_TO_NATURAL_KILLER_UP 236 0.5 1.84 0.006 
166 BOYLAN_MULTIPLE_MYELOMA_D_UP 59 0.5 1.84 0 
167 
GARGALOVIC_RESPONSE_TO_OXIDIZED
_PHOSPHOLIPIDS_GREEN_UP 17 0.65 1.84 0.004 
168 HAN_JNK_SINGALING_DN 34 0.62 1.84 0.006 
169 DORSEY_GAB2_TARGETS 29 0.67 1.83 0.004 
170 
SMIRNOV_CIRCULATING_ENDOTHELIOC
YTES_IN_CANCER_UP 153 0.54 1.83 0.004 
171 
RAGHAVACHARI_PLATELET_SPECIFIC_G
ENES 65 0.53 1.83 0.002 
172 
LIN_TUMOR_ESCAPE_FROM_IMMUNE_A
TTACK 15 0.66 1.83 0.002 
173 REACTOME_COLLAGEN_FORMATION 46 0.69 1.83 0.02 
174 PID_ILK_PATHWAY 39 0.56 1.83 0.004 
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175 BOYLAN_MULTIPLE_MYELOMA_C_D_DN 195 0.52 1.83 0.004 
176 GAVIN_FOXP3_TARGETS_CLUSTER_P7 60 0.57 1.83 0 
177 
WILCOX_PRESPONSE_TO_ROGESTERO
NE_DN 56 0.58 1.83 0.008 
178 DEMAGALHAES_AGING_UP 45 0.61 1.83 0.01 
179 BOSCO_TH1_CYTOTOXIC_MODULE 77 0.68 1.83 0.012 
180 GAVIN_FOXP3_TARGETS_CLUSTER_T4 73 0.5 1.83 0.002 
181 
ALTEMEIER_RESPONSE_TO_LPS_WITH_
MECHANICAL_VENTILATION 100 0.66 1.83 0.006 
182 
VART_KSHV_INFECTION_ANGIOGENIC_M
ARKERS_DN 112 0.49 1.83 0.002 
183 SENESE_HDAC2_TARGETS_UP 91 0.53 1.83 0.006 
184 
HELLEBREKERS_SILENCED_DURING_TU
MOR_ANGIOGENESIS 75 0.57 1.83 0.006 
185 
HERNANDEZ_MITOTIC_ARREST_BY_DOC
ETAXEL_1_DN 34 0.59 1.83 0.004 
186 PID_SYNDECAN_1_PATHWAY 42 0.64 1.82 0.022 
187 LEE_LIVER_CANCER_DENA_UP 58 0.52 1.82 0.002 
188 GU_PDEF_TARGETS_UP 68 0.62 1.82 0.008 
189 BURTON_ADIPOGENESIS_9 77 0.5 1.82 0.004 
190 
CROONQUIST_STROMAL_STIMULATION_
UP 53 0.67 1.82 0.012 
191 GHANDHI_DIRECT_IRRADIATION_UP 83 0.6 1.82 0.008 
192 PETRETTO_CARDIAC_HYPERTROPHY 32 0.65 1.82 0.004 
193 
REACTOME_RESPONSE_TO_ELEVATED_
PLATELET_CYTOSOLIC_CA2_ 69 0.55 1.82 0 
194 DER_IFN_BETA_RESPONSE_UP 98 0.55 1.82 0.006 
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195 VERRECCHIA_RESPONSE_TO_TGFB1_C2 24 0.7 1.82 0.008 
196 
SMID_BREAST_CANCER_NORMAL_LIKE_
UP 428 0.63 1.82 0.022 
197 DER_IFN_ALPHA_RESPONSE_UP 72 0.61 1.82 0.014 
198 
NOUSHMEHR_GBM_SILENCED_BY_METH
YLATION 32 0.58 1.82 0.002 
199 
TURASHVILI_BREAST_DUCTAL_CARCINO
MA_VS_DUCTAL_NORMAL_UP 36 0.64 1.81 0.023 
200 
GRAHAM_CML_QUIESCENT_VS_CML_DIV
IDING_UP 23 0.69 1.81 0.012 
201 NGUYEN_NOTCH1_TARGETS_UP 29 0.54 1.81 0.004 
202 
BERENJENO_TRANSFORMED_BY_RHOA_
REVERSIBLY_DN 21 0.7 1.81 0.006 
203 
BHATI_G2M_ARREST_BY_2METHOXYEST
RADIOL_UP 90 0.53 1.81 0.002 
204 
REACTOME_GPVI_MEDIATED_ACTIVATIO
N_CASCADE 29 0.58 1.81 0.006 
205 GROSS_HYPOXIA_VIA_ELK3_DN 134 0.53 1.81 0.012 
206 
TONKS_TARGETS_OF_RUNX1_RUNX1T1_
FUSION_ERYTHROCYTE_UP 145 0.51 1.81 0.006 
207 BILBAN_B_CLL_LPL_DN 37 0.59 1.81 0.008 
208 ZHENG_IL22_SIGNALING_UP 36 0.61 1.81 0.008 
209 KYNG_DNA_DAMAGE_DN 181 0.42 1.81 0 
210 
ZHENG_FOXP3_TARGETS_IN_THYMUS_U
P 153 0.48 1.81 0.008 
211 
BROWN_MYELOID_CELL_DEVELOPMENT




G_METASTASIS_DN 33 0.73 1.81 0.014 
213 GAURNIER_PSMD4_TARGETS 62 0.72 1.81 0.006 
214 
SASAI_RESISTANCE_TO_NEOPLASTIC_T
RANSFROMATION 49 0.61 1.81 0.018 
215 RICKMAN_HEAD_AND_NECK_CANCER_C 76 0.61 1.81 0.016 
216 
HOSHIDA_LIVER_CANCER_LATE_RECUR
RENCE_UP 55 0.51 1.81 0.008 
217 
HERNANDEZ_ABERRANT_MITOSIS_BY_D
OCETACEL_4NM_UP 21 0.64 1.81 0.01 
218 SHIN_B_CELL_LYMPHOMA_CLUSTER_8 31 0.63 1.81 0.006 
219 MAHADEVAN_RESPONSE_TO_MP470_UP 18 0.77 1.81 0.006 
220 
MASRI_RESISTANCE_TO_TAMOXIFEN_A
ND_AROMATASE_INHIBITORS_DN 18 0.72 1.81 0.01 
221 LU_TUMOR_ANGIOGENESIS_UP 25 0.65 1.81 0.01 
222 STEGER_ADIPOGENESIS_DN 21 0.78 1.8 0.008 
223 NAKAMURA_ADIPOGENESIS_EARLY_DN 37 0.64 1.8 0.014 
224 WORSCHECH_TUMOR_REJECTION_UP 44 0.66 1.8 0.012 
225 PID_SHP2_PATHWAY 51 0.53 1.8 0 
226 PID_INTEGRIN2_PATHWAY 27 0.68 1.8 0.002 
227 REACTOME_HEMOSTASIS 355 0.41 1.8 0 
228 KRASNOSELSKAYA_ILF3_TARGETS_UP 37 0.7 1.8 0.006 
229 ONDER_CDH1_TARGETS_2_UP 237 0.57 1.8 0.022 
230 RODRIGUES_THYROID_CARCINOMA_DN 65 0.52 1.8 0.006 
231 LIU_SMARCA4_TARGETS 44 0.57 1.8 0.012 
232 PID_IL12_STAT4PATHWAY 29 0.74 1.8 0.012 




ESTERONE_CLUSTER_16 67 0.56 1.8 0.018 
235 PID_AP1_PATHWAY 63 0.53 1.8 0.016 
236 
BOYAULT_LIVER_CANCER_SUBCLASS_G
56_DN 17 0.7 1.8 0.006 
237 REACTOME_PYRIMIDINE_METABOLISM 18 0.64 1.8 0.004 
238 KAAB_FAILED_HEART_VENTRICLE_DN 38 0.59 1.8 0.006 
239 POTTI_CYTOXAN_SENSITIVITY 31 0.58 1.8 0.01 
240 MA_MYELOID_DIFFERENTIATION_DN 36 0.55 1.8 0.002 
241 
OSWALD_HEMATOPOIETIC_STEM_CELL_
IN_COLLAGEN_GEL_UP 206 0.45 1.8 0.004 
242 TOMLINS_PROSTATE_CANCER_DN 40 0.63 1.8 0.02 
243 
CHIANG_LIVER_CANCER_SUBCLASS_CT
NNB1_DN 125 0.53 1.8 0.01 
244 
BOYLAN_MULTIPLE_MYELOMA_C_CLUST
ER_DN 25 0.63 1.8 0.006 
245 
LINDSTEDT_DENDRITIC_CELL_MATURATI
ON_D 66 0.59 1.8 0.014 
246 MCDOWELL_ACUTE_LUNG_INJURY_UP 43 0.61 1.8 0.012 
247 PID_GLYPICAN_1PATHWAY 23 0.64 1.8 0 
248 FOSTER_TOLERANT_MACROPHAGE_UP 115 0.49 1.79 0.004 
249 ONDER_CDH1_SIGNALING_VIA_CTNNB1 78 0.56 1.79 0.002 
250 
DAVICIONI_MOLECULAR_ARMS_VS_ERM
S_DN 163 0.48 1.79 0.004 
251 
WANG_CISPLATIN_RESPONSE_AND_XPC
_DN 202 0.41 1.79 0.002 
252 KIM_WT1_TARGETS_UP 202 0.5 1.79 0.012 
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253 MAHAJAN_RESPONSE_TO_IL1A_UP 74 0.52 1.79 0.006 
254 
HESS_TARGETS_OF_HOXA9_AND_MEIS1
_DN 66 0.61 1.79 0.02 
255 
REACTOME_CLASS_A1_RHODOPSIN_LIK
E_RECEPTORS 164 0.5 1.79 0.004 
256 SENESE_HDAC1_TARGETS_UP 353 0.46 1.79 0.004 
257 
PAPASPYRIDONOS_UNSTABLE_ATEROS
CLEROTIC_PLAQUE_DN 38 0.66 1.79 0.014 
258 LA_MEN1_TARGETS 21 0.63 1.79 0.006 
259 KAMIKUBO_MYELOID_MN1_NETWORK 16 0.66 1.79 0.006 
260 
VERRECCHIA_EARLY_RESPONSE_TO_T
GFB1 56 0.6 1.79 0.014 
261 RUTELLA_RESPONSE_TO_HGF_UP 392 0.45 1.79 0.008 
262 
NEMETH_INFLAMMATORY_RESPONSE_L
PS_UP 80 0.57 1.79 0.008 
263 
BERTUCCI_MEDULLARY_VS_DUCTAL_BR
EAST_CANCER_DN 124 0.52 1.79 0.018 
264 
DUNNE_TARGETS_OF_AML1_MTG8_FUSI
ON_UP 42 0.68 1.78 0.008 
265 WINTER_HYPOXIA_METAGENE 212 0.48 1.78 0.012 
266 VALK_AML_CLUSTER_5 29 0.69 1.78 0.014 
267 BROWNE_HCMV_INFECTION_24HR_DN 137 0.47 1.78 0.002 
268 SENESE_HDAC3_TARGETS_UP 389 0.42 1.78 0.004 
269 
GAUSSMANN_MLL_AF4_FUSION_TARGET
S_F_DN 27 0.59 1.78 0.008 
270 WANG_MLL_TARGETS 197 0.44 1.78 0.004 





T 50 0.53 1.78 0.009 
273 GAVIN_PDE3B_TARGETS 19 0.73 1.78 0.008 
274 SWEET_LUNG_CANCER_KRAS_DN 361 0.47 1.78 0.01 
275 WU_HBX_TARGETS_2_UP 22 0.58 1.78 0.008 
276 NAKAMURA_METASTASIS_MODEL_DN 32 0.59 1.78 0.01 
277 MANTOVANI_NFKB_TARGETS_UP 32 0.56 1.78 0.006 
278 NUTT_GBM_VS_AO_GLIOMA_UP 44 0.54 1.77 0.01 
279 
TAKEDA_TARGETS_OF_NUP98_HOXA9_F
USION_16D_UP 115 0.52 1.77 0.01 
280 
DIAZ_CHRONIC_MEYLOGENOUS_LEUKE
MIA_DN 107 0.54 1.77 0.01 
281 
MARCHINI_TRABECTEDIN_RESISTANCE_
DN 46 0.56 1.77 0.01 
282 ZHU_CMV_24_HR_DN 84 0.57 1.77 0.042 
283 BROWNE_HCMV_INFECTION_20HR_DN 92 0.46 1.77 0.004 
284 NAKAMURA_ADIPOGENESIS_LATE_DN 36 0.62 1.77 0.014 
285 
FAELT_B_CLL_WITH_VH_REARRANGEME
NTS_UP 43 0.51 1.77 0.008 
286 DELACROIX_RAR_TARGETS_DN 18 0.63 1.77 0.01 
287 PID_AVB3_OPN_PATHWAY 29 0.59 1.77 0.013 
288 KEGG_JAK_STAT_SIGNALING_PATHWAY 110 0.49 1.77 0.008 
289 
TSAI_RESPONSE_TO_IONIZING_RADIATI
ON 135 0.46 1.77 0.004 
290 PID_LYMPHANGIOGENESIS_PATHWAY 24 0.61 1.77 0.014 
291 SENGUPTA_NASOPHARYNGEAL_CARCIN 226 0.51 1.77 0.018 
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OMA_UP 
292 HOELZEL_NF1_TARGETS_UP 100 0.49 1.77 0.002 
293 PID_AVB3_INTEGRIN_PATHWAY 70 0.53 1.77 0.028 
294 
GRAESSMANN_APOPTOSIS_BY_SERUM_
DEPRIVATION_UP 401 0.39 1.77 0 
295 
BEGUM_TARGETS_OF_PAX3_FOXO1_FU
SION_UP 55 0.53 1.77 0.008 
296 
ZHOU_INFLAMMATORY_RESPONSE_LPS
_UP 242 0.43 1.76 0.006 
297 HELLER_HDAC_TARGETS_DN 260 0.43 1.76 0.002 
298 
GRAHAM_NORMAL_QUIESCENT_VS_NOR
MAL_DIVIDING_UP 58 0.57 1.76 0.012 
299 
ZHAN_MULTIPLE_MYELOMA_CD1_AND_C
D2_DN 36 0.53 1.76 0.006 
300 
ZHANG_TARGETS_OF_EWSR1_FLI1_FUSI
ON 82 0.49 1.76 0.002 
301 
EBAUER_TARGETS_OF_PAX3_FOXO1_FU
SION_UP 178 0.43 1.76 0.002 
302 
JAATINEN_HEMATOPOIETIC_STEM_CELL
_DN 176 0.6 1.76 0.025 
303 PID_INTEGRIN_CS_PATHWAY 23 0.66 1.76 0.01 
304 LEI_HOXC8_TARGETS_DN 16 0.68 1.76 0.014 
305 
HIRSCH_CELLULAR_TRANSFORMATION_
SIGNATURE_UP 228 0.47 1.76 0.014 
306 
GRAHAM_CML_QUIESCENT_VS_NORMAL
_DIVIDING_UP 46 0.6 1.76 0.01 





AND_CHOLESTEROL_UP 45 0.66 1.76 0.018 
309 PID_IL12_2PATHWAY 54 0.64 1.76 0.03 
310 KATSANOU_ELAVL1_TARGETS_DN 106 0.45 1.76 0.004 
311 HECKER_IFNB1_TARGETS 76 0.7 1.76 0.01 
312 WU_HBX_TARGETS_3_UP 18 0.58 1.76 0.004 
313 
SCHAEFFER_PROSTATE_DEVELOPMENT
_6HR_UP 127 0.44 1.76 0.007 
314 
DEURIG_T_CELL_PROLYMPHOCYTIC_LE
UKEMIA_DN 291 0.46 1.76 0.024 
315 MARKEY_RB1_CHRONIC_LOF_DN 97 0.52 1.76 0.014 
316 WONG_ENDMETRIUM_CANCER_DN 60 0.64 1.76 0.024 
317 
AMUNDSON_POOR_SURVIVAL_AFTER_G
AMMA_RADIATION_8G 90 0.48 1.76 0.01 
318 KEGG_PRION_DISEASES 28 0.61 1.76 0.004 
319 BURTON_ADIPOGENESIS_8 73 0.53 1.76 0.01 
320 BOYLAN_MULTIPLE_MYELOMA_PCA1_UP 84 0.56 1.76 0.013 
321 BOYLAN_MULTIPLE_MYELOMA_PCA3_UP 56 0.48 1.76 0.004 
322 LIANG_SILENCED_BY_METHYLATION_2 49 0.67 1.75 0.01 
323 DELASERNA_MYOD_TARGETS_DN 42 0.53 1.75 0.01 
324 
SCHAEFFER_PROSTATE_DEVELOPMENT
_12HR_UP 90 0.46 1.75 0.002 
325 
WEINMANN_ADAPTATION_TO_HYPOXIA_
DN 38 0.58 1.75 0.008 
326 AMIT_SERUM_RESPONSE_60_MCF10A 54 0.57 1.75 0.016 
327 GAUSSMANN_MLL_AF4_FUSION_TARGET 136 0.47 1.75 0.006 
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S_F_UP 
328 ZHOU_TNF_SIGNALING_4HR 51 0.46 1.75 0.004 
329 
SCHAEFFER_PROSTATE_DEVELOPMENT
_48HR_DN 275 0.45 1.75 0.008 
330 
XU_HGF_SIGNALING_NOT_VIA_AKT1_48
HR_UP 34 0.62 1.75 0.01 
331 KEGG_LEISHMANIA_INFECTION 60 0.6 1.75 0.016 
332 
CHEN_LVAD_SUPPORT_OF_FAILING_HE
ART_UP 97 0.52 1.75 0.016 
333 
FULCHER_INFLAMMATORY_RESPONSE_
LECTIN_VS_LPS_UP 435 0.41 1.75 0.004 
334 
SNIJDERS_AMPLIFIED_IN_HEAD_AND_NE
CK_TUMORS 34 0.58 1.75 0.014 
335 PID_PTP1BPATHWAY 45 0.52 1.75 0.004 
336 
ZHANG_RESPONSE_TO_IKK_INHIBITOR_
AND_TNF_UP 177 0.54 1.75 0.018 
337 WU_HBX_TARGETS_1_UP 15 0.69 1.75 0.002 
338 DURAND_STROMA_MAX_UP 210 0.43 1.74 0.004 
339 
KUROZUMI_RESPONSE_TO_ONCOCYTIC
_VIRUS 41 0.68 1.74 0.02 
340 
WANG_RESPONSE_TO_BEXAROTENE_D
N 23 0.56 1.74 0.006 
341 PARK_APL_PATHOGENESIS_DN 47 0.55 1.74 0.014 
342 HALMOS_CEBPA_TARGETS_UP 49 0.55 1.74 0.014 
343 
CHIARADONNA_NEOPLASTIC_TRANSFO
RMATION_KRAS_DN 123 0.49 1.74 0.012 





USION_10D_DN 104 0.56 1.74 0.019 
346 GAVIN_FOXP3_TARGETS_CLUSTER_P2 63 0.49 1.74 0 
347 
PAPASPYRIDONOS_UNSTABLE_ATEROS
CLEROTIC_PLAQUE_UP 49 0.59 1.74 0.025 
            
            
            
            
  Enriched in Luminal (nom pvalue<1%)         
Rank MSigDB SIZE ES NES NOM p-val 
1 
CHARAFE_BREAST_CANCER_LUMINAL_V
S_MESENCHYMAL_UP 321 -0.63 -2.1 0 
2 
WAMUNYOKOLI_OVARIAN_CANCER_LMP
_UP 192 -0.59 -2.05 0 
3 
REACTOME_PEROXISOMAL_LIPID_META
BOLISM 18 -0.77 -1.96 0 
4 LIM_MAMMARY_STEM_CELL_DN 313 -0.52 -1.96 0 
5 KEGG_LINOLEIC_ACID_METABOLISM 19 -0.71 -1.94 0 
6 
SHEDDEN_LUNG_CANCER_GOOD_SURVI
VAL_A5 60 -0.62 -1.88 0.004 
7 
CHARAFE_BREAST_CANCER_LUMINAL_V
S_BASAL_UP 272 -0.48 -1.88 0 
8 
KEGG_GLYCEROPHOSPHOLIPID_METAB
OLISM 52 -0.5 -1.85 0 





N 66 -0.5 -1.83 0 
11 
SMID_BREAST_CANCER_RELAPSE_IN_B
RAIN_DN 76 -0.53 -1.82 0.008 
12 
SCHUETZ_BREAST_CANCER_DUCTAL_IN
VASIVE_DN 78 -0.49 -1.79 0.008 
13 KEGG_PEROXISOME 63 -0.54 -1.79 0.004 
14 DOANE_BREAST_CANCER_CLASSES_UP 69 -0.53 -1.76 0.01 
15 
KEGG_VALINE_LEUCINE_AND_ISOLEUCI
NE_DEGRADATION 40 -0.6 -1.76 0.019 
16 
REACTOME_SULFUR_AMINO_ACID_MET
ABOLISM 22 -0.58 -1.75 0.008 
17 COLDREN_GEFITINIB_RESISTANCE_DN 148 -0.56 -1.75 0.034 
18 
LIEN_BREAST_CARCINOMA_METAPLASTI




M 135 -0.4 -1.74 0 
20 
FONTAINE_FOLLICULAR_THYROID_ADEN
OMA_UP 50 -0.47 -1.74 0.006 
21 
REACTOME_BRANCHED_CHAIN_AMINO_
ACID_CATABOLISM 16 -0.69 -1.74 0.01 
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